



**Keystone 65 Rx HMO  
Personal Choice 65<sup>SM</sup> Rx PPO  
Select Option<sup>®</sup> Rx PDP  
2025 Utilization Management  
Criteria: Prior Authorization**

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION  
ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on **06/24/2025**. For more recent information or other questions, please contact our Member Help Team: Keystone 65 Rx at **1-844-352-1699**, Personal Choice 65 Rx at **1-888-879-4293**, Select Option Rx at **1-888-678-7009** or, for TTY/TDD users, **711**, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit [www.ibxmedicare.com](http://www.ibxmedicare.com) to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2026, and from time to time during the year.

Independence Blue Cross offers PPO, HMO-POS, and HMO Medicare Advantage plans with a Medicare contract. Enrollment in Independence Blue Cross PPO, HMO-POS, and HMO Medicare Advantage plans depends on contract renewal.

Independence Blue Cross offers products through its subsidiaries Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.

## There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in *2025 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting [www.ibxmedicare.com](http://www.ibxmedicare.com).

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

## How to use this document

This document, along with *2025 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “PA” in the “Requirements” column of the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 325. The restriction information includes:

- **Prior Authorization**
  - Covered uses
  - Exclusion criteria
  - Required medical information
  - Age restrictions
  - Prescriber restrictions
  - Coverage duration
  - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 Rx at **1-844-352-1699**, Personal Choice 65 Rx at **1-888-879-4293**, or Select Option Rx at **1-888-678-7009** or, for TTY/TDD users, **711**.

# ABUSE DETERRENT OPIOID 2025

## Products Affected

- *hydrocodone bitartrate er oral capsule extended release 12 hour*
- *hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent*
- HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 20 MG, 30 MG, 40 MG, 60 MG, 80 MG
- NUCYNTA ER
- *oxycodone hcl oral tablet abuse-deterrent*
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT
- ROXYBOND
- XTAMPZA ER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following: (1) Prior use of TWO generic opioids OR (2) BOTH of the following: (a) there is a history of or a potential for drug abuse among the individual or a member of the individual's household AND (b) documentation of current patient-prescriber opioid treatment agreement
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACTEMRA SQ 2025

## Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PJIA, SJIA, RA, GCA, SSc-ILD): Concurrent therapy with other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists.
<b>Required Medical Information</b>	Part D is medically necessary when there is documentation of the following: Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) etanercept (Enbrel), (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ OR documentation demonstrating that a trial may be inappropriate. Systemic Juvenile Idiopathic Arthritis (SJIA): (1) Diagnosis of SJIA. (2) Inadequate response or inability to tolerate ONE of the following: (a) Non-steroidal antiinflammatory drug (NSAID), (b) Systemic glucocorticoid, (c) Methotrexate. Moderate to severe rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e., Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia, OR documentation demonstrating that a trial may be inappropriate. Giant Cell Arteritis (GCA): (1) Diagnosis of GCA. (2) Documentation of inadequate response/inability to tolerate oral corticosteroids. Systemic Sclerosis (SSc-ILD) (1): Diagnosis of SSc-ILD (2) Documentation of inadequate response/inability to tolerate a 3-month trial of ONE of the following:(a) mycophenolate mofetil, (b) cyclophosphamide, OR (c) azathioprine (3) Diagnosis of SSc-ILD confirmed by a high-resolution CT scan or biopsy
<b>Age Restrictions</b>	(PJIA, SJIA): Member is 2 years of age or older (RA, GCA, SSc-ILD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PJIA, SJIA, RA, GCA): Prescribed by or in consultation with a Rheumatologist (SSc-ILD) -Prescribed by or in consultation with a rheumatologist or pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ACTHAR HP 2025

## Products Affected

- ACTHAR
- ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR
- CORTROPHIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(All Indications): Scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins or porcine origin, or where congenital infections are suspected in infants. OR Administration of live or live attenuated vaccines in members receiving immunosuppressive doses of H.P. Acthar Gel.
<b>Required Medical Information</b>	Part D is medically necessary when ONE of the following is present: (1) Infantile Spasms (IS): (A) Diagnosis of IS. (B) Dosing for infantile spasms (West Syndrome) is in accordance with the United States Food and Drug Administration (FDA) approved labeling: not to exceed 150U/m2 daily (2) Acute Exacerbation of Multiple Sclerosis (AEMS): (A) Diagnosis of an AEMS, (B) Currently receiving maintenance treatment for MS (e.g. Avonex, Betaseron, Copaxone, Tecfidera, etc.), (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone) (D) Member is new to therapy with corticotropin OR member's multiple sclerosis exacerbations have been treated in the past with corticotropin AND member has benefitted from treatment with corticotropin for acute exacerbations of multiple sclerosis AND medication is being used to treat a new exacerbation of multiple sclerosis. (3) Acute Exacerbation of Psoriatic Arthritis (AEPsA): (A) Diagnosis of an AEPsA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (4) Acute Exacerbation of Rheumatoid Arthritis (AERA): (A) Diagnosis of an AERA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (5) Acute Exacerbation of Juvenile Rheumatoid Arthritis (AEJRA): (A) Diagnosis of an AEJRA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (6) Acute Exacerbation of Ankylosing Spondylitis (AEAS): (A) Diagnosis of an AEAS, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone).

PA Criteria	Criteria Details
<b>Age Restrictions</b>	(IS): Member is younger than 2 years of age. (MS): Member is 18 years of age and older. (All Other Indications): Member is 2 years of age and older
<b>Prescriber Restrictions</b>	(IS): Prescribed by or in consultation with a neurologist or neonatologist. (All Other Indications): Prescribed by or in consultation with a neurologist, rheumatologist, nephrologist, pulmonologist, ophthalmologist, dermatologist, allergist, immunologist.
<b>Coverage Duration</b>	(IS): 1 year (All Other Indications): 1 month
<b>Other Criteria</b>	Subject to Part B vs Part D review. (7) Nephrotic Syndrome (NS): (A) Diagnosis of NS, (B) Proteinuria greater than 3.5g/ 24 hours, (C) serum albumin less than 3 mg/dL, (D) Peripheral edema. (E) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (F) Member does not have uremia of the idiopathic type (8) Systemic Lupus Erythematosus (SLE): (A) Diagnosis of SLE (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (9) Systemic Dermatomyositis (SDM): (A) Diagnosis of SDM (polymyositis), (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (10) Severe Erythema Multiforme (SEM): (A) Diagnosis of SEM, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (11) Stevens-Johnson Syndrome (SJS): (A) Diagnosis of SJS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (12) Serum Sickness (SS): (A) Diagnosis of SS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (13) Inflammatory Ophthalmic Disease (IOD): (A) Diagnosis of IOD such as Keratitis, Iritis, Iridocyclitis, Diffuse posterior uveitis and choroiditis, Optic neuritis, Chorioretinitis, Anterior segment inflammation, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (14) Symptomatic Sarcoidosis (SSD): (A) Diagnosis of SSD, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (15) Edematous state: To induce a diuresis or a remission of proteinuria due to lupus erythematosus (ALL INDICATIONS): Dosing is in accordance with the United States Food and Drug Administration (FDA) approved labeling
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACUTE HAE AGENTS 2025

## Products Affected

- BERINERT
- FIRAZYR SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE
- *icatibant acetate subcutaneous solution prefilled*
- *syringe*
- RUCONEST
- SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED  
SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Part D is medically necessary when the following inclusion criteria is met: Hereditary Angioedema (HAE): (1) Used for the treatment of acute abdominal, facial or laryngeal attacks of HAE.
Age Restrictions	
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an allergist, pulmonologist, or immunologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# ACUTE SEIZURE ACTIVITY AGENTS 2025

## Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML
- VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescriber is a neurologist/epilepsy specialist
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ADALIMUMAB NON-PREFERRED PRODUCTS 2025

## Products Affected

- ABRILADA (1 PEN)
- ABRILADA (2 SYRINGE)
- *adalimumab-aaty (1 pen) subcutaneous auto-injector kit 80 mg/0.8ml*
- *adalimumab-aaty (2 pen)*
- *adalimumab-aaty (2 syringe)*
- *adalimumab-adaz*
- *adalimumab-fkjp (2 pen)*
- *adalimumab-fkjp (2 syringe)*
- *adalimumab-ryvk (2 pen)*
- *adalimumab-ryvk (2 syringe)*
- AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8ML
- AMJEVITA-PED 10KG TO <15KG
- AMJEVITA-PED 15KG TO <30KG
- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER
- HADLIMA
- HADLIMA PUSHTOUCH
- HULIO (2 PEN)
- HULIO (2 SYRINGE)
- HYRIMOZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- HYRIMOZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HYRIMOZ-CROHNS/UC STARTER
- HYRIMOZ-PED<40KG CROHN STARTER
- HYRIMOZ-PED>=40KG CROHN START
- HYRIMOZ-PLAQ PSOR/UEVIT START
- SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML
- SIMLANDI (1 SYRINGE)
- SIMLANDI (2 PEN)
- SIMLANDI (2 SYRINGE)
- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER
- YUSIMRY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia, OR documentation demonstrating that a trial may be inappropriate. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate TWO of the following: (a) Cosentyx, (b) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (c) Enbrel, (d) Xeljanz/Xeljanz XR, (e) Rinvoq, or documentation demonstrating that a trial may be inappropriate. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of moderate to severe JIA (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ OR documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Ustekinumab (i.e. Yesintek), (h) Orencia, (i) Otezla, OR documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla, OR documentation demonstrating that a trial may be inappropriate.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p>(RA, JIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (PsO, HS): Prescribed by or in consultation with a dermatologist. (CD, UC): Prescribed by or in consultation with a gastroenterologist. (UV): Prescribed by or in consultation with a rheumatologist or ophthalmologist.</p>
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Ustekinumab (i.e. Yesintek), (c) Skyrizi, (d) Rinvoq or documentation demonstrating that a trial may be inappropriate.</p> <p>Ulcerative Colitis (UC): (1) Diagnosis of UC. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Ustekinumab (i.e. Yesintek), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Skyrizi OR documentation demonstrating that a trial may be inappropriate.</p> <p>Hidradenitis Suppurativa (HS): (1) Diagnosis of HS (2) Inadequate response or inability to tolerate Cosentyx AND one of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), OR documentation demonstrating that a trial may be inappropriate.</p> <p>Uveitis (UV) (1) Diagnosis of non-infectious intermediate, posterior, or pan-uveitis. (2) Inadequate response or inability to tolerate BOTH of the following: (a) corticosteroid or immunosuppressive drug (e.g. azathioprine, cyclosporine, methotrexate, mycophenolate), AND (b) One of the following: (i) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF) OR documentation demonstrating that a trial may be inappropriate.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADALIMUMAB PREFERRED PRODUCTS 2025

## Products Affected

- *adalimumab-aacf* (2 pen)
- *adalimumab-aacf* (2 syringe)
- *adalimumab-aacf*(cd/uc/hs strt)
- *adalimumab-aacf*(ps/uv starter)
- *adalimumab-adbm* (2 pen)
- *adalimumab-adbm* (2 syringe)
- *adalimumab-adbm*(cd/uc/hs strt)
- *adalimumab-adbm*(ps/uv starter)
- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML
- HUMIRA-PSORIASIS/UEVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1)Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of moderate to severe JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, leflunomide, sulfasalazine. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO.
<b>Age Restrictions</b>	Member is within the age group listed in the FDA labeling for the indication
<b>Prescriber Restrictions</b>	(RA, JIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (PsO, HS): Prescribed by or in consultation with a dermatologist. (CD, UC): Prescribed by or in consultation with a gastroenterologist. (UV): Prescribed by or in consultation with a rheumatologist or ophthalmologist.
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of UC. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, aminosalicylate, azathioprine or 6-mercaptopurine). Hidradenitis Suppurativa (HS): (1) Diagnosis of HS. Uveitis (UV): (1) Diagnosis of non-infectious intermediate, posterior, or pan- uveitis. (2) Inadequate response or inability to tolerate corticosteroids and at least one immunosuppressive drug (e.g. azathioprine, cyclosporine, methotrexate, mycophenolate).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADBRY 2025

---

## Products Affected

- ADBRY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe AD (2) inadequate response or inability to tolerate ONE of the following: (a) one topical steroid (medium potency or higher) (b) topical tacrolimus (c) Eucrisa (crisaborole) ointment (d) Pimecrolimus cream
Age Restrictions	(AD): Member is 12 years of age or older
Prescriber Restrictions	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ADEMPAS 2025

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH, CTEPH) (Initial, Reauth): Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy, concurrent use with other soluble guanylate cyclase stimulators (e.g. Verquvo)
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II - IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (initial): (1) Diagnosis of persistent/recurrent CTPH (WHO Group 4) after surgical treatment or inoperable CTEPH.
<b>Age Restrictions</b>	(PAH, CTEPH) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PAH, CTEPH) (initial, Reauth): Prescribed by or in consultation with a pulmonologist or cardiologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth):12 months
<b>Other Criteria</b>	(PAH, CPTEH) (Reauth): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AFREZZA 2025

## Products Affected

- AFREZZA INHALATION POWDER 12 UNIT, 4 UNIT, 60X4 & 60X8 & 60X12 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(DM1, DM2) (Initial, Reauth): Member has chronic lung disease such as asthma or chronic obstructive pulmonary disease
<b>Required Medical Information</b>	Type 1 Diabetes Mellitus (DM1) (Initial): (1) Diagnosis of type 1 diabetes mellitus, (2) Used in combination with a long-acting insulin (e.g. Lantus), (3) Documented FEV1 within the last 60 days greater than or equal to 70% of expected normal as determined by the physician, (4) Spirometry (FEV1) has been completed prior to initiation of therapy to identify potential lung disease (must provide the result). Type 2 Diabetes Mellitus (DM2) (Initial): (1) Diagnosis of type 2 diabetes mellitus, (2) Documented FEV1 within the last 60 days greater than or equal to 70% of expected normal as determined by the physician, (3) Inadequate response or inability to tolerate one of the following: Novolin, Novolog, Humalog, Humulin, Insulin Lispro.
<b>Age Restrictions</b>	(DM1, DM2) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): Indefinite
<b>Other Criteria</b>	(DM1, DM2)(Reauth): (1) Spirometry value (FEV1) that has not declined greater than or equal to 20% from baseline. (2) Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AGAMREE 2025

## Products Affected

- AGAMREE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(DMD)(Initial): (1) Diagnosis of Duchenne muscular dystrophy (DMD) (2) Member has received genetic testing for a mutation of the dystrophin gene (3) One of the following: (a) Member has a confirmed mutation of the dystrophin gene (b) Muscle biopsy confirmed an absence of the dystrophin gene (4) Inadequate response or inability to tolerate ONE of the following: (a) prednisone (b) prednisolone (5) One of the following: (a) for members less than or equal to 50kg, dose will not exceed 6mg/kg of body weight once daily (b) For members greater than 50kg, dose will not exceed 300mg/day
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(DMD) (Initial, Reauth): Prescribed by or in consultation with a neurologist who has experience treating children with DMD.
<b>Coverage Duration</b>	(DMD) (Initial, Reauth): 12 months
<b>Other Criteria</b>	(DMD)(Reauth): (1) Member has experienced a benefit from therapy (e.g., improvement or preservation of muscle strength) (2) One of the following: (a) for members less than or equal to 50kg, dose will not exceed 6mg/kg of body weight once daily (b) For members greater than 50kg, dose will not exceed 300mg/day
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AIMOVIG 2025

## Products Affected

- AIMOVIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4-week trial of or contraindication to TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e) SNRI antidepressants: venlafaxine, duloxetine, (f) candesartan OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of or contraindication to TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v) SNRI antidepressants: venlafaxine, duloxetine (vi) candesartan.
<b>Age Restrictions</b>	(Migraines)(Initial, Reauth): Member 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraines)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist
<b>Coverage Duration</b>	(Migraines)(Initial): 6 months (Migraines)(Reauth): 12 months
<b>Other Criteria</b>	(Migraines)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AJOVY 2025

## Products Affected

- AJOVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate or contraindication to of Aimovig or Emgality. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate or contraindication to Aimovig or Emgality.
<b>Age Restrictions</b>	(Migraines)(Initial, Reauth): Member 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraines)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist
<b>Coverage Duration</b>	(Migraines)(Initial): 6 months (Migraines)(Reauth): 12 months
<b>Other Criteria</b>	(Migraines)(REAUTH): (1) Response to therapy as defined by a reduction headache days per month (defined as at least 4 hours duration and moderate intensity).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ALLERGEN SPECIFIC IMMUNOTHERAPY (SL) 2025

## Products Affected

- GRASTEK
- ODACTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial): (1) Severe, unstable or uncontrolled asthma (2) History of eosinophilic esophagitis
<b>Required Medical Information</b>	(Initial): (1) Member has a positive skin test or in vitro test for the listed pollen-specific IgE antibody. (2) Inadequate response or inability to tolerate an intranasal corticosteroid and an oral or intranasal antihistamine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with an allergist or immunologist.
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(Reauth): (1) Member has experienced improvement in the symptoms of their allergic rhinitis or a decrease in the number of medications needed to control allergy symptoms
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ALVAIZ 2025

## Products Affected

- ALVAIZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Idiopathic Thrombocytopenic Purpura (ITP)(Initial): (1) Diagnosis of relapsed/refractory, persistent, or chronic ITP. (2) Baseline platelet count is less than 30,000/mcL. (3) Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding. (4) Inadequate response or inability to tolerate ONE of the following: (a) corticosteroids, (b) immune globulin, (c) splenectomy. Refractory Severe Aplastic Anemia (RSAA)(Initial): (1) Diagnosis of refractory severe aplastic anemia. (2) Member has a platelet count less than 30,000/mcL. (3) Inadequate response or inability to tolerate immunosuppressive therapy with antithymocyte globulin and cyclosporine. Chronic Hepatitis C-Associated Thrombocytopenia (HEPC-TP): (1) Diagnosis of chronic hepatitis C-associated thrombocytopenia. (2) One of the following: (a) Planning to initiate and maintain interferon-based treatment, or (b) currently receiving interferon-based treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP, RSAA)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist. (HEPC-TP)(Initial, Continuation): Prescribed by or in consultation with Hematologist/oncologist, Gastroenterologist, Hepatologist, Infectious disease specialist, HIV specialist.
<b>Coverage Duration</b>	(ITP)(Initial):12mo (RSAA)(Initial):6mo (HEPC-TP)(Initial):3mo (ITP,RSAA,HEPC-TP)(Continuation):12mo

PA Criteria	Criteria Details
<b>Other Criteria</b>	(ITP)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. RSAA (Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. (HEPC-TP)(Continuation): (1) ONE of the following: (A) For members that started treatment with Alvaiz prior to initiation of treatment with interferon, both of the following: (i) Member is currently on antiviral interferon therapy for treatment of chronic hepatitis C, AND (ii) documentation that member reached a threshold platelet count that allows initiation of antiviral interferon therapy with Alvaiz treatment by week 9. OR (B) For members that started treatment with Alviaz while on concomitant treatment with interferon, member is currently on antiviral interferon therapy for treatment of chronic hepatitis C.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMBRISENTAN 2025

## Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AMPYRA 2025

## Products Affected

- AMPYRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS (Initial): Member has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
<b>Required Medical Information</b>	Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that member has difficulty walking. (3) Inadequate response or inability to tolerate dalfampridine (applies to brand Ampyra).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(MS) (Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(MS) (Reauth): Documentation of positive clinical response as evidenced by improvement in walking speed
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ANTICHOLINERGIC HRM 2025

## Products Affected

- *chlordiazepoxide-clidinium* mg
- LIBRAX
- *orphenadrine citrate er*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal suppository 12.5 mg, 25*
- *promethazine-phenylephrine*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	PA: 2 years
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ANTIDEPRESSANTS [SSRIS] ACH 2025

## Products Affected

- PAXIL ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Trial of three generic formulary selective serotonin reuptake inhibitors (SSRI). Applies to new starts.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PA: Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# APOKYN 2025

## Products Affected

- APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE
- *apomorphine hcl subcutaneous*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PD): Member using medication with any 5-HT3 antagonist (e.g. ondansetron, granisetron, dolasetron, palonosetron, alosetron)
<b>Required Medical Information</b>	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease, (2) Member is experiencing intermittent OFF Episodes, (3) Concomitant use of medication with other medications for the treatment of Parkinson's disease (e.g. carbidopa/levodopa, pramipexole, ropinirole, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PD): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AQNEURSA 2025

## Products Affected

- AQNEURSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Niemann-Pick disease type C (NPC): (1) Diagnosis of NPC (2) Diagnosis is confirmed by one of the following: (a) Genetically confirmed (deoxyribonucleic acid [DNA] sequence analysis) by mutations in both alleles of NPC1 or NPC2 (b) Mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane triol/oxysterols (greater than 2 x upper limit of normal) (3) Member has at least one neurological symptom of the disease (e.g., hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia) (4) Member weighs greater than or equal to 15kg (5) Requested drug will NOT be used in combination with Miplyffa (arimoclomol)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a specialist knowledgeable in the treatment of Niemann-Pick disease type C
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(NPC)(Reauth)(1) Member demonstrates positive clinical response to therapy (2) Requested drug will NOT be used in combination with Miplyffa (arimoclomol)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARIKAYCE 2025

## Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(MAC): (1) Diagnosis of Mycobacterium avium complex (MAC) lung disease (2) Medication is being used as part of a combination antibacterial drug regimen (3) Used in patients who have not achieved at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
Age Restrictions	Member is 18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or an infectious disease specialist
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ARMODAFINIL 2025

## Products Affected

- *armodafinil*
- NUVIGIL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>NARCOLEPSY: (1) Diagnosis of Narcolepsy confirmed by a sleep study (unless prescriber provides justification that a sleep study is not feasible).</p> <p>OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). (2) Both of the following (a): 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study is not feasible) AND (b) One of the following symptoms: Unintentional sleep episodes during wakefulness, or daytime sleepiness, or unrefreshing sleep, or fatigue, or insomnia, or waking up breath holding, gasping, or choking, or loud snoring, or breathing interruptions during sleep. SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no other medical or mental disorder accounting for the symptoms.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ATTRUBY 2025

## Products Affected

- ATTRUBY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Used in combination with a TTR silencer (e.g., Amvuttra) or a TTR stabilizer (e.g., Vyndaqel, Vyndamax)
<b>Required Medical Information</b>	Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR- CM)(Initial): (1) Submission of medical records (e.g. chart notes) confirming diagnosis of ATTR-CM confirmed by one of the following: (a) Member has a transthyretin (TTR) mutation (e.g. V122I), (b) cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, or (c) all of the following: echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, scintigraphy scan suggestive of cardiac TTR amyloidosis, and absence of light-chain amyloidosis, (2) One of the following: (a) History of heart failure (HF), with at least one prior hospitalization for HF, or (b) presence of clinical signs and symptoms of HF (e.g. dyspnea, edema), (c) Member has New York Heart Association (NYHA) Functional Class I, II, or III heart failure
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	(ATTR-CM)(Reauth): (1) Positive clinical response to therapy, (2) Member continues to have NYHA Functional Class I, II, or III heart failure.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AUSTEDO 2025

## Products Affected

- AUSTEDO & 18 & 24 & 30 MG
- AUSTEDO XR
- AUSTEDO XR PATIENT TITRATION ORAL  
TABLET EXTENDED RELEASE THERAPY PACK 12

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Chorea-Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Continuation): Prescribed by or in consultation with a neurologist or a psychiatrist.
<b>Coverage Duration</b>	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (CHD): Indefinite.
<b>Other Criteria</b>	(TD)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUTHORIZED GENERICS-AUTHORIZED BRAND ALTERNATIVES 2025

## Products Affected

- *dapagliflozin pro-metformin er* 25 mcg/act
- *dapagliflozin propanediol* • *fluticasone-salmeterol inhalation aerosol*
- *fluticasone furoate-vilanterol inhalation aerosol* • *mirabegron er*  
powder breath activated 100-25 mcg/act, 200-

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) At least 3 months of use of the brand product within the previous 365 days (document drug, duration, dose and date of use) (2) Both of the following: (a) Documentation provided stating that brand product has not been effective (b) Justification provided for why the target drug is expected to provide benefit when the brand product has not been shown to be effective. (3) One of the following: Requested drug is FDA-approved for the condition being treated OR if requested for an off-label indication, the off-label guideline approval criteria have been met
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until end of the contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUVELITY 2025

---

## Products Affected

- AUVELITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Major Depressive Disorder (MDD): (1) Diagnosis of major depressive disorder (MDD) (2) Inadequate response or inability to tolerate two formulary antidepressants indicated for MDD (e.g. bupropion, venlafaxine extended-release tablet or capsule, sertraline tablet, etc.)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(MDD): Approve if for continuation of therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# BENLYSTA SC 2025

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when the following are met: Systemic Lupus Erythematosus (SLE): (1) Diagnosis of active, autoantibody-positive SLE. (2) Member is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDS). Lupus Nephritis (LN): (1) Diagnosis of active lupus nephritis confirmed by kidney biopsy. (2) Member is receiving concurrent standard therapy (e.g. corticosteroids, immunosuppressants, azathioprine).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SLE): Prescribed by or in consultation with a rheumatologist. (LN): Prescribed by or in consultation with a nephrologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BESREMI 2025

## Products Affected

- BESREMI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BIMZELX 2025

## Products Affected

- BIMZELX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	<p>Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla, OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of active PsA (2) One of the following: (a) Actively inflamed joints (b) Dactylitis (c) Enthesitis (d) Axial disease (e) Active skin and/or nail involvement (3) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Ustekinumab (i.e. Yesintek), (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Non-radiographic axial spondyloarthritis (nr-axSpA): (1) Diagnosis of active nr-axSpA (2) Member has objective signs of inflammation (e.g., C-reactive protein [CRP] levels above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging [MRI], indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints) (3) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (4) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen). Ankylosing Spondylitis (AS): (1) Diagnosis of active AS. (2) Inadequate response or inability to tolerate two of the following: (a) Cosentyx, (b) Adalimumab (i.e., Humira, Adalimumab-ADB, Adalimumab-AACF), (c) Enbrel, (d) Xeljanz/Xeljanz XR, (e) Rinvoq or documentation demonstrating that a trial may be inappropriate.</p>
<b>Age Restrictions</b>	(PsO, PsA, nr-axSpA, AS, HS): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO, PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (nr-axSpA, AS): Prescribed by or in consultation with a rheumatologist. (HS): Prescribed by or in consultation with a dermatologist

PA Criteria	Criteria Details
<b>Coverage Duration</b>	(PsO, PsA, nr-axSpA, AS): Indefinite (HS)(Initial): 6 months (HS)(Reauth): 12 months
<b>Other Criteria</b>	Hidradenitis Suppurativa (HS)(Initial): (1) Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III) (2) Inadequate response or inability to tolerate two of the following: (i) Cosentyx SC (secukinumab) (ii) Adalimumab [i.e. Humira (Abbvie manufacturer), adalimumab ADBM, adalimumab AACF] or documentation demonstrating that a trial may be inappropriate. (HS)(Reauth): Member demonstrates positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BRAND ANTIPSYCHOTICS ACH 2025

---

## Products Affected

- LYBALVI
- ZYPREXA ORAL TABLET 20 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Trial of two generic formulary antipsychotics. Applies to new starts.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PA: Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# BYLVAY 2025

## Products Affected

- BYLVAY
- BYLVAY (PELLETS)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pruritus associated with progressive familial intrahepatic cholestasis (Pruritus with PFIC) (Initial): (1) Diagnosis of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), (2) Confirmed molecular diagnosis of PFIC type 1, 2, or 3, (3) Prescribed dose is consistent with FDA-approved package labeling and does not exceed a total daily dose of 6mg (4) An inadequate response or inability to tolerate at least ONE of the following treatments used for the relief of pruritus: (a) Ursodeoxycholic acid (e.g. Ursodiol) (b) Antihistamines (e.g. diphenhydramine, hydroxyzine) (c) Rifampin (d) Bile acid sequestrants (e.g. Questran, Colestid, Welchol). Cholestatic Pruritus with Alagille Syndrome (CPALGS) (Initial): (1) Diagnosis of Alagille Syndrome. (2) Molecular genetic testing confirms mutations in the JAG1 or NOTCH2 gene (3) Member is experiencing both of the following: (a) moderate to severe cholestatic pruritus (b) member has a serum bile acid concentrations above the upper limit of the normal reference for the reporting laboratory (4) An inadequate response or inability to tolerate at least two of the following treatments used for the relief of pruritus: (a) Ursodeoxycholic acid (e.g. Ursodiol) (b) Antihistamines (e.g. diphenhydramine, hydroxyzine) (c) Rifampin (d) Bile acid sequestrants (e.g. Questran, Colestid, Welchol).
<b>Age Restrictions</b>	(Pruritus with PFIC) (Initial, Reauth): Member is 3 months of age or older (CPALGS)(Initial, Reauth): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(Pruritus with PFIC)(CPALGS)(Initial, Reauth): Prescribed by or in consultation with a hepatologist or gastroenterologist
<b>Coverage Duration</b>	(PPFIC, CPALGS)(Initial): 6mo (PPFIC)(Reauth): Indefinite (CPALGS)(Reauth): End of contract year
<b>Other Criteria</b>	(Pruritus with PFIC) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. improvement in pruritus symptoms), (2) Prescribed dose is consistent with FDA-approved package labeling and does not exceed a total daily dose of 6mg. (CPALGS) (Reauth): Positive clinical response to therapy (e.g. reduced bile acids, reduction in pruritis symptoms or ItchRO pruritis score).

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# CAMZYOS 2025

## Products Affected

- CAMZYOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Obstructive hypertrophic cardiomyopathy (HCM) (1) Diagnosis of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). (2) Member's baseline left ventricular ejection fraction (LVEF) is greater than or equal to 55%. (3) Documentation of Valsalva left ventricular outflow tract (LVOT) gradient assessment at baseline. (4) Inadequate response or inability to tolerate one of the following: (a) one non-vasodilating beta-blocker (e.g. bisoprolol, propranolol), (b) one calcium-channel blocker (e.g. diltiazem, verapamil)
<b>Age Restrictions</b>	(HCM) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(HCM) (Initial, Reauth): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): 12 months
<b>Other Criteria</b>	(HCM) (Reauth): (1) Documentation of improvement in functional capacity and symptoms. (2) Member's left ventricular ejection fraction (LVEF) is greater than or equal to 50%. (3) Member does not have worsening heart failure symptoms.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CAPLYTA 2025

## Products Affected

- CAPLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate two generic antipsychotic products (e.g. aripiprazole, olanzapine, quetiapine, paliperidone). Bipolar Depression (BD): (1) Diagnosis of bipolar depression (2) Medication will be used as monotherapy or as adjunctive therapy with lithium or valproate (3) Inadequate response or inability to tolerate two medications indicated for bipolar depression (e.g. fluoxetine, Latuda, quetiapine, olanzapine)
<b>Age Restrictions</b>	(Schizophrenia, BP): member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Schizophrenia, BP): Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CARBAGLU 2025

## Products Affected

- CARBAGLU ORAL TABLET SOLUBLE
- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hyperammonemia Type III (HTIII): (1) Hyperammonemia due to the deficiency of the hepatic enzyme N-acetyl glutamate synthase (NAGS). Acute Hyperammonemia due to Propionic Acidemia or Methylmalonic Acidemia (AH): (1) Hyperammonemia due to propionic acidemia or methylmalonic acidemia.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a provider who specializes in the treatment of metabolic disorders
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CAYSTON 2025

## Products Affected

- CAYSTON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of CF. (2) Evidence of Pseudomonas Aeruginosa in the lungs. (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam. (4) FEV1 between 25% and 75% of predicted
<b>Age Restrictions</b>	(CF): Member is 7 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist OR infectious disease specialist or Specialist affiliated with a CF care center.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Reauth: (1) Evidence of Pseudomonas aeruginosa in the lungs (2) Documentation of positive clinical response to therapy (e.g. improvement in lung function demonstrated by improved FEV1)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CERDELGA 2025

---

## Products Affected

- CERDELGA

PA Criteria	Criteria Details
Exclusion Criteria	(GD): Member is CYP2D6 Ultra Rapid Metabolizer (URM)
Required Medical Information	Gaucher disease (GD): (1) Diagnosis of Type 1 Gaucher disease and member is CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) as detected by an FDA-cleared test for determining CYP2D6 genotype.
Age Restrictions	(GD): Member is 18 years of age or older
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# CHOLBAM 2025

## Products Affected

- CHOLBAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(BASD, PD)(Initial, Reauth): Extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorders
<b>Required Medical Information</b>	Bile Acid Synthesis Disorder (BASD) (initial): (1) Diagnosis of bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorder (PD) (initial): (1) Diagnosis of peroxisomal disorder. (2) Used as adjunctive treatment. (3) Member exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(BASD, PD): Hepatologist, Gastroenterologist, Medical geneticist, other specialist that treats inborn errors of metabolism
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): Indefinite
<b>Other Criteria</b>	(BASD,PD) (Reauth): Documentation of improved liver function tests from the start of treatment.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CIALIS 2025

---

## Products Affected

- CIALIS ORAL TABLET 5 MG
- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	(BPH): Concurrent use of nitrates.
Required Medical Information	Benign prostatic hyperplasia (BPH): (1) Diagnosis of BPH. (2) Inadequate response or inability to tolerate an alpha blocker (e.g. tamsulosin, terazosin) or a 5-alpha reductase inhibitor (e.g. dutasteride, finasteride).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# CIBINQO 2025

## Products Affected

- CIBINQO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AD): Concurrent use with any other biologic immunomodulator, Janus Kinase (JAK) inhibitors, or other immunosuppressants (e.g. azathioprine, cyclosporine)
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of refractory, moderate to severe AD (2) Inadequate response or inability to tolerate one systemic drug product, including biologics (e.g. Dupixent, methylprednisolone, prednisone) or member has a contraindication, intolerance, or treatment is inadvisable with both of the following FDA-approved atopic dermatitis therapies: Adbry (tralokinumab-ldrm) AND Dupixent (dupilumab) or documentation that a trial may be inappropriate.
<b>Age Restrictions</b>	(AD): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIMZIA 2025

## Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AS, PsA, PsO, RA, CD, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) secukinumab (Cosentyx), (b) Adalimumab (i.e., Humira, Adalimumab-ADB, Adalimumab-AACF), (c) etanercept (Enbrel), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq), or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Ustekinumab (i.e. Yesintek), (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate. Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e., Humira, Adalimumab-ADB, Adalimumab-AACF), (b) ustekinumab (i.e. Yesintek) , (c) risankizumab (Skyrizi), (d) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(AS, PsA, PsO, RA, CD, nr-axSpA): Member is 18 years of age or older. (PJIA): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(CD): Prescribed by or in consultation with a gastroenterologist. (RA, AS, nr-axSpA, PJIA): Prescribed by or in consultation with a rheumatologist. (PsA, PsO): prescribed by or in consultation with a dermatologist or rheumatologist.

PA Criteria	Criteria Details
Coverage Duration	Indefinite
Other Criteria	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA (2) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen). Polyarticular juvenile idiopathic arthritis (PJIA): Diagnosis of active PJIA. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e., Humira, Adalimumab-ADBM, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ, or documentation demonstrating that a trial may be inappropriate.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# CINRYZE 2025

## Products Affected

- CINRYZE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when: Hereditary Angioedema (HAE): (1) Diagnosis of hereditary angioedema (HAE) (2) For prophylaxis against HAE attacks.
<b>Age Restrictions</b>	(HAE): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COBENFY 2025

## Products Affected

- COBENFY
- COBENFY STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate TWO of the following atypical antipsychotic agents: aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, ziprasidone
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	(Schizophrenia): Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# COMBINATION NSAID PRODUCTS 2025

## Products Affected

- *ibuprofen-famotidine*
- *naproxen-esomeprazole mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(All Indications)(Initial): An inadequate response or inability to tolerate a two-week trial of BOTH of the following: (1) Concurrent administration of each of the components of the requested product, and (2) At least ONE generic alternative (when available) of each of the individual components of the requested product.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(All Indication) (Initial, Reauth): 1 year
<b>Other Criteria</b>	(All Indications)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CORLANOR 2025

## Products Affected

- CORLANOR
- *ivabradine hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Chronic Heart Failure (CHF): (1)Diagnosis of chronic heart failure. (2) stable, symptomatic chronic heart failure (3) left ventricular ejection fraction less than or equal to 35% and (4) sinus rhythm with resting heart rate greater than or equal to 70 beats per minute. (5) Member is clinically stable for at least 4 weeks on an optimized regimen which includes 2 of the following therapies: (a) maximally tolerated doses of beta blockers or inability to tolerate beta blockers, (b) ACE inhibitors or ARBs or inability to tolerate ACE inhibitor or ARB. (c) maximally tolerated doses of Sodium-glucose co-transporter 2 (SGLT2) inhibitor [e.g. Jardiance (empagliflozin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin and metformin)] (d) maximally tolerated doses of mineralocorticoid receptor antagonist (MRA) [e.g. eplerenone, spironolactone]</p> <p>Chronic Heart Failure due to Dilated Cardiomyopathy in pediatric patients ages 6 months and older (CHF-DC): (1) Diagnosis of chronic heart failure due to dilated cardiomyopathy (2) Member is in sinus rhythm with an elevated heart rate.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHF, CHF-DC): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# COSENTYX SQ 2025

## Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsA, PsO, AS, nr-axSpA, ERA, HS): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe plaque psoriasis. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA, (2) Inadequate response or inability to tolerate two NSAIDs. Active Enthesitis-related Arthritis (ERA): (1) Diagnosis of active enthesitis-related arthritis (ERA), (2) Inadequate response or inability to tolerate methotrexate, (3) Inadequate response or inability to tolerate at least one NSAID (e.g. ibuprofen, naproxen, meloxicam, celecoxib) Hidradenitis Suppurativa (HS): (1) Diagnosis of HS.
<b>Age Restrictions</b>	(AS, nr-axSpA, HS): Member is 18 years of age or older. (PsO): Member is 6 years of age or older (PsA): Member is 2 years of age or older. (ERA): Member is 4 years of age or older.
<b>Prescriber Restrictions</b>	(PsO, HS): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AS, nr-axSpA, ERA): Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CRENESSITY 2025

## Products Affected

- CRENESSITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Congenital Adrenal Hyperplasia (CAH)(Initial): (1) Submission of medical records confirming diagnosis of classic 21- hydroxylase deficiency congenital adrenal hyperplasia (2) Member is receiving chronic treatment with glucocorticoid (GC) replacement therapy (e.g., hydrocortisone, methylprednisolone) for adrenal insufficiency as ONE of the following: (a) For members 4 to 17 years old, daily GC dose is greater than 12 mg/m <sup>2</sup> /day in hydrocortisone dose equivalents (b) for members 18 years of age or older, daily GC dose is greater than 13 mg/m <sup>2</sup> /day in hydrocortisone dose equivalents
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(CAH)(Reauth): (1) Member demonstrates positive clinical response to therapy (e.g., lowered androgen levels, reduced daily dose of steroids) (2) Member continues to receive chronic treatment with glucocorticoid (GC) replacement therapy (e.g., hydrocortisone, methylprednisolone)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CRESEMBA [ORAL] 2025

## Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Invasive Aspergillosis (IA): (1) For use in the treatment of invasive aspergillosis after inadequate response or inability to tolerate Voriconazole (oral Vfend). Mucormycosis (MC): (1) Diagnosis of invasive mucormycosis
<b>Age Restrictions</b>	(IA, MC): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(All Indications): Prescribed by or in consultation with an infectious disease specialist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CREXONT 2025

## Products Affected

- CREXONT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial) (1) One of the following diagnoses: (A) Parkinson's disease (B) Post-encephalitic parkinsonism (C) Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication (2) Inadequate response or inability to tolerate BOTH of the following: (A) Generic carbidopa-levodopa immediate release or Generic carbidopa-levodopa extended release (B) Rytary
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial)(Reauth): 12 months
<b>Other Criteria</b>	(Reauth) (1) Member demonstrates positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CYSTEAMINE PRODUCTS 2025

## Products Affected

- CYSTADROPS
- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystinosis: (1) Diagnosis of cystinosis, (2) Member has corneal cystine crystal accumulation
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or a specialist with experience in treating cystinosis with corneal cystine crystal accumulation
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# DALFAMPRIDINE 2025

## Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS (Initial): Member has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
<b>Required Medical Information</b>	Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that member has difficulty walking.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(MS) (Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(MS) (Reauth): Documentation of positive clinical response as evidenced by improvement in walking speed
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DAYBUE 2025

## Products Affected

- DAYBUE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Rett syndrome (RS)(Initial): (1) Diagnosis of Rett syndrome (2) One of the following: (a) Presence of all of the following clinical signs and symptoms: (i) a pattern of development, regression, then recovery or stabilization (ii) partial or complete loss of purposeful hand skills such as grasping with fingers, reaching for things, or touching things on purpose (iii) partial or complete loss of spoken language (iv) repetitive hand movements, such as wringing the hands, washing, squeezing, clapping, or rubbing (v) gait abnormalities, including walking on toes or with an unsteady, wide-based, stiff-legged gait (b) Molecular genetic testing confirms mutations in the MECP2 gene
<b>Age Restrictions</b>	(RS)(Initial)(Reauth): member is 2 years of age or older
<b>Prescriber Restrictions</b>	(RS)(Initial)(Reauth): Prescribed by or in consultation with one of the following specialists: geneticist, pediatrician, neurologist
<b>Coverage Duration</b>	(Initial)(Reauth): 12 months
<b>Other Criteria</b>	(RS)(Reauth): (1) Documentation of positive clinical response to therapy as evidenced by an improvement in clinical signs and symptoms from baseline (e.g. hand behavior, walking/standing, speech, quality of life)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DAYVIGO 2025

## Products Affected

- DAYVIGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Insomnia: (1) Diagnosis of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. (2) Inadequate response or inability to tolerate generic ramelteon (Rozerem) AND Belsomra (suvorexant).
Age Restrictions	(Insomnia): Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# DEFERASIROX 2025

## Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*
- EXJADE
- JADENU
- JADENU SPRINKLE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(NTDT, CIO-BT)(Initial, Continuation): GFR is less than 40mL/min/1.73m, platelet counts less than 50,000/mcL
<b>Required Medical Information</b>	Chronic Iron Overload in Non transfusion-dependent thalassemia (NTDT) (Initial): (1) Diagnosis of Chronic iron overload in Non transfusion-dependent thalassemia syndromes,(2) liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw), (3) serum ferritin greater than 300 mcg/L. (4) Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months). Chronic Iron Overload Caused by Blood Transfusions (CIO-BT)(Initial): (1) Diagnosis of chronic iron overload caused by blood transfusions (transfusional hemosiderosis). (2) Serum ferritin levels consistently greater than 1,000 mcg/L (as demonstrated with at least two lab values within the previous two months).
<b>Age Restrictions</b>	(NTDT)(Initial, Continuation): Member is 10 years of age or older. (CIO-BT) (Initial, Continuation): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial):3 months. (Continuation): 6 months
<b>Other Criteria</b>	(CIO-BT)(Continuation): (1) Decreased serum ferritin level compared with the baseline level for transfusion- dependent anemia. (NTDT)(Continuation): (1) Decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DIACOMIT 2025

## Products Affected

- DIACOMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet syndrome (DS): (1) Diagnosis of seizures associated with Dravet syndrome (DS), (2) Used in combination with clobazam.
<b>Age Restrictions</b>	Member is 6 months of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DICHLORPHENAMIDE 2025

## Products Affected

- KEVEYIS
- ORMALVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial, Reauth): Concomitant use of high dose Aspirin, severe pulmonary disease and hepatic insufficiency
<b>Required Medical Information</b>	One of the following (1) Diagnosis of Primary hyperkalemic periodic paralysis, (2) Diagnosis of Primary hypokalemic periodic paralysis (3) Diagnosis of Paramyotonia Congenita with periodic paralysis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial): 3 months (Reauth): Indefinite
<b>Other Criteria</b>	(Reauth): Member has had a positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DICLOFENAC 3% PRODUCTS 2025

## Products Affected

- *diclofenac sodium external gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Actinic Keratoses: (1) Diagnosis of Actinic Keratoses
Age Restrictions	Actinic Keratoses: Member is 18 years of age or older
Prescriber Restrictions	
Coverage Duration	90 days
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# DICLOFENAC EPOLAMINE 2025

## Products Affected

- *diclofenac epolamine external*
- FLECTOR EXTERNAL
- LICART EXTERNAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
<b>Required Medical Information</b>	(1): Inadequate response or inability to tolerate at least 2 prescription strength topical NSAIDs (i.e. Diclofenac Gel 1%, Diclofenac Topical Solution 1.5%)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DOJOLVI 2025

## Products Affected

- DOJOLVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD): (1) Diagnosis of molecularly confirmed LC-FAOD, (2) Will be used as a source of calories and fatty acids (3) Not used with any other medium-chain triglyceride (MCT) product (4) Disease has been confirmed by at least two of the following: Disease specific elevation of acyl-carnitines on a newborn blood spot or in plasma, Low enzyme activity in cultured fibroblasts, one or more known pathogenic mutations in CPT2, ACADVL, HADHA, or HADHB
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g. geneticist, cardiologist, gastroenterologist, etc.)
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DOPTELET 2025

## Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Liver Disease (CLD): (1) Diagnosis of Chronic Liver Disease (CLD) (2) Baseline platelet count less than 50,000/mcL. Member is scheduled to undergo a procedure. Chronic Immune Thrombocytopenia (ITP)(Initial): (1) Baseline platelet count less than 30,000/mcL. (2) Inadequate response or inability to tolerate one of the following: (a) corticosteroids (b) immunoglobulins (c) splenectomy (d) Rituxan (rituximab)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist
<b>Coverage Duration</b>	(CLD): 1 month. (ITP): 12 months
<b>Other Criteria</b>	(ITP)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	Yes

# DUPIXENT 2025

## Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO- MG/2ML  
INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 200 MG/1.14ML, 300

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic agents
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of moderate-severe atopic dermatitis. (2) inadequate response or inability to tolerate ONE of the following: (a) one topical steroid (medium potency or higher), (b) topical tacrolimus, (c) topical pimecrolimus, (d) topical eucrisa (crisaborole). Asthma (Initial): (1) ONE of the following: (a) Member has oral corticosteroid-dependent asthma or (b) Member has blood eosinophil levels of at least 150 cells/mcL at baseline or at least 300 cells/mcL within the past 12 months, (2) ONE of the following: (a) Member has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or (b) Any prior intubation for asthma exacerbation, or (c) prior asthma-related hospitalization within the past 12 months, (3) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. Chronic Rhinosinusitis with Nasal Polyposis(CRSwNP)(Initial): (1) Diagnosis of chronic rhinosinusitis with nasal polyposis, (2) concurrent use of intranasal corticosteroid. Eosinophilic esophagitis (EoE)(Initial): (1) Diagnosis of eosinophilic esophagitis (EoE) (2) Member has symptoms of esophageal dysfunction (e.g. dysphagia, food impaction, gastroesophageal reflux disease [GERD]/heartburn symptoms, chest pain, abdominal pain (3) Member has at least 15 intraepithelial eosinophils per high power (HPF) (4) Other causes of esophageal eosinophilia have been excluded (5) Member weighs at least 15 kg (b) (6) Inadequate response or inability to tolerate at least an 8-week trial of one of the following: (a) proton pump inhibitors (e.g. pantoprazole, omeprazole (b) Topical (esophageal) corticosteroids (e.g. budesonide, fluticasone).
<b>Age Restrictions</b>	(Asthma)(Initial, Reauth): Member is 6 years old or older. (AD): Member is 6 months of age or older. (CRSwNP)(Initial, Reauth): Member is 12 years of age or older PN)(COPD)(Initial, Reauth): Member is 18 years of age or older (EoE)(Initial, Reauth): Member is 1 year of age or older



PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(Initial/Reauth) Prescribed by/in consultation with: (AD): Dermatologist, allergist, or immunologist (Asthma)(COPD): Allergist, immunologist or pulmonologist (CRSwNP): Allergist, immunologist or ENT specialist (EoE): Gastroenterologist, allergist, or immunologist (PN): Allergist/immunologist or dermatologist
<b>Coverage Duration</b>	(AD): Indefinite (Asthma, CRSwNP, EoE, PN, COPD): 12 months
<b>Other Criteria</b>	<p>Prurigo Nodularis (PN)(Initial): (1) Diagnosis of Prurigo Nodularis (PN) (2) inadequate response or inability to tolerate one medium or higher potency topical corticosteroid. Chronic obstructive pulmonary disease (COPD)(Initial): (1) Diagnosis of COPD (2) Presence of Type 2 inflammation evidenced by blood eosinophils greater than or equal to 300 cells/mcL at baseline (3) Member is receiving ONE of the following therapies for at least 3 months: (a) Triple therapy (i.e., an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA) (b) If ICS are contraindicated, a LAMA and a LABA (4) Member has had ONE of the following within the past 12 months: (a) At least two exacerbations where systemic corticosteroids [intramuscular, intravenous, or oral (e.g., prednisone)] were required at least once (b) COPD-related hospitalization (5) Member experiences dyspnea during everyday activities (e.g., needs to stop for breath when walking on level ground) (Asthma)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications) (2) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. (CRSwNP) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction of nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NC: 0-3 scale]), (2) Used in combination with another agent for CRSwNP. (EoE)(Reauth): (1) Documentation of a positive clinical response to therapy as evidenced by improvement of at least one of the following from baseline: (a)Symptoms (e.g. dysphagia, food impaction, heartburn, chest pain), (b) Histologic measures (e.g. esophageal intraepithelial eosinophil count), (c) Endoscopic measures (e.g. edema, furrows, exudates, rings, strictures). (PN)(Reauth): (1) Documentation of a positive clinical response to therapy (e.g. reduction in the number of nodular lesions from baseline, or improvement in symptoms from baseline) (COPD)(Reauth): (1) Member demonstrates a positive clinical response to therapy (e.g., improved lung function, a reduction in COPD exacerbations) (2) Member continues to receive ONE of the following therapies: (a) Triple therapy (i.e., an inhaled corticosteroid (ICS), a long-acting</p>

PA Criteria	Criteria Details
	muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA) (b) If ICS are contraindicated, a LAMA and a LABA
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DUVYZAT 2025

## Products Affected

- DUVYZAT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Duchenne muscular dystrophy (DMD) (Initial): (1) Diagnosis of Duchenne muscular dystrophy (DMD) (2) Diagnosis confirmed by ONE of the following: (a) Mutation of the dystrophin gene (b) Absence of the dystrophin protein confirmed by muscle biopsy (3) Member is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.) prior to initiating Duvyzat (4) Duvyzat will be used concomitantly with a corticosteroid regimen
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(DMD) (Initial) (Reauth): Prescribed by or in consultation with a neurologist who has experience treating children with Duchenne Muscular Dystrophy (DMD)
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(DMD) (Reauth): (1) Member has experienced a benefit from therapy (e.g., improvement in preservation of muscle strength) (2) Member is maintaining ambulatory status without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.) (3) Member continues to receive concomitant corticosteroid regimen.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EBGLYSS 2025

## Products Affected

- EBGLYSS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD)(Initial) (1) Diagnosis of moderate to severe atopic dermatitis (2) ONE of the following: (a) Involvement of at least 10% body surface area (BSA) (b) SCORing Atopic Dermatitis (SCORAD) index value of at least 25. (3) Member weighs at least 40 kg. (4) Inadequate response or inability to tolerate TWO of the following: (a) Adbry (tralokinumab-ldrm), (b) Dupixent (dupilumab) (c) Rinvoq (upadacitinib).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an Allergist/Immunologist or Dermatologist
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(Reauth) Member demonstrates positive clinical response to therapy as evidenced by at least ONE of the following: (a) Reduction in body surface area involvement from baseline (b) Reduction in SCORing Atopic Dermatitis (SCORAD) index value from baseline
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EGRIFTA 2025

## Products Affected

- EGRIFTA SV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(HIV-L): (1) hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, or head irradiation or trauma, (2) hypersensitivity to tesamorelin and/or mannitol, (3) malignancy, active (either newly diagnosed or recurrent) malignancies should be inactive and completely treated prior to initiating therapy, (4) pregnancy.
<b>Required Medical Information</b>	HIV-Associated Lipodystrophy (HIV-L): (1) Diagnosis of HIV-associated lipodystrophy, (2) one of the following: (a) waist-circumference of greater than or equal to 95 cm (37.4 inches) in men, OR (b) waist-circumference of greater than or equal to 94 cm (37 inches) for women, (3) one of the following: (a) Waist-to-hip ratio of greater than or equal to 0.94 for men, OR (b) waist-to-hip ratio of greater than or equal to 0.88 for women, (4) body mass index (BMI) greater than 20 kg/m <sup>2</sup> , (5) fasting blood glucose (FBG) levels less than or equal to 150 mg/dL (8.33 mmol/L), (6) Member has been on a stable regimen of antiretrovirals (e.g. NRTIs, NNRTI, Protease Inhibitors, Integrase Inhibitors) for at least 8 weeks.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HIV-L): Prescribed by or in consultation with HIV-infection specialist OR endocrinologist.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EMFLAZA 2025

## Products Affected

- *deflazacort*
- EMFLAZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Duchenne Muscular Dystrophy (DMD): (1) Diagnosis of Duchenne Muscular Dystrophy (DMD) (2) Diagnosis confirmed by ONE of the following: (a) Mutation of the dystrophin gene (b) Absence of the dystrophin protein confirmed by muscle biopsy (3) Inadequate response or inability to tolerate prednisone or prednisolone
<b>Age Restrictions</b>	(DMD): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(DMD): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EMGALITY 2025

## Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of or contraindication to TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e) SNRI antidepressants: venlafaxine, duloxetine. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of or contraindication to TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v) SNRI antidepressants: venlafaxine, duloxetine (vi) candesartan. Episodic Cluster Headaches (ECH) (Initial): (1) Diagnosis of episodic cluster headache, (2) Member has experienced at least 2 cluster periods lasting 6 days to 365 days, separated by pain-free periods lasting at least three months
<b>Age Restrictions</b>	(Migraine, ECH)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraine, ECH)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, pain specialist
<b>Coverage Duration</b>	(Migraine, ECH)(Initial): 6 months, (Migraine, ECH)(Reauth): 12 months
<b>Other Criteria</b>	(Migraine)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity). (ECH)(REAUTH): (1) Response to therapy as defined by a reduction in weekly cluster headache attacks.
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No



# EMSAM 2025

## Products Affected

- EMSAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Major depressive disorder (MDD): (1) Diagnosis of major depressive disorder. (2) Inadequate response or inability to tolerate ONE SSRI or SNRI. (3) 4-5 half-lives (approximately 1 week) has elapsed after discontinuation of antidepressants without long half-lives OR at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives (e.g. fluoxetine).
<b>Age Restrictions</b>	(MDD): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENBREL 2025

## Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED
- SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, PJIA, PsO, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine). Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of moderate to severe PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Leflunomide, Sulfasalazine. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO. Ankylosing Spondylitis (AS): (1) Diagnosis of AS, (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate.
<b>Age Restrictions</b>	(PJIA, PsA): Member is 2 years of age or older. (RA, AS): Member is 18 years of age or older. (PsO): Member is 4 years of age or older
<b>Prescriber Restrictions</b>	(RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (PsO): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENDARI 2025

## Products Affected

- ENDARI
- *l-glutamine oral packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Sickle Cell Disease (SCD)(Initial): (1) One of the following: (A) Member is using Endari with concurrent hydroxyurea therapy, OR (B) Member has an inadequate response or inability to tolerate hydroxyurea. (2) Member has had 2 or more painful sickle cell crises within the past 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SCD)(Initial, Reauth): Prescribed by or in consultation with a hematologist or oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(Reauth): Documentation of positive clinical response to therapy (e.g. reduction in the number of sickle cell crises)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENSPRYNG 2025

## Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Neuromyelitis Optica Spectrum Disorder (NMOSD)(Initial): (1) Diagnosis of NMSOD, (2) Member is anti-aquaporin-4 (AQP4) antibody positive.
Age Restrictions	
Prescriber Restrictions	(NMOSD)(Initial, Reauth): Prescribed by or in consultation with a neurologist or ophthalmologist
Coverage Duration	(Initial, Reauth): 12 months
Other Criteria	(NMOSD)(Reauth): Positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ENTYVIO SQ 2025

## Products Affected

- ENTYVIO PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(UC, CD): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ulcerative Colitis (UC): (1) Diagnosis of moderately to severely active Ulcerative Colitis (2) One of the following: (A) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADBM, Adalimumab-AACF), (b) ustekinumab (i.e. Yesintek), (c) upadacitinib (Rinvoq), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) risankizumab (Skyrizi) OR documentation demonstrating that a trial may be inappropriate. (B) One of the following: (a) Medication will be used as a maintenance dose following two doses of Entyvio IV for induction (b) Member is currently established on Entyvio IV. Crohn's Disease (CD): (1) Diagnosis of moderately to severely active CD (2) One of the following: (A) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, adalimumab-adbm, Adalimumab-AACF), (b) Ustekinumab (i.e. Yesintek), (c) Skyrizi, (d) Rinvoq or documentation demonstrating that a trial may be inappropriate. (B) One of the following: (a) Medication will be used as a maintenance dose following two doses of Entyvio IV for induction (b) Member is currently established on Entyvio IV.
<b>Age Restrictions</b>	(UC, CD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(UC, CD): Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EPIDIOLEX 2025

## Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet Syndrome (DS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. (3) Concurrent use with additional anti-epileptic(s). Lennox-Gastaut Syndrome (LGS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid, or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. (3) Concurrent use with additional anti-epileptic(s). Tuberous Sclerosis Complex (TSC): (1) Concurrent use with additional anti-epileptic(s). (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy
<b>Age Restrictions</b>	(DS, LGS, TCS): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(DS, LGS, TCS): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EPSOLAY 2025

---

## Products Affected

- EPSOLAY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(Rosacea): (1) Diagnosis of rosacea (2) Member has inflammatory lesions (3) inadequate response or inability to tolerate one of the formulary topical products for rosacea (e.g. azelaic acid gel, metronidazole cream or gel) for sufficient duration (minimum 30-day supply)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ESBRIET 2025

## Products Affected

- ESBRIET
- *pirfenidone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IPF): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(REAUTH) (IPF): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# EUCRISA 2025

## Products Affected

- EUCRISA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Atopic Dermatitis (AD): (1) Diagnosis of mild to moderate atopic dermatitis (2) Inadequate response or inability to tolerate at least ONE of the following in patients 2 years of age or older: (a) topical tacrolimus OR topical pimecrolimus, OR (b) generic, prescription medium potency or higher topical steroid.
Age Restrictions	(AD): Member is 3 months of age or older
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# EVEKEO 2025

## Products Affected

- *amphetamine sulfate*
- EVEKEO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Attention Deficit Hyperactivity Disorder (ADHD): (1) Diagnosis of ADHD. (2) Inadequate response or inability to tolerate TWO generic stimulant products (e.g. amphetamine/dextroamphetamine, methylphenidate) Narcolepsy: (1) Diagnosis of narcolepsy.
<b>Age Restrictions</b>	(ADHD): Member is 3 years of age or older. (Narcolepsy): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of Contract Year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EVENITY 2025

## Products Affected

- EVENITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary for: Post Menopausal Osteoporosis (PMO): (1) Diagnosis of PMO defined as ONE of the following: (a) Bone mineral density T-score less than or equal to -2.50 OR (b) Documented history of an osteoporotic non- collision fracture [e.g. vertebral, hip, nonvertebral]) AND (2) Member is at high risk of fracture as defined by one of the following: (a) Member has risk factors for a fracture (e.g. endocrine disorders, gastrointestinal disorders, use of medications associated with low bone mass or bone loss such as corticosteroids) OR (b) Inadequate response or inability to tolerate ONE of the following: (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs), OR (iv) Denosumab (Prolia). (3) Cumulative lifetime therapy does not exceed 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EVRYSDI 2025

## Products Affected

- EVRYSDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Spinal Muscular Atrophy (SMA)(Initial): (1) Diagnosis of SMA, (2) Member has confirmed mutations in chromosome 5q that leads to SMN protein deficiency.
Age Restrictions	
Prescriber Restrictions	(SMA)(Initial, Reauth): Prescribed by or in consultation with a neurologist
Coverage Duration	(Initial)(Reauth): 12 months
Other Criteria	(SMA)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in ability to sit without support)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# EXTENDED RELEASE METFORMIN 2025

## Products Affected

- *metformin hcl er (mod)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(DM2)(Initial, Reauth): (1) Serum creatinine levels greater than or equal to 1.5 mg/dL in males, or serum creatinine levels greater than or equal to 1.4 mg/dL in females. (2) Hepatic impairment. (3) Metabolic acidosis, including diabetic ketoacidosis. (4) Used for preventing weight gain.
<b>Required Medical Information</b>	Diabetes Mellitus Type 2 (DM2)(Initial): (1) Diagnosis of DM2. (2) Member has a HgbA1C greater than 6.5%. All Indications: (1) Inadequate response or inability to tolerate a 12 week trial of both of the following: (a) Immediate release metformin, and (b) Extended-release metformin (generic Glucophage XR)
<b>Age Restrictions</b>	(DM2 for tablets) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): End of contract year.
<b>Other Criteria</b>	(DM2)(Reauth): Member has had a positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EYSUVIS 2025

---

## Products Affected

- EYSUVIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dry Eye Disease (DED)(Initial): (1) Diagnosis of DED (2) Trial and failure for a minimum 14 days duration of therapy, contraindication, or intolerance to 0.5% loteprednol suspension
Age Restrictions	
Prescriber Restrictions	(DED)(Initial, Reauth): Prescribed by or in consultation with an ophthalmologist or optometrist.
Coverage Duration	(Initial, Reauth): 14 days
Other Criteria	(DED)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in dry eye symptoms).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# FABHALTA 2025

## Products Affected

- FABHALTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Paroxysmal Nocturnal Hemoglobinuria (PNH) (Initial): (1) Diagnosis of PNH, (2) Member's Hemoglobin (Hb) level is less than 10 g/dL despite prior eculizumab (Soliris) or ravulizumab-cwvz (Ultomiris) therapy Primary immunoglobulin A nephropathy (IgAN)(Initial)(1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) (2) Member is at risk of rapid disease progression (3) Used to reduce proteinuria (4) Member has an estimated glomerular filtration rate (eGFR) of greater than or equal to 20 mL/min/1.73 m <sup>2</sup> (5) An inadequate response or inability to tolerate a minimum 90-day trial of a maximally tolerated dose of one of the following (a) An angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril) (b) An angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PNH) Prescribed by or in consultation with hematologist/oncologist (IgAN) Prescribed by or in consultation with a nephrologist
<b>Coverage Duration</b>	(PNH) (Initial): 6 months, (Cont): 12 months (IgAN) (Initial)(Cont): 12 months
<b>Other Criteria</b>	(PNH) (Continuation): (1) Positive clinical response to therapy (e.g. improvement in hemoglobin level, hemoglobin stabilization, decrease in the number of red blood cell transfusions). (IgAN) (Continuation): (1) Member demonstrates a positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FASENRA 2025

## Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic agents for asthma/allergic conditions (e.g. dupilumab [Dupixent], mepolizumab [Nucala], omalizumab [Xolair], reslizumab [Cinqair])
<b>Required Medical Information</b>	Part D is medically necessary when there is a documentation of the following: Severe Asthma (SA)(Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by ONE of the following at initiation of therapy (a) blood eosinophil levels are at least 150 cells/microliter if dependent on daily oral corticosteroids or (b) blood eosinophil levels are at least 300 cells/microliter AND, (2) ONE of the following: (a) Member has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or (b) Any prior intubation for asthma exacerbation, or (c) prior asthma-related hospitalization within the past 12 months, AND (3) Member is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g. leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product). Eosinophilic Granulomatosis with Polyangiitis (EGPA)(Initial): (1) Diagnosis of EGPA (2) Member's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy) (3) Member is currently receiving corticosteroid therapy (e.g., prednisolone, prednisone) unless there is a contraindication or intolerance to corticosteroid therapy
<b>Age Restrictions</b>	(SA)(Initial): Member is 6 years of age or older. EGPA) (Initial, Reauth): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	(SA)(Initial): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist. (EGPA)(Initial)(Reauth): Prescribed by or in consultation with pulmonologist, Rheumatologist or allergy/immunology specialist
<b>Coverage Duration</b>	(Initial)(Reauth): 12 months



PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review (SA) (Reauth): (1) Member is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g. leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product). (2) Positive clinical response to therapy (e.g. reduction in exacerbations, decreased use of rescue medications) (EGPA) (Reauth): (1) Member demonstrates a positive clinical response to therapy (e.g. increase in remission time).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FERRIPROX 2025

## Products Affected

- *deferiprone*
- FERRIPROX ORAL SOLUTION
- FERRIPROX ORAL TABLET 1000 MG
- FERRIPROX TWICE-A-DAY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Transfusional Iron Overload (TIO): (1) Diagnosis of transfusional iron overload due to one of the following: (a) Thalassemia syndromes, (b) sickle cell disease, (c) other transfusion-dependent anemias. (2) Inadequate response or inability to tolerate current chelation therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FILSPARI 2025

## Products Affected

- FILSPARI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Immunoglobulin A nephropathy (IgAN)(Initial): (1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) (2) Member is at risk of rapid disease progression (3) Used to slow kidney function decline (4) Member has an estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.75 m <sup>2</sup> (5) Member has had an inadequate response or inability to tolerate at minimum 90-day trial of a maximally tolerated dose of one of the following (a) Angiotensin-receptor blockers (ARB) (e.g., losartan, valsartan), (b) Angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril) (6) Medication will not be used in combination with any of the following (a) Angiotensin receptor blockers, (b) Endothelin receptor antagonists (ERAs) (e.g., ambrisentan, bosentan, Opsumit), (c) Aliskiren
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IgAN)(Initial)(Continuation): Prescribed by or in consultation with a nephrologist
<b>Coverage Duration</b>	(Initial)(Continuation): 12 months
<b>Other Criteria</b>	(IgAN)(Continuation): (1) Documentation of positive clinical response to therapy from baseline as demonstrated by a decrease in urine protein-to-creatinine ration (UPCR). (2) Medication will not be used in combination with any of the following (a) Angiotensin receptor blockers, (b) Endothelin receptor antagonists (ERAs) (e.g., ambrisentan, bosentan, Opsumit), (c) Aliskiren
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FILSUVEZ 2025

## Products Affected

- FILSUVEZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(EB)(Initial): (1) Diagnosis of one of the following: (a) Dystrophic epidermolysis bullosa (DEB) (b) Junctional epidermolysis bullosa (JEB) (2) Disease is confirmed by one of the following: (a) genetic testing confirms mutation in one of the following genes: (i) for DEB, collagen type VII (COL7A1) (ii) For JEB, one of the following mutations (ITGA6, ITGB4, collagen type XVII (COL17A1), LAMA3, LAMB3, LAMC2, ITGA3, LAMA3A) (b) skin biopsy (3) Medication is being used for the treatment of wounds (4) Wounds associated with DEB or JEB are present for at least 21 days and less than 9 months old (5) Member does not have signs of infection for wound being treated (6) Member has no evidence or history of basal or squamous cell carcinoma for wound being treated (7) Member does not have history of stem cell transplant or gene therapy (i.e. Vyjuvek) for the treatment of epidermolysis bullosa
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(EB) (Initial, Reauth): Prescribed by or in consultation with a dermatologist with expertise in the treatment of epidermolysis bullosa.
<b>Coverage Duration</b>	(EB)(Initial): 3 months, (Reauth): 6 months
<b>Other Criteria</b>	(EB)(Reauth): (1) member demonstrates positive clinical response to therapy (2) Member does not have signs of infection for wound being treated (3) Member has no evidence or history of basal squamous cell carcinoma for would being treated
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FINTEPLA 2025

## Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet Syndrome (DS): Inadequate response or inability to tolerate ONE of the following: (a) clobazam, (b) valproic acid, (c) divalproex sodium, (d) topiramate. Lennox-Gastaut Syndrome (LGS): (1) Diagnosis of seizures associated with Lennox-Gastaut Syndrome (LGS) (2) Inadequate response or inability to tolerate ONE of the following: valproic acid, lamotrigine, topiramate, felbamate, clobazam.
<b>Age Restrictions</b>	(DS, LGS): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(DS, LGS): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	Indefinite.
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FIRDAPSE 2025

## Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(LEMS)(Initial, Continuation): history of seizures
<b>Required Medical Information</b>	Lambert-Eaton Myasthenic Syndrome (LEMS)(Initial): (1) Diagnosis of LEMS. (2) Neurological symptoms persist after treatment of malignancy, when malignancy is present.
<b>Age Restrictions</b>	(LEMS)(Initial, Continuation): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(LEMS)(Initial, Continuation): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	(Initial):90 Days, (Continuation): Indefinite
<b>Other Criteria</b>	(LEMS)(CONTINUATION): Positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GALAFOLD 2025

## Products Affected

- GALAFOLD

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Fabry Disease (FD)(Initial): (1) Member has amenable galactosidase alpha gene (GLA) variant based on in vitro assay data (2) Will not be used in combination with enzyme replacement therapy for FD (e.g. agalsidase beta or pegunigalsidase alfa)
<b>Age Restrictions</b>	(FD)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(FD)(Initial, Reauth): Prescribed by or in consultation with a clinical genetics specialist OR a nephrologist
<b>Coverage Duration</b>	(Initial): 6 months, (Reauth): Indefinite
<b>Other Criteria</b>	(FD)(Reauth): (1) Positive clinical response to therapy (2) Will not be used in combination with enzyme replacement therapy for FD (e.g. agalsidase beta or pegunigalsidase alfa)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GATTEX 2025

## Products Affected

- GATTEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Short Bowel Syndrome (SBS)(Initial): (1) Diagnosis of Short Bowel Syndrome, (2) individual receives parenteral support at least three times per week for at least 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SBS): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	(Initial, Reauth): 6 months
<b>Other Criteria</b>	(SBS)(REAUTH): (1)Reduction in parenteral support from baseline (prior to initiation of Gattex therapy)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# GOCOVRI 2025

## Products Affected

- GOCOVRI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dyskinesia in Parkinson's disease (DPD): (1) Diagnosis of PD (2) Member is experiencing dyskinesia. (3) Member is receiving levodopa based therapy (4) Inadequate response or inability to tolerate amantadine immediate-release. Parkinson's Disease with OFF episodes (PD with OFF episodes): (1) Diagnosis of Parkinson's disease. (2) Concurrent use of carbidopa/levodopa containing product. (3) Member is experiencing intermittent OFF episodes. (4) Member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(DPD, PD with OFF episodes): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GRALISE 2025

---

## Products Affected

- *gabapentin (once-daily)*
- GRALISE ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Post Herpetic Neuralgia (PHN): (1) Diagnosis of post herpetic neuralgia, (2) Inadequate response to gabapentin immediate release or pregabalin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# GROWTH HORMONES 2025

## Products Affected

- GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE
- GENOTROPIN SUBCUTANEOUS CARTRIDGE
- HUMATROPE INJECTION CARTRIDGE
- NORDITROPIN FLEXPOR SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED
- ZOMACTON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Growth Failure in Children (GFC)(Initial): (A) Diagnosis of growth hormone deficiency confirmed by one of the following: (I) Height is documented by one of the following (utilizing age and gender growth charts related to height): (a) Height is greater than 2.0 standard deviations [SD] below midparental height (b) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) (II) Growth velocity is greater than 2 SD below mean for age and gender (III) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed is greater than 2 years compared with chronological age), (B) documentation of bone age, (C) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine. (2) Small for Gestational Age (SGA)(Initial): (A) Diagnosis of SGA, (B) Clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth Failure Associated with Chronic Kidney Disease (GF-CKD) (Initial), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency (Initial), (5) Diagnostically confirmed Growth Hormone Deficiency in adults (GHDA)(Initial), OR (6) Idiopathic Short Stature (ISS)(Initial): (A) Diagnosis of ISS defined by height standard deviation score (SDS) less than or equal to 2.25, (B) Documentation of growth velocity less than 25th percentile for bone age.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(All Other Indications)(Initial): Prescribed by or in consultation with an endocrinologist. (GF-CKD)(Initial) : Prescribed by or in consultation with an endocrinologist or nephrologist
<b>Coverage Duration</b>	(Initial, Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	(GHDA)(Continuation): Annual clinical re-evaluation by the treating endocrinologist. (GFC)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist (SGA, ISS)(Continuation): (1) Increase in growth velocity from baseline, (2) Annual clinical re-evaluation by the treating endocrinologist. (GF-CKD)(Continuation): (1) No history of renal transplant, (2) Annual clinical re-evaluation by the treating endocrinologist. (Growth Failure Associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or Short Stature Homeobox-Containing Gene (SHOX) Deficiency)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HAEGARDA 2025

---

## Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hereditary Angioedema (HAE): (1) Diagnosis of hereditary angioedema (HAE), (2) For prophylaxis against HAE attacks.
Age Restrictions	(HAE): Member is 6 years of age or older
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# HETLIOZ 2025

## Products Affected

- HETLIOZ
- *tasimelteon*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Non-24 Hour Sleep-Wake Cycle (Non-24)(Initial): (1) Diagnosis of a circadian period greater than 24 hours (also known as non-24-hour sleep-wake disorder), (2) Member is totally blind (has no light perception). Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS)(Initial): (1) Diagnosis of SMS, (2) Member is experiencing nighttime sleep disturbances.
<b>Age Restrictions</b>	(SMS)(Initial): Member is 16 years of age or older
<b>Prescriber Restrictions</b>	(Non-24, SMS)(Initial, Reauth): Prescribed by or in consultation with a sleep specialist or neurologist.
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(Non-24)(Reauth): Documentation of positive clinical response (SMS)(Reauth): Documentation of positive clinical response to therapy (e.g. improvement in nighttime total sleep time, improvement in nighttime sleep quality)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HETLIOZ LQ 2025

## Products Affected

- HETLIOZ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)(Initial): (1) Diagnosis of SMS, (2) Member is experiencing nighttime sleep disturbances
<b>Age Restrictions</b>	(SMS)(Initial): Member is 3 to 15 years of age
<b>Prescriber Restrictions</b>	(SMS)(Initial, Reauth): Prescribed by or in consultation with a sleep specialist or neurologist.
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(SMS)(Reauth): Documentation of positive clinical response to therapy (e.g. improvement in nighttime total sleep time, improvement in nighttime sleep quality)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HIGH DOSE OPIOIDS 2025

## Products Affected

- BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG
- DILAUDID ORAL TABLET 4 MG, 8 MG
- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr*
- *hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent*
- *hydromorphone hcl er oral tablet extended release 24 hour*
- *hydromorphone hcl oral tablet 4 mg, 8 mg*
- HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 100 MG
- *levorphanol tartrate oral tablet 3 mg*
- *methadone hcl oral solution*
- *methadone hcl oral tablet*
- *morphine sulfate er beads oral capsule extended release 24 hour 120 mg*
- *morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg*
- MS CONTIN ORAL TABLET EXTENDED RELEASE 60 MG
- NUCYNTA ER
- NUCYNTA ORAL TABLET 100 MG, 75 MG
- *oxycodone hcl oral tablet 30 mg*
- *oxycodone hcl oral tablet abuse-deterrent*
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT
- *oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 40 mg*
- *oxymorphone hcl oral tablet 10 mg*
- ROXICODONE ORAL TABLET 30 MG
- ROXYBOND
- XTAMPZA ER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	NEW TO HIGH DOSE OPIOID THERAPY : ONE of the following (A) pain associated with cancer, (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year



PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable. CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (b) member has clinically meaningful improvement in pain and functioning that outweighs risks to patient safety AND (c) member is not being treated for substance abuse
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HORIZANT 2025

---

## Products Affected

- HORIZANT ORAL TABLET EXTENDED RELEASE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Postherpetic neuralgia (PHN): (1) Diagnosis of PHN and (2) Inadequate response or inability to tolerate gabapentin or pregabalin. Restless legs syndrome (RLS): (1) Diagnosis of RLS and (2) Inadequate response or inability to tolerate pramipexole or ropinirole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# HRM 2025

## Products Affected

- ALLZITAL
- ASCOMP-CODEINE
- *butalbital-acetaminophen oral capsule*
- *butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet*
- *chlorzoxazone oral*
- *clemastine fumarate oral syrup*
- *clemastine fumarate oral tablet 2.68 mg*
- DEMEROL INJECTION SOLUTION 25 MG/ML, 50 MG/ML
- *dipyridamole oral*
- FIORICET ORAL CAPSULE
- FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG
- INDOCIN ORAL
- INDOCIN RECTAL
- *indomethacin oral suspension*
- *indomethacin rectal suppository 50 mg*
- *meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml*
- *meperidine hcl oral solution*
- *meperidine hcl oral tablet 50 mg*
- *meprobamate*
- *metaxalone oral tablet 400 mg, 800 mg*
- *pentazocine-naloxone hcl*
- *promethazine hcl oral solution 6.25 mg/5ml*
- RYVENT
- TENCON ORAL TABLET 50-325 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM CYCLOBENZAPRINE 2025

## Products Affected

- AMRIX
- *cyclobenzaprine hcl er*
- *cyclobenzaprine hcl oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Acute Muscle Spasms (AMS): (1) Diagnosis of Acute Muscle Spasms (AMS);(2) Prescriber attestation that drug will be used only for short periods. All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	AMS: 1 year. Other dx: 2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM ESTROGENS 2025

## Products Affected

- ACTIVELLA ORAL TABLET 1-0.5 MG
- ANGELIQ
- BIJUVA
- CLIMARA
- CLIMARA PRO
- DIVIGEL
- DOTTI
- ELESTRIN
- ESTRACE ORAL
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- EVAMIST
- FYAVOLV
- JINTELI
- LYLLANA
- MENOSTAR
- MIMVEY
- MINIVELLE
- *norethindrone-eth estradiol*
- PREMARIN ORAL
- VIVELLE-DOT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets or cream, etc.) OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM KETOROLAC 2025

---

## Products Affected

- *ketorolac tromethamine oral*
- SPRIX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ONE of the following: (1) Inadequate response or inability to tolerate TWO alternative NSAIDs such as meloxicam, naproxen, celecoxib, ibuprofen, etc. OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	One Month
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# HRM NON BENZODIAZEPINE HYPNOTICS 2025

## Products Affected

- AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG
- AMBIEN ORAL TABLET 10 MG
- EDLUAR SUBLINGUAL TABLET SUBLINGUAL 10 MG
- *eszopiclone oral tablet 3 mg*
- LUNESTA ORAL TABLET 3 MG
- *zolpidem tartrate er oral tablet extended release 12.5 mg*
- *zolpidem tartrate oral capsule*
- *zolpidem tartrate oral tablet 10 mg*
- *zolpidem tartrate sublingual tablet sublingual 3.5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	(Initial, Reauth): Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 2 years
<b>Other Criteria</b>	(REAUTH): Prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM NORGESIC 2025

## Products Affected

- NORGESIC
- *norgesic forte*
- *orphenadrine-aspirin-caffeine oral tablet 25-385-30 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) For age 65 and older: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly. (2) Inadequate response or inability to tolerate two generic skeletal muscle relaxants (e.g. tizanidine, chlorzoxazone 500mg, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	PA: 2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HRM SHORT TERM SKELETAL MUSCLE RELAXANTS 2025

## Products Affected

- *carisoprodol oral*
- SOMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Acute Muscle Spasms (AMS): (1) Diagnosis of Acute Muscle Spasms (AMS):(2) Prescriber attestation that drug will be used only for short periods. All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	(AMS): 1 year. (All other indications): 2 years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# HYFTOR 2025

## Products Affected

- HYFTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Facial Angiofibroma (FA)(Initial): (1) Diagnosis of facial angiofibroma associated with tuberous sclerosis complex
<b>Age Restrictions</b>	(FA) (Initial, Reauth): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(FA) (Initial, Reauth): Prescribed by or in consultation with a dermatologist, neurologist, or geneticist.
<b>Coverage Duration</b>	(Initial): 6 months, (Reauth): Indefinite
<b>Other Criteria</b>	(FA) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. improvement in size or redness of facial angiofibroma)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ILUMYA 2025

## Products Affected

- ILUMYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, adalimumab-ADB, adalimumab-AACF), (b) Enbrel, (c) Skyrizi, (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsO): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INBRIJA 2025

## Products Affected

- INBRIJA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
Age Restrictions	
Prescriber Restrictions	(PD): Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# INCRELEX 2025

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(GHGD, PIGF-1D) (Initial and Continuation): Known or suspected malignancy, closed epiphyses, concurrent GH therapy
<b>Required Medical Information</b>	Growth Hormone Gene Deletion (GHGD): (Initial) (1) Diagnosis of growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Severe Primary IGF-1 Deficiency (PIGF-1D): (Initial) (1) Diagnosis of Severe primary IGF-1 deficiency AND (2) height standard deviation score less than or equal to -3.0 AND (3) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone.
<b>Age Restrictions</b>	(GHGD, PIGF-1D) (Initial and Continuation): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(GHGD, PIGF-1D) (Initial and Continuation) Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial and continuation): 12 months
<b>Other Criteria</b>	(GHGD, PIGF-1D)(CONTINUATION): (1) Documentation of increase in growth velocity from baseline AND (2) Annual clinical re-evaluation by an endocrinologist AND (3) BOTH of the following: (a) Expected adult height is not obtained (b) documentation of expected adult height goal
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INGREZZA 2025

## Products Affected

- INGREZZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD) (Initial): (1) Diagnosis of moderate to severe tardive dyskinesia (2) documentation of baseline AIMS and (3) one of the following: (a) persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication, or (b) member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD) (Initial, Reauth): Prescribed by or in consultation with a neurologist or a psychiatrist
<b>Coverage Duration</b>	(TD) (Initial): 3 months (TD)(Reauth): indefinite (CHD): Indefinite
<b>Other Criteria</b>	(TD) (Reauthorization): Valbenazine (Ingrezza) is reapproved with documentation of positive clinical response, as demonstrated by improvement in AIMS, to Ingrezza therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INHALED TOBRAMYCIN 2025

## Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF): (1) Diagnosis of cystic fibrosis AND (2) evidence of P. aeruginosa in the lungs (3) FEV1 between 25% and 80%, (4) Member not colonized with Burkholderia cepacia.
Age Restrictions	(CF): Member is 6 years of age or older
Prescriber Restrictions	(CF): Prescribed by or in consultation with a pulmonologist, infectious disease specialist or Specialist affiliated with a CF care center.
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# INJECTABLE METHOTREXATE 2025

## Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML
- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of severe, active rheumatoid arthritis (RA), (2) Inadequate response or inability to tolerate oral methotrexate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate oral methotrexate. Polyarticular juvenile idiopathic arthritis (pJIA): (1) Diagnosis of pJIA, (2) Inadequate response or inability to tolerate oral methotrexate. Psoriasis: (1) Diagnosis of severe psoriasis, (2) Inadequate response to BOTH of the following: (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.).
<b>Age Restrictions</b>	(Psoriasis): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, pJIA): Recommended by rheumatologist. (PSA): Recommended by a rheumatologist or dermatologist. (Psoriasis): Recommended by dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# INSULIN GLARGINE 2025

## Products Affected

- *insulin glargine max solostar*
- *insulin glargine solostar subcutaneous solution pen-injector 300 unit/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(DM): (1) Diagnosis of Diabetes Mellitus (2) inadequate response or inability to tolerate two of the following: (a) brand Lantus (b) Toujeo (c) Tresiba (3) Documentation provided stating that the Brand products has not been effective (4) Justification provided for why the target drug is expected to provide benefit when the Brand products have not been shown to be effective
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# INTRAVENOUS IMMUNE GLOBULINS (IVIG) 2025

## Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/200ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PANZYGA
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial): History of hypersensitivity (including anaphylaxis or severe systemic reaction) to immune globulin or any component of the preparation.
<b>Required Medical Information</b>	Part D is medically necessary when ONE of the following is present: (1) Autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (i.e. steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (i.e. steroids, immunosuppressants). (2) Acute Idiopathic Thrombocytopenia Purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures (c) severe thrombocytopenia (platelets less than 20,000 per uL) or (d) high risk for intracerebral hemorrhage. (3) Chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL. (4) Chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy. (5) Hematopoietic stem cell transplant and IgG less than 400mg/dL. (6) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis. (7) Solid organ transplant. (8) Chronic Inflammatory Demyelinating Polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids. (9) Dermatomyositis or Polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants. (10) Guillain Barre syndrome with impaired function (i.e. unable to stand or walk without aid).
<b>Age Restrictions</b>	

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g. immunologist, hematologist, neurologist).
<b>Coverage Duration</b>	(All Indications): 6 months
<b>Other Criteria</b>	Subject to Part B vs Part D review. (11) Lambert Eaton myasthenic syndrome and an inadequate response or inability to tolerate steroids, immunosuppressants, or cholinesterase inhibitors (12) Multifocal motor neuropathy diagnosed by electrodiagnostic studies. (13) Acute exacerbations of multiple sclerosis (MS) unresponsive to steroids. (14) Myasthenia gravis and an inadequate response or inability to tolerate at least 8 weeks of standard therapy (e.g. corticosteroids, azathioprine, cyclosporine, cyclophosphamide, cholinesterase inhibitors) (15) Myasthenic crisis (16) Stiff person syndrome and an inadequate response or inability to tolerate standard therapy (e.g. muscle relaxants, benzodiazepines, and gabapentin-related medications) (17) Severe, active SLE and an inadequate response or inability to tolerate steroids (18) Kawasaki disease. (19) Infections in Low-birthweight Neonates when severe hypogammaglobulinemia (IgG greater than or equal to 400 mg/dL) is present. (20) Graves' Ophthalmopathy (21) Immune mediated Necrotizing Myopathy when resistant to treatment with glucocorticoids and immunosuppressants (22) Graves disease (All Indications)(CONTINUATION): (1) Documentation of clinical improvement as appropriate to the diagnosis (e.g. clinical improvement in symptoms, Rankin score and Activities of Daily Living (ADL) scores, etc.)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# IQIRVO 2025

## Products Affected

- IQIRVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary biliary cholangitis (PBC)(Initial): (1) Diagnosis of primary biliary cholangitis (PBC) (also known as primary biliary cirrhosis) (2) One of the following: (a) Both of the following: (i) Member has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol) (ii) Used in combination with ursodeoxycholic acid (UDCA) (b) History of contraindication or intolerance to ursodeoxycholic acid (UDCA)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PBC)(Initial, Reauth): Prescribed by or in consultation with hepatologist or gastroenterologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(PBC)(Reauth): (1) Member demonstrates positive clinical response to therapy (e.g., ALP level less than 1.67 times ULN, total bilirubin less than or equal to ULN, ALP decrease greater than equal to 15 percent from baseline).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ISTURISA 2025

## Products Affected

- ISTURISA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cushing's disease (CD): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative (3) Member has inadequate response or inability to tolerate Signifor [LAR].
Age Restrictions	(CD): Member is 18 years of age or older
Prescriber Restrictions	(CD): Prescribed by or in consultation with an endocrinologist
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# JOENJA 2025

## Products Affected

- JOENJA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(APDS)(Initial): (1) Diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS) (2) Molecular genetic testing confirms mutations in the PIK3CD or PIK3R1 gene (3) Member weighs greater than or equal to 45kg (4) Both of the following (a) Presence of nodal and/or extranodal proliferation (e.g. lymphadenopathy, splenomegaly, hepatomegaly) (b) Presence of other clinical findings and manifestations consistent with APDS (e.g. recurrent sino-pulmonary infections, bronchiectasis, enteropathy) (5) Inadequate response or inability to tolerate at least one standard of care treatment for APDS (e.g. Immunoglobulin replacement therapy)
<b>Age Restrictions</b>	(APDS)(Initial)(Reauth): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(APDS)(Initial)(Reauth): Prescribed by or in consultation with hematologist, geneticist or immunologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): 12 months
<b>Other Criteria</b>	(APDS)(Reauth): (1) Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# JUXTAPID 2025

## Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(HoFH)(Initial, Reauth): Moderate-severe liver impairment, active liver disease, unexplained LFT abnormalities. Juxtapid: Pregnancy, concomitant use with strong or moderate CYP3A4 inhibitors.
<b>Required Medical Information</b>	Homozygous Familial Hypercholesterolemia (HoFH): (1) Diagnosis of HoFH with ONE of the following: (a) Genetic confirmation of 2 mutant alleles at the LDL receptor. Apo B, PCSK9, or ARH adaptor protein gene locus (b) Untreated LDL-C greater than 500 mg/dL or treated LDL cholesterol greater than or equal to 300 mg/dL or treated non-HDL cholesterol greater than or equal to 330 mg/dL together with either of the following: (i) Tendinous xanthoma prior to 10 years of age (ii) Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents AND (2) Inadequate response or inability to tolerate the combination of BOTH of the following: (a) Either ezetimibe or a Bile Acid Sequestrant (e.g. cholestyramine) AND (b) ONE of the following: (i) ONE high potency statin at the maximally tolerated dose (e.g. atorvastatin, rosuvastatin) OR (ii) Inability to tolerate statin therapy as determined by one of the following: (A) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (B) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (C) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (D) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) Inadequate response or inability to tolerate BOTH of the following: (a) Repatha and (b) Praluent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HoFH)(Initial, Reauth): Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 6 months
<b>Other Criteria</b>	(HoFH)(REAUTH): (1) Documentation of reduction in LDL level since initiation of therapy

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# JYNARQUE 2025

## Products Affected

- JYNARQUE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Autosomal Dominant Polycystic Kidney Disease (ADPKD): (Initial): (1) Diagnosis of autosomal dominant polycystic kidney disease with risk of rapidly progressing kidney disease (2) Baseline serum transaminases and bilirubin prior to initiation of therapy.
<b>Age Restrictions</b>	(Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(Initial and Reauth): Prescribed by or in consultation with a nephrologist or kidney transplant specialist
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 12 months.
<b>Other Criteria</b>	(REAUTH): (1) ONE of the following (a) decline in kidney function has slowed or (b) kidney pain has improved and (2) serum transaminase less than 3 times the upper limit of normal and (3) bilirubin less than 2 times upper limit of normal
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KALYDECO 2025

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis with documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, (2) Mutation was documented by an FDA-cleared CF mutation test to detect the presence of the CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions.
<b>Age Restrictions</b>	(CF): Member is 1 month of age or older for granules. Member is 6 years of age or older for tablets
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with is a pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KERENDIA 2025

## Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic kidney disease associated with type 2 diabetes (CKD with T2D): (1) Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), (2) One of the following (a) Minimum 30-day trial of a maximally tolerated dose and member will continue therapy with ONE of the following (i) generic angiotensin-converting enzyme (ACE) inhibitor (e.g. benazepril, lisinopril), (ii) generic angiotensin II receptor blocker (ARB) (e.g. losartan, valsartan), (b) Member has contraindication or intolerance to ACE inhibitors or ARBs
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KEVZARA 2025

## Products Affected

- KEVZARA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PMR): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Polymyalgia Rheumatica (PMR): (1) Diagnosis of polymyalgia rheumatica (2) Inadequate response or inability to tolerate corticosteroids (e.g. prednisone). Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of active polyarticular juvenile idiopathic arthritis (PJIA) (2) Member weighs at least 63 kg (3) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, adalimumab-adb, adalimumab-AACF) (b) Enbrel, (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(RA, PMR): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, PMR, PJIA): Prescribed by or in consultation with a rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KINERET 2025

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, NOMID, DIRA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, adalimumab-ADB, adalimumab-AACF), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Neonatal-Onset Multisystem Inflammatory Disease (NOMID): (1) Diagnosis of NOMID. (2) Diagnosis has been confirmed by one of the following: (a) NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation (b) Evidence of active inflammation including both of the following: (i) clinical symptoms (e.g. rash, fever, arthralgia) (ii) elevated acute phase reactants (e.g. ESR, CRP). Deficiency of Interleukin-1 Receptor Antagonist (DIRA): (1) Diagnosis of DIRA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(RA, NOMID, DIRA): Prescribed by or in consultation with a rheumatologist or pediatric specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KORLYM 2025

## Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(HCS): Pregnancy
<b>Required Medical Information</b>	Hyperglycemia in members with Cushing Syndrome (HCS): (1) Hyperglycemia secondary to hypercortisolism in adult member with endogenous Cushing syndrome, (2) member has type 2 diabetes mellitus or glucose intolerance, (3) member has failed surgery or is not a candidate for surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HCS): Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LETAIRIS 2025

## Products Affected

- LETAIRIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) Inadequate response or inability to tolerate ambrisentan
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIDOCAINE TRANSDERMAL PATCH 2025

## Products Affected

- *lidocaine external patch 5 %*
- LIDOCAN
- TRIDACAINE II

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia. Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of diabetic peripheral neuropathy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# LITFULO 2025

## Products Affected

- LITFULO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Alopecia Areata): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists JAK inhibitors, or potent immunosuppressants such as azathioprine, cyclosporine
<b>Required Medical Information</b>	Alopecia Areata (AA): (1) Diagnosis of alopecia areata (2) Member has at least 50% scalp hair loss (3) Other causes of hair loss have been ruled out (e.g. androgenetic alopecia, trichotillomania, tinea capitis, psoriasis) (4) Inadequate response or inability to tolerate one previous treatment for alopecia areata (e.g. topical, intralesional, or systemic corticosteroids, topical immunotherapy)
<b>Age Restrictions</b>	(Alopecia Areata): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AA): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(AA): Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIVDELZI 2025

## Products Affected

- LIVDELZI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary biliary cholangitis (PBC)(Initial): (1) Diagnosis of primary biliary cholangitis (PBC) (also known as primary biliary cirrhosis). (2) ONE of the following: (A) BOTH of the following: (i) Member has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol), (ii) Used in combination with ursodeoxycholic acid (UDCA), (B) History of contraindication or intolerance to ursodeoxycholic acid (UDCA), (3) Requested drug will not be used in combination with Ocaliva (obeticholic acid) or Iqirvo (elafibranor).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an Hepatologist or Gastroenterologist
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(Reauth) (1) Member demonstrates positive clinical response to therapy (e.g., ALP level less than 1.67 times ULN, TB (total bilirubin) less than or equal to ULN, ALP decrease greater than or equal to 15% from baseline), (2) Requested drug will not be used in combination with Ocaliva (obeticholic acid) or Iqirvo (elafibranor)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIVMARLI 2025

## Products Affected

- LIVMARLI ORAL SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cholestatic Pruritus with Alagille Syndrome (CPALGS) (Initial): (1) Diagnosis of Cholestatic Pruritus with Alagille Syndrome. (2) Diagnosis of ALGS confirmed by BOTH of the following: (A) Molecular genetic testing confirms mutations in the JAG1 or NOTCH2 gene (B) ONE of the following (i) total serum bile acid greater than 2 times upper limit of normal (ii) conjugated bilirubin greater than 1 mg/dl (iii) fat soluble vitamin deficiency otherwise unexplainable, or (iv) gamma-glutamyl transpeptidase (GGT) greater than 3 times upper limit of normal (3) Member is experiencing moderate to severe cholestatic pruritus (4) An inadequate response or inability to tolerate at least two of the following treatments used for the relief of pruritus: (a) Ursodeoxycholic acid (e.g. Ursodiol) (b) Antihistamines (e.g. diphenhydramine, hydroxyzine) (c) Rifampin (d) Bile acid sequestrants (e.g. Questran, Colestid, Welchol)
<b>Age Restrictions</b>	(CPALGS): Member is 3 months of age or older. (PFIC): Member is 12 months of age or older
<b>Prescriber Restrictions</b>	(CPALGS, PFIC) (Initial, Reauth): Prescribed by or in consultation with a gastroenterologist or hepatologist.
<b>Coverage Duration</b>	(CPALGS, PFIC)(Initial): 6 months (CPALGS, PFIC)(Reauth): End of contract year
<b>Other Criteria</b>	Progressive Familial Intrahepatic Cholestasis (PFIC) (Initial): (1) BOTH of the following: (A) Diagnosis of Progressive familial intrahepatic cholestasis (PFIC) (B) Molecular genetic testing confirms mutations in the ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or MYO5B gene (2) Member is experiencing moderate to severe cholestatic pruritus (3) Patient has had an inadequate response to at least two of the following treatments used for the relief of pruritus: (i) Ursodeoxycholic acid (e.g., Ursodiol) (ii) Antihistamines (e.g., diphenhydramine, hydroxyzine) (iii) Rifampin (iv) Bile acid sequestrants (e.g. Questran, Colestid, Welchol) (CPALGS, PFIC) (Reauth): Positive clinical response to therapy (e.g. reduced bile acids, reduction in pruritis severity score)

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# LIVTENCITY 2025

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cytomegalovirus (CMV): (1) Diagnosis of cytomegalovirus (CMV) infection/disease, (2) Member is a recipient of one of the following (a) Hematopoietic stem cell transplant, (b) solid organ transplant, (3) Inadequate response to a minimum 2 weeks duration or inability to tolerate one of the following therapies at an appropriately indicated dose (a) intravenous (IV) ganciclovir, (b) oral valganciclovir, (c) intravenous (IV) foscarnet, (d) intravenous (IV) cidofovir, (4) Member weighs greater than or equal to 35kg
<b>Age Restrictions</b>	(CMV): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(CMV): Prescribed by or in consultation with a provider who specializes in one of the following areas (1) transplant, (2) infectious disease (3) Oncology
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LODOCO 2025

## Products Affected

- LODOCO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(CV)(Initial): (1) Diagnosis of cardiovascular disease (CV) (2) Used for the secondary prevention of CV disease (e.g. very high risk patients) (3) Member is on guideline therapy management for multiple risk factors (e.g. dyslipidemia, hypertension, hyperglycemia) associated with CV disease
<b>Age Restrictions</b>	(CV)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 6 months
<b>Other Criteria</b>	(CV)(Reauth): (1) Documentation of positive clinical response is provided
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LUMRYZ 2025

## Products Affected

- LUMRYZ
- LUMRYZ STARTER PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CN, EDSN (Initial, Reauth): Concurrent use of sedative hypnotics and alcohol
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy, (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible, Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible and (3) Inadequate response or inability to tolerate BOTH of the following: (a) modafinil or armodafinil and (b) one stimulant based product
<b>Age Restrictions</b>	(CN, EDSN)(Initial, Reauth): Member is 7 years of age or older
<b>Prescriber Restrictions</b>	(CN, EDSN)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LYRICA CR 2025

## Products Affected

- LYRICA CR
- *pregabalin er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Neuropathic Pain Associated with Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of neuropathic pain associated with diabetic peripheral neuropathy, (2) inadequate response or inability to tolerate gabapentin or pregabalin. Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia (2) inadequate response or inability to tolerate gabapentin or pregabalin.
<b>Age Restrictions</b>	(DPN, PHN): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# METFORMIN IR 2025

## Products Affected

- *metformin hcl oral tablet 625 mg, 750 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(DM) (Initial): (1) Diagnosis of Type 2 Diabetes Mellitus (DM2) (2) Inadequate response to at least a 12-week trial of generic metformin 500mg, metformin 850mg, or metformin 1000mg as evidenced by Hemoglobin A1C level above the member's goal, or inability to tolerate generic metformin 500mg, metformin 850mg, or metformin 1000mg.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(DM) (Reauth): (1) Member has experienced an objective response to therapy demonstrated by an improvement in HbA1c from baseline
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# METHOCARBAMOL 1000MG TAB 2025

---

## Products Affected

- *methocarbamol oral tablet 1000 mg*
- TANLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Inadequate response or inability to tolerate two generic skeletal muscle relaxants (e.g. tizanidine, chlorzoxazone 500mg, etc.)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# MIPLYFFA 2025

## Products Affected

- MIPLYFFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Niemann-Pick disease type C (NPC) (Initial) (1) Diagnosis of (NPC) (2) Diagnosis is confirmed by ONE of the following: (a) Genetically confirmed (deoxyribonucleic acid [DNA] sequence analysis) by mutations in both alleles of NPC1 or NPC2 (b) Mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane triol/oxysterols (greater than 2 x upper limit of normal) (3) Member has at least one neurological symptom of the disease (e.g., hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia) (4) Requested drug will be used in combination with miglustat (5) Requested drug will NOT be used in combination with Aqneursa (levacetylleucine)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a specialist knowledgeable in the treatment of Niemann-Pick disease type C
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(Reauth)(1) Member demonstrates positive clinical response to therapy (2) Requested drug will be used in combination with miglustat (3) Requested drug will NOT be used in combination with Aqneursa (levacetylleucine)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MODAFINIL 2025

## Products Affected

- *modafinil oral*
- PROVIGIL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>NARCOLEPSY: (1) Diagnosis of Narcolepsy confirmed by a sleep study (unless prescriber provides justification that a sleep study is not feasible).</p> <p>OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). (2) Both of the following (a): 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study is not feasible) AND (b) One of the following symptoms: Unintentional sleep episodes during wakefulness, or daytime sleepiness, or unrefreshing sleep, or fatigue, or insomnia, or waking up breath holding, gasping, or choking, or loud snoring, or breathing interruptions during sleep. SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no other medical or mental disorder accounting for the symptoms. Multiple Sclerosis (MS) Related Fatigue: (1) Diagnosis of Multiple Sclerosis (MS) related fatigue</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# MULPLETA 2025

## Products Affected

- MULPLETA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Chronic Liver Disease (CLD): (1) Diagnosis of Chronic Liver Disease (CLD) (2) Member is scheduled to undergo a procedure (3) Documentation of baseline platelet count less than 50,000/mcL
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# MYALEPT 2025

---

## Products Affected

- MYALEPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Generalized Lipodystrophy (GL): (1) Diagnosis of congenital or acquired generalized lipodystrophy.
Age Restrictions	
Prescriber Restrictions	(GL): Prescribed by or in consultation with an endocrinologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# MYCAPSSA 2025

## Products Affected

- MYCAPSSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Acromegaly)(Initial): (1) One of the following: (a) Inadequate response to surgical resection and/or pituitary irradiation, (b) member is not a candidate for surgical resection or pituitary irradiation (2) Inadequate response or inability to tolerate a dopamine agonist (e.g. bromocriptine or cabergoline) at maximally tolerated doses (3) Member has responded to and tolerated treatment with octreotide or lanreotide.
<b>Age Restrictions</b>	(Acromegaly): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(Acromegaly) (Reauth): Positive clinical response to therapy (e.g. reduction or normalization of IGF-1/GH level for same age and sex)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# MYFEMBREE 2025

## Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Uterine Leiomyomas (UL)(Initial): (1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), (2) Member is premenopausal, (3) ONE of the following: (a) Inadequate response or inability to tolerate one of the following for no more than 30 days: combination (estrogen/progestin) contraceptive, progestins, tranexamic acid, OR (b) Member has had a previous interventional therapy to reduce bleeding (e.g. uterine-artery embolization and magnetic resonance-guided focused ultrasonography), (4) Treatment duration of therapy has not exceeded a total of 24 months.</p> <p>(Endometriosis)(Initial) (1) Diagnosis of moderate to severe pain associated with endometriosis (2) member is premenopausal (3) One of the following (a) Inadequate response or inability to tolerate one of the following for at least 3 months (danazol, combination (estrogen/progestin) contraceptive, progestins (b) member has had surgical ablation to prevent recurrence (4) Treatment duration of therapy has not exceeded a total of 24 months</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	<p>(UL) (Reauth): (1) Member has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g. significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.), (2) Treatment duration of therapy has not exceeded a total of 24 months.</p> <p>(Endometriosis)(Reauth) (1) Member has improvement in pain associated with endometriosis (e.g. improvement in dysmenorrhea and Non menstrual pelvic pain) (2) Treatment duration of therapy has not exceeded a total of 24 months</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# MYTESI 2025

## Products Affected

- MYTESI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Noninfectious Diarrhea associated with HIV/AIDS (NID): (1) Diagnosis of HIV/AIDS and member is on antiretroviral therapy. (2) Member requires symptomatic relief of non-infectious diarrhea. (3) Inadequate response or inability to tolerate at least one anti-diarrheal medication (e.g. loperamide, atropine/diphenoxylate, etc.). (4) Infectious diarrhea (e.g. cryptosporidiosis, C. Difficile, etc.) has been ruled out.
<b>Age Restrictions</b>	(NID): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NEMLUVIO 2025

## Products Affected

- NEMLUVIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prurigo Nodularis (PN)(Initial): (1) Diagnosis of prurigo nodularis (2) Inadequate response or inability to tolerate one medium or higher potency topical corticosteroid (3) Inadequate response or inability to tolerate Dupixent (dupilumab) Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe atopic dermatitis (AD) (2) ONE of the following: (a) Involvement of at least 10% body surface area (BSA) (b) SCORing Atopic Dermatitis (SCORAD) index value of at least 25 (3) Will be used in combination with topical corticosteroids with or without calcineurin inhibitors (3) Inadequate response or inability to tolerate TWO of the following: (a) Adbry (tralokinumab-ldrm), (b) Dupixent (dupilumab) (c) Rinvoq (upadacitinib).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PN)(AD): Prescribed by or in consultation with an Allergist/Immunologist or Dermatologist
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(PN)(Reauth): (1) Member demonstrates a positive clinical response to therapy. (AD)(Reauth): (1) Member demonstrates positive clinical response to therapy as evidenced by at least ONE of the following: (a) Reduction in body surface area involvement from baseline (b) Reduction in SCORing Atopic Dermatitis (SCORAD) index value from baseline
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NEXLETOL/NEXLIZET 2025

## Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Heterozygous Familial Hypercholesterolemia (HeFH) OR Primary hyperlipidemia (PH). (Initial): (1) One of the following: (A) Diagnosis of HeFH, OR (B) Diagnosis of Primary hyperlipidemia (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after at least 8 weeks of one low, moderate or high-intensity statin therapy and member will continue to receive statin therapy at maximally tolerated dose OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) One of the following: (A) Member has been receiving at least 8 weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy OR (B) Member has contraindication or intolerance to ezetimibe (Zetia).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	Established cardiovascular disease (CVD) or high risk for a CVD event but without established CVD (Initial): (1) One of the following: (A) Diagnosis of established cardiovascular disease (CVD) (e.g., coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease) OR (B) Diagnosis of a high risk for a CVD event but without established CVD [e.g., diabetes mellitus (type 1 or type 2) in females over 65 years of age or males over 60 years of age] (2) One of the following: (A) Member is statin intolerant as evidenced by an inability to tolerate at least two statins, with at least one started at the lowest starting daily dose, due to intolerable symptoms or clinically significant biomarker changes of liver function or muscle function (e.g., creatine kinase) (B) Member has a contraindication to all statins (3) ONE of the following LDL-C values within the last 120 days (A) LDL-C greater than or equal to 55 mg/dL with ASCVD OR (B) LDL-C greater than or equal to 100 mg/dL without ASCVD (4) One of the following (A) For Nexletol, ONE of the following: (i) Member has been receiving at least 12 weeks of generic ezetimibe therapy (ii) Patient has a history of contraindication, or intolerance to ezetimibe OR (B) For Nexlizet, member has been receiving at least 12 weeks of generic ezetimibe therapy (HeFH, PH) (Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (CVD) (Continuation): (1) Positive Clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NGENLA 2025

## Products Affected

- NGENLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Growth Failure in Children (GFC)(Initial): (1) Diagnosis of growth hormone deficiency confirmed by one of the following: (a) Height is documented by one of the following (utilizing age and gender growth charts related to height): (i) Height is greater than 2.0 standard deviations [SD] below midparental height (ii) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) (b) Growth velocity is greater than 2 SD below mean for age and gender (c) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g. delayed is greater than 2 years compared with chronological age) (2) documentation of bone age, (3) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine.
<b>Age Restrictions</b>	(GFC) (Initial, Continuation): Member is 3 years of age or greater.
<b>Prescriber Restrictions</b>	(GFC) (Initial, Continuation): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(GFC) (Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist (2) Growth velocity greater than or equal to 2.5 cm/year.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NON-ORAL ANTIBIOTICS 2025

## Products Affected

- DALVANCE
- NUZYRA
- SIVEXTRO
- VABOMERE
- ZEMDRI
- ZERBAXA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Part D is medically necessary when documentation of a current bacterial infection and an inadequate response or inability to tolerate at least TWO drugs to which the organism is susceptible OR the requested agent is the only antibiotic to which the organism is susceptible.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with an infectious disease specialist OR oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 1 month
<b>Other Criteria</b>	Subject to Part B vs Part D review. Subject to additional clinical review for ESRD-related use - if applicable. (REAUTH): Prescriber attests that an infectious disease consult determines that a longer duration of therapy is required.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# NON-ORAL CHEMO AGENTS 2025

## Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy. Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NON-PREFERRED GLP-1 AGONISTS 2025

## Products Affected

- SOLIQUA
- XULTOPHY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(DM2): (1) One of the following: (a) For members requiring ongoing treatment for type 2 diabetes mellitus, submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus (b) Submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values (i) A1C greater than or equal to 6.5 percent (ii) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (iii) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during OGTT (oral glucose tolerance test) (2) Inadequate response or inability to tolerate a minimum 90 day-supply of two of the following preferred brands: Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NON-PREFERRED HEPATITIS C AGENTS 2025

## Products Affected

- SOVALDI
- VOSEVI
- ZEPATIER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Documentation of member's Hepatitis C genotype. (2) Prescribed regimen is consistent with the current AASLD/ IDSA guidance. (3) Inability to tolerate ONE of the following when appropriate per the current AASLD/IDSA guidance: Harvoni, Epclusa, or Mavyret.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# NON-PREFERRED USTEKINUMAB SQ 2025

## Products Affected

- OTULFI SUBCUTANEOUS
- PYZCHIVA SUBCUTANEOUS
- SELARSDI SUBCUTANEOUS
- STEQEYMA SUBCUTANEOUS
- *ustekinumab-ttwe subcutaneous*
- WEZLANA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Part D is medically necessary when: Crohn's Disease (CD)(Initial): (1) Diagnosis of moderate to severe CD (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Skyrizi, (c) Rinvoq (d) Ustekinumab (i.e. Yesintek) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC)(Initial): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Rinvoq, (c) Xeljanz/Xeljanz XR, (d) Skyrizi (e) Ustekinumab (i.e. Yesintek) OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA)(Initial): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Orencia, (h) Otezla, (i) Ustekinumab (i.e. Yesintek) OR documentation demonstrating that a trial may be inappropriate. Plaque psoriasis (PsO)(Initial): Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Otezla, (f) Ustekinumab (i.e. Yesintek) OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CD, UC): prescribed by or in consultation with a Gastroenterologist. (PsO): prescribed by or in consultation with a Dermatologist. (PsA): prescribed by or in consultation with a Dermatologist or Rheumatologist
<b>Coverage Duration</b>	(CD, UC, PsA, PsO): 12 months
<b>Other Criteria</b>	(CD, UC, PsA, PsO): (Reauth): (1) Member demonstrates positive clinical response to therapy

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# NOURIANZ 2025

## Products Affected

- NOURIANZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
Age Restrictions	
Prescriber Restrictions	(PD): Prescribed by or in consultation with a neurologist.
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# NOXAFIL 2025

## Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Treatment of invasive aspergillosis (TAI): Diagnosis of TAI. Prophylaxis of Invasive Aspergillus Infections (AI): (1) For use in prophylaxis of invasive Aspergillus infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend). Prophylaxis of Invasive Candida Infections(CI): (1) For use in prophylaxis of invasive Candida infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend).
<b>Age Restrictions</b>	(TAI): Member is 13 years of age or older. (AI, CI): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(All Indications): Prescribed by or in consultation with an infectious disease specialist, transplant specialist, hematologist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NOXAFIL 300MG PAK 2025

## Products Affected

- NOXAFIL ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Prophylaxis of Invasive Aspergillus Infections (AI): (1) For use in prophylaxis of invasive Aspergillus infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend). Prophylaxis of Invasive Candida Infections(CI): (1) For use in prophylaxis of invasive Candida infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend).
Age Restrictions	(AI, CI): Member is 2 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist, transplant specialist, hematologist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
Coverage Duration	Remainder of contract year
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# NUCALA 2025

## Products Affected

- NUCALA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(SA, EGPA, CRSwNP) Concurrent therapy with any other biologics for asthma/allergic conditions (e.g. benralizumab [Fasenra], dupilumab [Dupixent], omalizumab [Xolair], reslizumab [Cinqair])
<b>Required Medical Information</b>	Part D is medically necessary when there is documentation of ONE of the following: Severe Asthma with Eosinophilic Phenotype (SA) (Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by one of the following: a) blood eosinophil levels are at least 150 cells/microliter at initiation of therapy (measured within 6 weeks of dosing), or b) blood eosinophil levels at least 300 cells/microliter within the past 12 months. (2) Member has had at least two or more asthma exacerbations requiring systemic corticosteroids within the past 12 months OR member has had any prior intubation for an asthma exacerbation OR Member has had a prior asthma-related hospitalization within the past 12 months, AND Member is currently treated with high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g. long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Initial): (1) Diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA), (2) Member's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy), and (3) Member is currently receiving corticosteroid therapy (e.g. prednisolone, prednisone). Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (Initial): (1) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP). (2) Unless contraindicated, the member has had an inadequate response to at least a 2 month treatment with an intranasal corticosteroid (e.g. fluticasone, mometasone). (3) Used in combination with intranasal corticosteroid for CRSwNP.
<b>Age Restrictions</b>	(SA) (Initial, Reauth): Member is 6 years of age or older. (HES) (Initial, Reauth): Member is 12 years of age or older. (CRSwNP, EGPA) (Initial, Reauth): Member is 18 years of age or older.

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(SA): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist. (EGPA): Prescribed by or in consultation with a rheumatologist. (HES): Prescribed by or in consultation with either allergist/immunologist or hematologist. (CRSwNP): Prescribed by or in consultation with allergist, immunologist, otolaryngologist or pulmonologist.
<b>Coverage Duration</b>	(Initial): 12 months. (Reauth): 12 months.
<b>Other Criteria</b>	Subject to Part B vs Part D review. Hyper eosinophilic Syndrome (HES) (Initial): (1) Diagnosis of HES. (2) All of the following: (a) Member has been diagnosed for at least 6 months, (b) Verification that other non-hematologic secondary causes have been ruled out (e.g. drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy), (c) member is FIP1-like1-platelet derived growth factor receptor alpha kinase (FIP1L1-PDGFR kinase)-negative. (3) Member has uncontrolled HES defined by both of the following: (a) Pre-treatment blood eosinophil count greater than or equal to 1000 cells/microliter, (b) Member has experienced 2 or more flares within the past 12 months. (4) Inadequate response or inability to tolerate one of the following: (a) corticosteroid therapy (e.g. prednisone), (b) cytotoxic/immunosuppressive therapy (e.g. hydroxyurea, cyclosporine, imatinib). (SA)(Reauth): (1) Member is currently treated with high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g. long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. (EGPA) (Reauth): (1) Positive clinical response to therapy (e.g. increase in remission time). (HES) (Reauth): (1) Positive clinical response (e.g. reduction in corticosteroid use, reduction of blood eosinophil count, reduction in flares). (CRSwNP) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction of nasal polyps score [NPS: 0-8 scale], improvement in nasal obstruction symptoms via visual analog scale [VAS: 0-10 scale]), (2) Used in combination with intranasal corticosteroid for CRSwNP.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUEDEXTA 2025

## Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PBA): Presence of Prolonged QT interval, Congenital long QT Syndrome, or Torsades de pointes documented by a cardiac test (e.g. electrocardiogram)
<b>Required Medical Information</b>	Pseudobulbar Affect (PBA): (1) Diagnosis of Pseudobulbar affect (2) Member has one of the following underlying conditions: (a) Amyotrophic lateral sclerosis (b) Multiple sclerosis (c) Alzheimer's disease (d) Parkinson's disease (e) Stroke (f) Traumatic brain injury
<b>Age Restrictions</b>	(PBA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PBA): Prescribed by or in consultation with a neurologist or psychiatrist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUPLAZID 2025

## Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hallucinations and Delusions Parkinson Disease Psychosis (HDPDP): Inadequate response or inability to tolerate ONE of the following (a) quetiapine or (b) clozapine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NURTEC 2025

## Products Affected

- NURTEC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Medication will be used in combination with another oral CGRP inhibitor. (MP) (Initial, Reauth): Medication used in combination with another CGRP inhibitor for the preventive treatment of migraines.
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan. Preventative Treatment of Migraines (MP) (Initial): (1) Diagnosis of episodic migraines defined as 4 to 18 migraine days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine, (f) (candesartan).
<b>Age Restrictions</b>	(AM)(MP)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(MP)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(MP)(Initial): 6 months. (AM)(MP)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea). (MP)(Reauth): (1) Positive clinical response to therapy (e.g. reduction in headache frequency and/or intensity, use of acute migraine medications [e.g. nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, naproxen), triptans (e.g. eletriptan, rizatriptan, sumatriptan)] has decreased since the start of CGRP therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OCALIVA 2025

## Products Affected

- OCALIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary biliary cholangitis (PBC): (1) Diagnosis of Primary biliary cholangitis (PBC) (2) Used in combination with ursodeoxycholic acid (e.g. Urso, Urso Forte, ursodiol), OR (2) inability to tolerate ursodeoxycholic acid. (3) Member has one of the following: (a) no cirrhosis or (b) compensated cirrhosis with no evidence of portal hypertension.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PBC) (Initial, Reauth): Prescribed by or in consultation with a hepatologist or gastroenterologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): Indefinite
<b>Other Criteria</b>	(PCB)(Reauth): Positive clinical response to Ocaliva therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OFEV 2025

## Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): (1) Diagnosis of SSc-ILD confirmed by a high resolution CT scan or biopsy. Chronic Fibrosing Interstitial Lung Disease (ILDs) with progressive phenotype (Initial): (1) Confirmed by high resolution CT scan (HRCT) showing at least 10% of lung volume with fibrotic features, (2) Disease has a progressive phenotype as observed by one of the following: (a) decline of forced vital capacity (FVC), (b) worsening of respiratory symptoms, (c) increased extent of fibrosis seen on imaging.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IPF, SSc-ILD, ILDs): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(REAUTH) (IPF, ILDs, SSc-ILD): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OHTUVAYRE 2025

## Products Affected

- OHTUVAYRE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when: Chronic Obstructive Pulmonary Disease (COPD)(Initial): (1) Diagnosis of maintenance treatment of chronic obstructive pulmonary disease (COPD) (2) Both of the following: (A) Post-bronchodilator forced expiratory volume [FEV1]/forced vital capacity [FVC] ratio less than 0.70 (B) Post-bronchodilator FEV1 percent predicted greater than 30% and less than or equal to 70%. (3) Member is symptomatic despite being on at least TWO therapies indicated for the treatment of COPD and will continue to be treated with the therapies (e.g. long-acting muscarinic antagonists [e.g., tiotropium], long-acting beta agonist [e.g., formoterol]), unless there is a contraindication or intolerance (4) Member experiences dyspnea during everyday activities (e.g., short of breath when walking up a slight hill)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial)(Reauth) 12 months
<b>Other Criteria</b>	Subject to Part B vs Part D review. (COPD)(Reauth) (1) Member demonstrates a positive clinical response to therapy. (2) Member continues to be treated with at least two therapies indicated for the treatment of COPD (e.g. long-acting muscarinic antagonists [e.g., tiotropium], long-acting beta agonist [e.g., formoterol]), unless there is a contraindication or intolerance.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# OLUMIANT 2025

## Products Affected

- OLUMIANT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, Alopecia Areata): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists, JAK inhibitors, or potent immunosuppressants such as azathioprine, cyclosporine
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, adalimumab-ADB, adalimumab-AACF), (b) Enbrel (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Alopecia Areata (AA): (1) Diagnosis of alopecia areata (2) Member has at least 50% scalp hair loss (3) Other causes of hair loss have been ruled out (e.g. androgenetic alopecia, trichotillomania, tinea capitis, psoriasis) (4) Inadequate response or inability to tolerate one previous treatment for alopecia areata (e.g. topical, intralesional, or systemic corticosteroids, topical immunotherapy)
<b>Age Restrictions</b>	(RA, Alopecia Areata): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA): Prescribed by or in consultation with a rheumatologist (AA): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(RA, Alopecia Areata): Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OMVOH SQ 2025

## Products Affected

- OMVOH (300 MG DOSE)
- OMVOH SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(UC): Concurrent therapy with biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ulcerative Colitis (UC): (1) Diagnosis of moderately to severely active Ulcerative Colitis (2) One of the following: (A) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) ustekinumab (i.e. Yesintek), (c) upadacitinib (Rinvoq), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) risankizumab (Skyrizi) OR documentation demonstrating that a trial may be inappropriate (B) Will be used as a maintenance dose following the intravenous induction doses. Crohn's Disease (CD)(Initial): (1) Diagnosis of moderately to severely active CD (2) One of the following: (A) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Ustekinumab (i.e. Yesintek), (c) Skyrizi, (d) Rinvoq or documentation demonstrating that a trial may be inappropriate. (B) Will be used as a maintenance dose following the intravenous induction doses
<b>Age Restrictions</b>	(UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(UC)(CD) : Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	(UC) Indefinite (CD) 12 months
<b>Other Criteria</b>	(CD)(Reauth): Member demonstrates positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ONGENTYS 2025

## Products Affected

- ONGENTYS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
Age Restrictions	
Prescriber Restrictions	(PD): Prescribed by or in consultation with a neurologist.
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ONYCHOMYCOSIS AGENTS 2025

## Products Affected

- JUBLIA
- *tavaborole*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Onychomycosis: (1) Diagnosis of onychomycosis of the toenail(s) due to <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> . (2) Diagnosis confirmed by one of the following: (a) positive potassium hydroxide (KOH) preparation, (b) culture, or (c) histology. (3) Condition is causing debility or a disruption in member's activities of daily living. (4) Inadequate response or inability to tolerate BOTH of the following: (a) oral generic terbinafine, AND (b) oral generic itraconazole OR topical generic ciclopirox.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# ONYDA XR 2025

## Products Affected

- ONYDA XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Attention Deficit Hyperactivity Disorder (ADHD) (Initial) (1) Diagnosis of ADHD (2) Member is unable to swallow solid dosage forms (e.g., oral tablet, capsule) (3) Inadequate response or inability to tolerate TWO of the following: (a) generic atomoxetine, (b) generic guanfacine ER, (c) generic clonidine ER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial)(Reauth): 12 months
<b>Other Criteria</b>	(Reauth) (1) Member demonstrates positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OPIPZA 2025

## Products Affected

- OPIPZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Schizophrenia: (1) Diagnosis of treatment of schizophrenia (2) Inadequate response or inability to tolerate aripiprazole and an additional generic formulary antipsychotic product. Major depressive disorder (MDD): (1) Diagnosis of adjunctive treatment of MDD (2) Inadequate response or inability to tolerate aripiprazole and quetiapine. Autistic disorder: (1) Diagnosis of irritability associated with autistic disorder (2) Inadequate response or inability to tolerate aripiprazole and risperidone. Tourette's disorder: (1) Diagnosis of treatment of Tourette's disorder (2) Inadequate response or inability to tolerate aripiprazole.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OPSYNVI 2025

## Products Affected

- OPSYNVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PAH)(Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis is confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Member is currently on both of the following for the treatment of pulmonary arterial hypertension (a) macitentan (Opsumit) (b) Tadalafil
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial, Continuation): Prescribed by or in consultation with pulmonologist or cardiologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OPZELURA 2025

## Products Affected

- OPZELURA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD) (Initial): (1) For short-term, non-continuous treatment of chronic atopic dermatitis. (2) Inadequate response or inability to tolerate at least TWO of the following: (a) topical tacrolimus OR topical pimecrolimus, OR (b) generic, prescription medium potency or higher topical steroid, OR (c) Eucrisa. (3) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine). Nonsegmental Vitiligo (NV)(Initial): (1) Diagnosis of nonsegmental vitiligo (2) Inadequate response or inability to tolerate one of the following (a) medium or higher potency topical corticosteroid (b) pimecrolimus cream (c) tacrolimus ointment (3) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine).
<b>Age Restrictions</b>	(AD, NV): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD) (Initial, Reauth): Prescribed by or in consultation with a dermatologist or allergist/immunologist (NV) (Initial, Reauth): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	(AD)(Initial): 8 Weeks, (Reauth): End of contract year (NV)(Initial): 6 months, (Reauth): 12 months
<b>Other Criteria</b>	(AD) (Reauth): Positive clinical response to therapy. (NV)(Reauth): (1) Documentation of positive clinical response to therapy (2) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ORAL ANTIBIOTICS 2025

## Products Affected

- NUZYRA
- SIVEXTRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Documentation of a current bacterial infection and an inadequate response or inability to tolerate TWO antibiotics to which the organism is susceptible OR the requested medication is the only antibiotic to which the organism is susceptible.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with an infectious disease specialist OR oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 1 month
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable. (REAUTH): Prescriber attests that an infectious disease consult determines that a longer duration of therapy is required.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL CHEMO AGENTS 2025

---

## Products Affected

- *abiraterone acetate*
- ABIRTEGA
- AFINITOR
- AFINITOR DISPERZ
- AKEEGA
- ALECENSA
- ALUNBRIG
- AUGTYRO
- AYVAKIT
- BALVERSA
- *bexarotene*
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE ORAL TABLET
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DANZITEN
- *dasatinib*
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- FOTIVDA
- FRUZAQLA
- GAVRETO
- *gefitinib*
- GILOTRIF
- GLEEVEC
- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG
- GOMEKLI
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate oral*
- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- *imkeldi*
- INLYTA
- INQOVI
- INREBIC
- IRESSA
- ITOVEBI
- IWILFIN
- JAKAFI
- JAYPIRCA
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KOSELUGO
- KRAZATI
- *lapatinib ditosylate*
- LAZCLUZE
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- LYTGobi (12 MG DAILY DOSE)
- LYTGobi (16 MG DAILY DOSE)
- LYTGobi (20 MG DAILY DOSE)
- MEKINIST
- MEKTOVI
- NERLYNX
- NEXAVAR

- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO
- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET 100 MG
- OJJAARA
- ONUREG
- ORGOVYX
- ORSERDU
- *pazopanib hcl*
- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO ORAL TABLET
- REVLIMID
- REVUFORJ
- REZLIDHIA
- ROMVIMZA
- ROZLYTREK
- RUBRACA
- RYDAPT
- SCEMBLIX
- *sorafenib tosylate*
- SPRYCEL
- STIVARGA
- *sunitinib malate*
- SUTENT
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA
- TARGRETIN
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID ORAL CAPSULE 100 MG, 50 MG
- TIBSOVO
- TORPENZ
- TRUQAP ORAL TABLET 200 MG
- TUKYSA
- TURALIO ORAL CAPSULE 125 MG
- TYKERB
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VONJO
- VORANIGO
- VOTRIENT
- WELIREG
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- YONSA
- ZEJULA ORAL TABLET
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET
- ZYTIGA

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL PAH AGENTS 2025

## Products Affected

- OPSUMIT
- ORENITRAM
- ORENITRAM MONTH 1
- ORENITRAM MONTH 2
- ORENITRAM MONTH 3

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORENCIA SQ 2025

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, pJIA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Psoriatic arthritis (PsA): (1) Diagnosis of PsA. Polyarticular Juvenile idiopathic arthritis (pJIA): (1) Diagnosis of JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, leflunomide, sulfasalazine.
<b>Age Restrictions</b>	(pJIA, PsA): Member is 2 years of age or older. (RA): member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, pJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORIAHNN 2025

## Products Affected

- ORIAHNN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Uterine Leiomyomas (UL)(Initial): (1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), (2) Member is premenopausal, (3) ONE of the following: (a) Inadequate response or inability to tolerate one of the following for no more than 30 days: combination (estrogen/progestin) contraceptive, progestins, tranexamic acid, OR (b) Member has had a previous interventional therapy to reduce bleeding (e.g. uterine-artery embolization and magnetic resonance-guided focused ultrasonography), (4) Treatment duration of therapy has not exceeded a total of 24 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(UL) (Reauth): (1) Member has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g. significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.), (2) Treatment duration of therapy has not exceeded a total of 24 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORILISSA 2025

## Products Affected

- ORILISSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pain Associated with Endometriosis (PAE): (1) Diagnosis of Pain Associated with Endometriosis (PAE) (2) Documentation of ONE of the following, (a) Inadequate response or inability to tolerate BOTH of the following (i) one nonsteroidal anti-inflammatory drug AND (ii) one contraceptive OR (b) Member has had surgical ablation to prevent recurrence. (3) Treatment duration does not exceed 24 months (150mg tablet) or 6 months (200mg tablet).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months for 150mg tablet, 6 months for 200mg tablet
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ORKAMBI 2025

---

## Products Affected

- ORKAMBI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(CF): Diagnosis of CF other than those homozygous for the F508del mutation
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of CF, (2) Member is homozygous for the F508del mutation in the CFTR gene (3) If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
<b>Age Restrictions</b>	(CF): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORLADEYO 2025

## Products Affected

- ORLADEYO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hereditary Angioedema (HAE): (1) Diagnosis of HAE, (2) For prophylaxis against HAE attacks.
Age Restrictions	(HAE): Member is 12 years of age or older
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an immunologist, allergist or pulmonologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# OTEZLA 2025

## Products Affected

- OTEZLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Oral Ulcers Associated with Behcet's Disease (OU-BD): (1) Diagnosis of OU-BD. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. Plaque psoriasis (PsO): (1) Diagnosis of PsO.
<b>Age Restrictions</b>	(OU-BD, PsA): Member is 18 years of age or older. (PsO) Member is 6 years of age and older.
<b>Prescriber Restrictions</b>	(PsA, OU-BD): Prescribed by or in consultation with a Rheumatologist or Dermatologist. (PsO): Prescribed by or in consultation with dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OVERACTIVE BLADDER AGENTS (OAB) ACH 2025

## Products Affected

- DETROL ORAL TABLET 2 MG
- OXYTROL
- VESICARE
- VESICARE LS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Trial of three of the following: oxybutynin, darifenacin, Myrbetriq, tolterodine, trospium, solifenacin. Always applies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PA: Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# OXERVATE 2025

## Products Affected

- OXERVATE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Neurotrophic keratitis (NK)(Initial): (1) Diagnosis of NK. (2) Submission of chart documentation indicating treatment of left eye, right eye, or both
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(NK) (Initial, Reauth) Prescribed by or in consultation with an ophthalmologist or Optometrist.
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	(NK)(Reauth): (1)Submission of chart documentation indicating treatment of left eye, right eye, or both, (2) Member has received less than or equal to 8 weeks of therapy (one course of therapy) per affected eye(s), (3) Documentation of clinical rationale for treatment greater than 8 weeks (e.g. member has a recurrence of neurotrophic keratitis, or treatment of a different eye), (4) Documentation of clinical response to prior Oxervate therapy, (5) Member will not exceed a total of 16 weeks of Oxervate therapy per affected eye(s).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PALYNZIQ 2025

## Products Affected

- PALYNZIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Phenylketonuria (PK)(Initial): (1) Member has uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, (2) Member will continue to have phenylalanine blood levels measured periodically during therapy.
<b>Age Restrictions</b>	(PK)(Initial, Continuation): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months, (Continuation): Indefinite
<b>Other Criteria</b>	(PK)(CONTINUATION): (1) A positive clinical response to Palynziq therapy as determined by prescriber.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## PART D VS EXCLUDED 2025

### Products Affected

- CRINONE
- IMVEXXY MAINTENANCE PACK
- IMVEXXY STARTER PACK
- INTRAROSA
- OSPHENA
- VFEND IV
- *voriconazole intravenous*
- ZTLIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# PDE INHIBITOR AGENTS FOR PAH 2025

## Products Affected

- ADCIRCA
- ALYQ
- *tadalafil (pah)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, (4) inadequate response or inability to tolerate generic tadalafil (Applies to Brand Adcirca only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(PAH)(Reauth): (1) Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PRALUENT 2025

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia, (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p> <p>Atherosclerotic cardiovascular disease (ASCVD) (Initial): (1) Diagnosis of atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid), (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months (Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASVCD)(CONTINUATION): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PREFERRED GLP-1 AGONISTS 2025

## Products Affected

- *liraglutide*
- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(DM2): (1) One of the following: (a) For members requiring ongoing treatment for type 2 diabetes mellitus, submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus (b) Submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values (i) A1C greater than or equal to 6.5 percent (ii) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (iii) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during OGTT (oral glucose tolerance test)
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Indefinite
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# PREFERRED HEPATITIS C AGENTS 2025

## Products Affected

- EPCLUSA
- HARVONI
- *ledipasvir-sofosbuvir*
- MAVYRET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Documentation of member's Hepatitis C Genotype. (2) Prescribed regimen is consistent with the current AASLD/IDSA guidance.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# PRETOMANID 2025

## Products Affected

- *pretomanid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Multidrug Resistant Tuberculosis (MDRTB): (1) Diagnosis of pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive MDRTB. (2) Medication will be used as part of a combination regimen with bedaquiline (Sirturo) and linezolid.
Age Restrictions	(MDRTB): Member is 18 years of age or older
Prescriber Restrictions	
Coverage Duration	26 weeks
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# PROCYSBI 2025

## Products Affected

- PROCYSBI ORAL PACKET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Nephrotic Cystinosis (NC) (Initial): (1) Diagnosis of nephrotic cystinosis, (2) inadequate response or titration from cysteamine bitartrate immediate-release capsules (Cystagon).
<b>Age Restrictions</b>	(NC): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(NC)(Initial, Reauth): Prescribed by or in consultation with a nephrologist.
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 6 months.
<b>Other Criteria</b>	(NCB)(REAUTH): Positive Clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROLIA 2025

## Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>Part D is medically necessary when all of the following criteria are met:</p> <p>Osteoporosis (OS) (Initial): ALL of the following: (1) Diagnosis of osteoporosis confirmed by one of the following: (a) T-score less than or equal to -2.5 (b) history of osteoporotic fracture (e.g. vertebral, hip, non-vertebral) or (c) multiple risk factors for fracture. (2) ONE of the following: (a) inadequate response or inability to tolerate at least one other osteoporosis medicine (e.g. oral bisphosphonates, calcitonin, estrogens, selective estrogen receptor modulator (SERMs)) or (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted or (c) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less). Osteopenia (OPN) (Initial): BOTH of the following: (1) Diagnosis of osteopenia confirmed by a T-score less than -1.0, but greater than -2.5. (2) One of the following: (a) Member is receiving adjuvant aromatase inhibitor therapy for breast cancer (b) member is receiving androgen deprivation therapy for non-metastatic prostate cancer. Prophylaxis of Postmenopausal Osteoporosis (PO) (Initial): BOTH of the following: (1) BMD T score less than -1.0 and greater than -2.5. (2) ONE of the following: (a) Inadequate response or inability to tolerate an oral bisphosphonates or a selective estrogen receptor modulator (SERMs) or (b) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less) not receiving dialysis or diagnosed with stage 5 kidney disease.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review. Glucocorticoid Induced Osteoporosis (GCO)(Initial): ALL of the following: (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) ONE of the following: (a)Inadequate response or inability to tolerate ONE of the following: (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs)., (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted, (c) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PROMACTA 2025

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Chronic Idiopathic Thrombocytopenic Purpura (ITP)(Initial): (1) Diagnosis of relapsed/refractory, persistent, or chronic ITP. (2) Baseline platelet count is less than 30,000/mcL. (3) Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding. (4) Inadequate response or inability to tolerate ONE of the following: (a) corticosteroids, (b) immune globulin, (c) splenectomy. First-Line for Severe Aplastic Anemia(FLSAA): (1) Diagnosis of severe aplastic anemia. (2) Used for first-line treatment (i.e., member has not received prior immunosuppressive therapy). (3) Member meets at least TWO of the following: (a) absolute neutrophil count less than 500/mcL, (b) platelet count less than 20,000/mcL, (c) absolute reticulocyte count less than 60,000/mcL. (4) Used in combination with standard immunosuppressive therapy (e.g. Atgam [antithymocyte globulin equine] and cyclosporine). Refractory Severe Aplastic Anemia (RSAA)(Initial): (1) Diagnosis of refractory severe aplastic anemia. (2) Member has a platelet count less than 30,000/mcL. (3) Inadequate response or inability to tolerate immunosuppressive therapy with antithymocyte globulin and cyclosporine. Chronic Hepatitis C-Associated Thrombocytopenia (HEPC-TP): (1) Diagnosis of chronic hepatitis C-associated thrombocytopenia. (2) One of the following: (a) Planning to initiate and maintain interferon-based treatment, or (b) currently receiving interferon-based treatment.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP, FLSAA, RSAA)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist. (HEPC-TP)(Initial, Continuation): Prescribed by or in consultation with Hematologist/oncologist, Gastroenterologist, Hepatologist, Infectious disease specialist, HIV specialist.
<b>Coverage Duration</b>	(ITP)Initial,Cont.=12mo.(FLSAA)=6mo.(RSAA)Initial=6mo.(HEPC-TP)Initial=3mo.(RSAA,HEPC-TP)Cont.=12mo.

PA Criteria	Criteria Details
<b>Other Criteria</b>	(ITP, RSAA)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. (HEPC-TP)(Continuation): (1) ONE of the following: (A) For members that started treatment with Promacta prior to initiation of treatment with interferon, both of the following: (i) Member is currently on antiviral interferon therapy for treatment of chronic hepatitis C, AND (ii) member reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9. (B) For members that started treatment with Promacta while on concomitant treatment with interferon, member is currently on antiviral interferon therapy for treatment of chronic hepatitis C.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PYRUKYND 2025

## Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hemolytic anemia with pyruvate kinase deficiency (HAWPKD) (Initial): (1) Diagnosis of hemolytic anemia confirmed by the presence of chronic hemolysis (e.g. increased indirect bilirubin, elevated lactated dehydrogenase [LDH], decreased haptoglobin, increased reticulocyte count) (2) Diagnosis of pyruvate kinase deficiency confirmed by molecular testing of ALL of the following mutations on the PKLR gene: (a) Presence of at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 was a missense variant, (b) Member is not homozygous for the c. 1436G A (p.R479H) variant, (c) Member does not have 2 non-missense variants (without the presence of another missense variant) in the PKLR gene (3) Hemoglobin is less than or equal to 10g/dL (4) Member has symptomatic anemia or is transfusion dependent (5) Other causes of hemolytic anemia (e.g. infections, toxins, drugs) have been ruled out.
<b>Age Restrictions</b>	(HAWPKD) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(HAWPKD) (Initial, Reauth): Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(HAWPKD)(Reauth): (1) Documentation of positive clinical response to therapy, (e.g. reduction in transfusions compared to the member's historical transfusion burden, improvement in markers of hemolysis from baseline (e.g. bilirubin, lactated dehydrogenase [LDH], haptoglobin, reticulocyte count)).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QUALAQUIN 2025

## Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Use for treatment or prevention of nocturnal leg cramps
<b>Required Medical Information</b>	Uncomplicated Malaria: (1) Diagnosis of uncomplicated malaria due to (a) plasmodium falciparum malaria or (b) plasmodium vivax . (2) One of the following: (a) Both of the following: (i) treatment in areas of chloroquine-sensitive malaria (ii) Inadequate response or inability to tolerate chloroquine or hydroxychloroquine, or (b) treatment in areas of chloroquine-resistant malaria. Babesiosis: (1) Diagnosis of babesiosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Babesiosis: 10 days Uncomplicated Malaria: 14 Days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QULIPTA 2025

## Products Affected

- QULIPTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(MP) (Initial, Reauth): Medication will be used in combination with another CGRP inhibitor for the preventive treatment of migraines.
<b>Required Medical Information</b>	Migraine Prevention (MP)(Initial): (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND (2) Inadequate response or inability to tolerate BOTH of the following: (a) Emgality AND (b) Aimovig.
<b>Age Restrictions</b>	(Migraine Prevention) (Initial, Reauth): Member 18 years of age
<b>Prescriber Restrictions</b>	(Migraine Prevention) (Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist
<b>Coverage Duration</b>	(Migraine Prevention) (Initial): 6 months (Migraine Prevention) (Reauth): 12 months
<b>Other Criteria</b>	(Migraine Prevention) (Reauth): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QUVIVIQ 2025

---

## Products Affected

- QUVIVIQ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(Insomnia): (1) Diagnosis of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (2) inadequate response or inability to tolerate ramelteon and Belsomra
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# RADICAVA 2025

## Products Affected

- RADICAVA ORS STARTER KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Amyotrophic Lateral Sclerosis (ALS)(Initial): (1) Diagnosis of definite or probable ALS per the revised El Escorial World Federation of Neurology criteria. (2) Normal respiratory function defined as forced vital capacity (FVC) of greater than or equal to 80% at the start of treatment. (3) Scores of 2 points or greater on each individual item of the ALS Functional Rating Scale-revised (ALSFRS-R).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ALS)(Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): 6 months.
<b>Other Criteria</b>	(ALS)(Reauth): (1) Member shows benefit from therapy (e.g. slowing of decline of functional abilities).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RAVICTI 2025

## Products Affected

- RAVICTI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(UCD): Acute hyperammonemia. N-acetyl glutamate synthase (NAGS) deficiency
<b>Required Medical Information</b>	Urea Cycle Disorder (UCD): (1) Diagnosis of urea cycle disorder involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AAS) confirmed via enzymatic, biochemical, or genetic testing. (2) Inadequate response or inability to tolerate sodium phenylbutyrate (3) Inadequate response to one of the following: Dietary protein restriction or Amino acid supplementation
<b>Age Restrictions</b>	(UCD): Member is 2 months of age or older
<b>Prescriber Restrictions</b>	(UCD) (Initial) (Reauth): Prescribed by or in consultation with a specialist focused on the treatment of metabolic disorders
<b>Coverage Duration</b>	Initial: 6 months Reauth: 12 months
<b>Other Criteria</b>	(Reauth) (1) Documentation of positive clinical response to therapy (e.g. plasma ammonia or amino acid levels within normal limits) (2) Will be used concomitantly with dietary protein restriction and, in some cases, dietary supplements.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# RECORLEV 2025

## Products Affected

- RECORLEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cushing's Syndrome (CS) (Initial): (1) Diagnosis of Cushing's syndrome (2) Member is being treated for endogenous hypercortisolemia (e.g. pituitary adenoma, ectopic tumor, adrenal adenoma) (3) One of the following: (a) Member is not a candidate for surgery, (b) surgery has not been curative (4) Inadequate response or inability to tolerate oral ketoconazole
<b>Age Restrictions</b>	(CS) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CS) (Initial) (Reauth): Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial) (Reauth): 12 months
<b>Other Criteria</b>	(CS) (Reauth): (1) Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REPATHA 2025

## Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia. Atherosclerotic cardiovascular disease (ASCVD)(Initial): (1) Diagnosis of ASCVD confirmed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (HLA, ASCVD) (Initial): ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASCVD)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# RESPIRATORY ENZYMES 2025

## Products Affected

- ARALAST NP INTRAVENOUS SOLUTION  
RECONSTITUTED 1000 MG
- GLASSIA INTRAVENOUS SOLUTION 1000  
MG/50ML
- PROLASTIN-C INTRAVENOUS SOLUTION
- ZEMAIRA INTRAVENOUS SOLUTION  
RECONSTITUTED 1000 MG

PA Criteria	Criteria Details
Exclusion Criteria	(ATT): (1) IgA deficiency with known anti-IgA antibody.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# REZDIFFRA 2025

## Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(MASH) (Initial): (1) Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) (2) Documentation of ONE of the following: (a) FibroScan-aspartate aminotransferase (FAST) (b) MRI-aspartate aminotransferase (MAST) (c) Liver biopsy (3) Documentation that disease is fibrosis stage F2 or F3 as confirmed by ONE of the following: (a) FibroScan (b) Fibrosis-4 index (FIB-4) (c) Magnetic Resonance Elastography (MRE). (4) Presence of greater than or equal to 3 metabolic risk factors (e.g. Type 2 diabetes, hypertension, obesity) (5) Drug is used as adjunct to lifestyle modification (e.g. dietary or caloric restriction, exercise, behavioral support, community-based program)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth) Prescribed by or in consultation with a gastroenterologist or hepatologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(MASH) (Reauth): (1) Member demonstrates positive response to therapy (e.g. MASH resolution, fibrosis stage improvement, etc.) (2) Member has not progressed to cirrhosis
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REZUROCK 2025

## Products Affected

- REZUROCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic graft-versus-host disease (cGVHD) (Initial): (1) Diagnosis of chronic graft-versus-host disease, (2) Inadequate response or inability to tolerate two or more lines of systemic therapy (e.g. corticosteroids, mycophenolate, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(cGVHD) (Initial/Reauth): Prescribed by or in consultation with one of the following (1) Hematologist, (2) Oncologist, (3) physician experienced in the management of transplant patients
<b>Coverage Duration</b>	(Initial/Reauth): 12 months
<b>Other Criteria</b>	(cGVHD) (Reauth): (1) Member does not show evidence of progressive disease while on therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RINVOQ 2025

## Products Affected

- RINVOQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, AD, UC, AS, nr- AxSPA, CD, PJIA): Concurrent use with any other biologic disease modifying antirheumatic drug (DMARD), other JAK inhibitors, or potent immunosuppressants (e.g. azathioprine, cyclosporine).
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severely active RA. (2) Member has inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine (3) Member had inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab- ADBM, Adalimumab-AACF) OR documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADBM, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate. Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe atopic dermatitis, (2) Inadequate response of or inability to tolerate at least ONE of the following: (a) medium or higher potency topical corticosteroid, (b) pimecrolimus cream, (c) Topical tacrolimus cream, (d) Eucrisa (crisaborole) ointment (3) Inadequate response or inability to tolerate at least one systemic drug product for the treatment of atopic dermatitis (examples include, but are not limited to Dupixent, Adbry or documentation that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of Ulcerative Colitis (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Humira, Adalimumab-ADBM, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(RA, UC, AS, nr-AxSPA, CD): Member is 18 years of age or older (AD): Member is 12 years of age or older. (PsA, PJIA): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(RA, AS, nr-AxSPA, PJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist. (UC, CD): Prescribed by or in consultation with a gastroenterologist.

PA Criteria	Criteria Details
Coverage Duration	Indefinite
Other Criteria	<p>Ankylosing Spondylitis (AS): (1) Diagnosis of active ankylosing spondylitis. (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF) OR documentation demonstrating that a trial may be inappropriate. Non-radiographic axial spondylarthritis (nr-AxSPA): (1) Diagnosis of nr-AxSPA (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF, Cimzia) or documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID. Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine) (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF) OR documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of active PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, adalimumab-ADB, Adalimumab-AACF), or documentation demonstrating that a trial may be inappropriate.</p>
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# RINVOQ LQ 2025

## Products Affected

- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsA, pJIA): Concurrent use with any other biologic disease modifying antirheumatic drug (DMARD), other JAK inhibitors, or potent immunosuppressants (e.g. azathioprine, cyclosporine).
<b>Required Medical Information</b>	Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of active PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsA, pJIA): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (pJIA): Prescribed by or in consultation with a rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RIVFLOZA 2025

## Products Affected

- RIVFLOZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PH1)(Initial): (1) Diagnosis of primary hyperoxaluria type 1 (PH1) (2) Disease has been confirmed by both of the following: (a) One of the following: (i) elevated urinary oxalate excretion (ii) elevated plasma oxalate concentration (iii) spot urinary oxalate to creatinine molar ratio greater than normal for age (b) One of the following: (i) genetic testing demonstrating a mutation in the alanine: glyoxylate aminotransferase (AGXT) gene (ii) Liver biopsy demonstrating absence or reduced alanine: glyoxylate aminotransferase (AGT) activity (3) Member has preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m2)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PH1) (Initial, Reauth): Prescribed by or in consultation with one of the following: hepatologist, nephrologist, urologist, geneticist, specialist with expertise in the treatment of PH1
<b>Coverage Duration</b>	(PH1) (Initial, Reauth): 12 months
<b>Other Criteria</b>	(PH1) (Reauth): Member demonstrates positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SAMSCA 2025

## Products Affected

- SAMSCA
- *tolvaptan oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Hyponatremia: (1) Members who are unable to sense or appropriately respond to thirst, (2) hypovolemic hyponatremia, (3) concomitant use of strong CYP3A inhibitors
<b>Required Medical Information</b>	Hyponatremia: (1) Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia (2) Treatment has been initiated or re-initiated in a hospital setting prior to discharge within the past 30 days
<b>Age Restrictions</b>	Hyponatremia: Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	Hyponatremia: Prescribed by or in consultation with a cardiologist, endocrinologist or nephrologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SEROSTIM 2025

## Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION  
RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Wasting or Cachexia Associated with HIV (WC-HIV): (1) Diagnosis of wasting or cachexia associated with HIV. AND (2) One of the following: (a) Unintentional weight loss of greater than 10% over the last 12 months OR unintentional weight loss of greater than 7.5% over the last 6 months OR loss of 5% body cell mass within 6 months OR body mass index less than 20kg/m <sup>2</sup> OR (b) One of the following: (i) Patient is male, BCM less than 35% of total body weight, BMI less than 27kg/m <sup>2</sup> OR (ii) Patient is female, BCM less than 23% of total body weight, BMI less than 27kg/m <sup>2</sup> AND (3) Member is receiving concomitant antiretroviral therapy AND (4) Nutritional evaluation since onset of wasting first occurred AND (5) Patient has tried and failed or unable to tolerate either dronabinol or megestrol acetate.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(WC-HIV): Prescribed by or in consultation with a HIV specialist or infectious disease specialist
<b>Coverage Duration</b>	48 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIGNIFOR 2025

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cushing's disease (CD)(Initial): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative
<b>Age Restrictions</b>	(CD)(Initial): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CD)(Initial, Reauth): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CD)(Reauth): Documentation of positive clinical response (e.g. clinically meaningful reduction in 24- hour urinary free cortisol levels, improvement in signs or symptoms of the disease)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SILDENAFIL 2025

## Products Affected

- REVATIO ORAL TABLET
- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH, RP): Documentation of concomitant nitrate use
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Mean pulmonary artery pressure greater than or equal 25 mm Hg at rest or greater than 30 mm Hg with exertion. Raynaud's Phenomenon (RP): (1) Diagnosis of secondary Raynaud's phenomenon. (2) Inadequate response or inability to tolerate a calcium channel blocker.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH, RP): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SILIQ 2025

## Products Affected

- SILIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO)(Initial, Reauth): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque psoriasis (PsO)(Initial): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, adalimumab-ADB, adalimumab-AACF), (b) etanercept (Enbrel), (c) Skyrizi, (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsO)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO)(Initial, Reauth): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(Initial): 16 weeks (Reauth) 1 year
<b>Other Criteria</b>	(PsO) (Reauth): (1) Member has positive response to therapy as evidenced by one of the following: (i) Reduction in the body surface area (BSA) involvement from baseline, (ii) Improvement in symptoms (e.g. pruritus, inflammation) from baseline.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIMPONI 2025

## Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AS, PsA, RA, UC): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e., Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR, (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Ustekinumab (i.e. Yesintek), (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), and (b) Xeljanz/Xeljanz XR, (c) Ustekinumab (i.e. Yesintek), (d) Rinvoq, (e) Skyrizi OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(AS, PsA, RA, UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (UC): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	



PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# SIRTURO 2025

## Products Affected

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB): (1) Diagnosis of MDR-TB. (2) Member weighs at least 15kg (applies to members 5 to less than 18 years of age). (3) One of the following: (a) Medication will be used in combination with at least 3 other drugs to which the member's MDR-TB isolate has been shown to be susceptible in vitro OR (b) If in vitro testing results are unavailable, treatment will be initiated in combination with at least 4 other drugs to which the member's MDR-TB isolate is likely to be susceptible. (4) Sirturo (bedaquiline) will be administered by directly observed therapy (DOT).
<b>Age Restrictions</b>	(MDR-TB): Member is 5 years of age or older.
<b>Prescriber Restrictions</b>	(MDR-TB): Prescribed by or in consultation with infectious disease specialist or pulmonologist
<b>Coverage Duration</b>	24 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYCLARYS 2025

## Products Affected

- SKYCLARYS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Friedreich Ataxia (FA)(Initial): (1) Diagnosis of Friedreich Ataxia (FA) confirmed by genetic testing demonstrating mutation in the FXN gene (2) Member has a Modified Friedreich's Ataxia Rating Scale (mFARS) score of greater than or equal to 20 and less than or equal to 80 (3) Member has B-type natriuretic peptide value less than or equal to 200 pg/ml
<b>Age Restrictions</b>	(FA)(Initial)(Reauth): member is 16 years of age or older
<b>Prescriber Restrictions</b>	(FA)(Initial)(Reauth): Prescribed by or in consultation with one of the following specialists: neurologist, neurogeneticist, Physiatrist (Physical Medicine and Rehabilitation Specialist)
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): 12 months
<b>Other Criteria</b>	(FA)(Reauth): (1) Documentation of positive clinical response to therapy as evidenced by one of the following: (a) an increase in peak work (in Watts/kg) during exercise testing from baseline (b) a decrease in the rate of progression of Modified Friedreich's Ataxia Rating Scale (mFARS)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYRIZI SC 2025

## Products Affected

- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, CD, UC): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque psoriasis (PsO): Diagnosis of moderate to severe PsO. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. Crohn's Disease (CD): (1) Diagnosis of CD. (2) One of the following: (a) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine). (b) Used as a maintenance therapy following induction therapy with the IV formulation. Ulcerative Colitis (UC): (1) Diagnosis of moderately to severely active UC (2) One of the following: (a) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, aminosalicylate, azathioprine or 6-mercaptopurine) (b) will be used as a maintenance dose following the intravenous induction doses.
<b>Age Restrictions</b>	(PsO, PsA, CD, UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation a dermatologist (PsA): Prescribed by or consultation with a rheumatologist or dermatologist (CD, UC): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Part B drug applies only to beneficiaries enrolled in an MA-PD plan.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYTROFA 2025

## Products Affected

- SKYTROFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Growth Failure in Children (GFC)(Initial): (1) Diagnosis of growth hormone deficiency confirmed by one of the following: (a) Height is documented by one of the following (utilizing age and gender growth charts related to height): (i) Height is greater than 2.0 standard deviations [SD] below mid parental height (ii) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender). (2) Growth velocity is greater than 2 SD below mean for age and gender. (3) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g. delayed is greater than 2 years compared with chronological age). (4) documentation of bone age, abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine (5) Inadequate response or inability to tolerate both of the following: Genotropin and Nutropin AQ or Nutropin AQ NuSpin
<b>Age Restrictions</b>	(GFC) (Initial, Reauth): Member is 1 years of age or greater
<b>Prescriber Restrictions</b>	(GFC)(Initial): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(GFC) (Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist (2) Growth velocity greater than or equal to 2.5 cm/year. (GHDA)(Continuation): Annual clinical re-evaluation by the treating endocrinologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SOGROYA 2025

## Products Affected

- SOGROYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Growth Failure in Children (GFC)(Initial): (1) Diagnosis of growth hormone deficiency confirmed by one of the following: (a) Height is documented by one of the following (utilizing age and gender growth charts related to height): (i) Height is greater than 2.0 standard deviations [SD] below mid parental height (ii) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender). (b) Growth velocity is greater than 2 SD below mean for age and gender.(c) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g. delayed is greater than 2 years compared with chronological age) (2) documentation of bone age, (3) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine (4) Inadequate response or inability to tolerate both of the following: Genotropin and Nutropin AQ, or Nutropin AQ NuSpin. Diagnostically confirmed Growth Hormone Deficiency in adults (GHDA)(Initial)
<b>Age Restrictions</b>	(GFC) (Initial, Continuation): Member is 2.5 years of age or greater. (GHDA)(Initial, Continuation): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	(GFC, GHDA)(Initial, Continuation): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(GFC) (Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist (2) Growth velocity greater than or equal to 2.5 cm/year. (GHDA)(Continuation): Annual clinical re-evaluation by the treating endocrinologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SOHONOS 2025

## Products Affected

- SOHONOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(FOP)(Initial): (1) Diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) (2) Molecular genetic testing confirms mutations in the ACVR1 gene
<b>Age Restrictions</b>	(FOP) (Initial, Reauth): For female members: 8 years of age or older. For male members: 10 years of age or older
<b>Prescriber Restrictions</b>	(FOP) (Initial, Reauth): Prescribed by or in consultation with geneticist or orthopedic physician
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(FOP)(Reauth): (1) Documentation is provided that member demonstrates positive clinical response to therapy (e.g. reduction in volume in new abnormal bone growth)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SOTATERCEPT 2025

## Products Affected

- WINREVAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to III (2) inadequate response or inability to tolerate TWO of the following: (a) Endothelin Receptor Antagonist (bosentan, ambrisentan, macitentan) (b) Phosphodiesterase 5 inhibitor (tadalafil, sildenafil) (c) IV prostacyclin therapy (treprostinil, epoprostenol) (3) Member continues to receive other PAH therapies (e.g., ambrisentan, tadalafil)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial) (Reauth): Prescribed by or in consultation with cardiologist or pulmonologist.
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(PAH)(Reauth): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SOTYKTU 2025

## Products Affected

- SOTYKTU

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Plaque Psoriasis (PsO): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	(PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsO): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SPEVIGO SQ 2025

## Products Affected

- SPEVIGO SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(GPP)(Initial): (1) Diagnosis of generalized pustular psoriasis (GPP) as defined by both of the following: (a) Primary, sterile, macroscopically visible pustules on non-acral skin (excluding cases where pustulation is restricted to psoriatic plaques) (b) Disease is relapsing (more than 1 episode) or persistent (more than 3 months) (2) Subcutaneous formulation will not be used to treat GPP flare (3) Member weighs at least 40 kg
<b>Age Restrictions</b>	(GPP) (Initial, Reauth): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(GPP): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(GPP)(Reauth): Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# STELARA SQ 2025

## Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(CD, UC, PsA, PsO): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Part D is medically necessary when: Plaque psoriasis (PsO): Diagnosis of moderate to severe PsO. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. methotrexate) Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC.
<b>Age Restrictions</b>	(CD, UC): Member is 18 years of age or older. (PsO, PsA): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	(CD, UC): prescribed by or in consultation with a Gastroenterologist. (PsO): prescribed by or in consultation with a Dermatologist. (PsA): prescribed by or in consultation with a Dermatologist or Rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SUNOSI 2025

## Products Affected

- SUNOSI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NARCOLEPSY: (1) One of the following: (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) (b) prescriber provides justification that a sleep study is not feasible, (2) Inadequate response or inability to tolerate modafinil or armodafinil. OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), (2) documentation that the medication is being used as an adjunct treatment for the underlying obstruction, (3) inadequate response or inability to tolerate modafinil or armodafinil.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SYMDEKO 2025

## Products Affected

- SYMDEKO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis. (2) One of the following: a) Member is homozygous for the F508del mutation, or b) Member has at least one tezacaftor/ivacaftor responsive mutation in the CFTR gene. (3) If the member's genotype is unknown, an FDA-cleared test must be used to detect the presence of CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test
<b>Age Restrictions</b>	(CF): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SYMLIN 2025

## Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION  
PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION  
PEN-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(DM): Gastroparesis.
<b>Required Medical Information</b>	Diabetes Mellitus (DM): (1) Diagnosis of diabetes (Type 1 or Type 2). (2) inadequate response to optimal insulin monotherapy. (3) concurrent use of mealtime insulin.
<b>Age Restrictions</b>	(DM): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TADLIQ 2025

## Products Affected

- TADLIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to III, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, (4) inadequate response or inability to tolerate generic tadalafil
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(PAH)(Reauth): (1) Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TAFAMIDIS 2025

## Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)(Initial): (1) Diagnosis of ATTR-CM confirmed by one of the following: (a) Member has a transthyretin (TTR) mutation (e.g. V122I), (b) cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, or (c) all of the following: echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, scintigraphy scan suggestive of cardiac TTR amyloidosis, and absence of light-chain amyloidosis, (2) One of the following: (a) History of heart failure (HF), with at least one prior hospitalization for HF, or (b) presence of clinical signs and symptoms of HF (e.g. dyspnea, edema), (3) Member has New York Heart Association (NYHA) Functional Class I, II, or III heart failure
<b>Age Restrictions</b>	(ATTR-CM) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ATTR-CM) (Initial, Reauth): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(ATTR-CM)(Reauth): (1) Positive clinical response to therapy, (2) Member continues to have NYHA Functional Class I, II, or III heart failure.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TAKHZYRO 2025

## Products Affected

- TAKHZYRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Part D is medically necessary when: Hereditary Angioedema (HAE): (1) Diagnosis of HAE. (2) For prophylaxis against HAE attacks.
Age Restrictions	
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TALTZ 2025

## Products Affected

- TALTZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, AS, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	<p>Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) ONE of the following: (A) For members 6 to 17 years of age: an inadequate response or inability to tolerate two of the following: (a) Enbrel, (b) Cosentyx, (c) Ustekinumab (i.e. Yesintek) or documentation demonstrating that a trial may be inappropriate, OR (B) For members 18 years of age or older: an inadequate response or inability to tolerate two of the following: (a) Cosentyx (b) Enbrel (c) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF) (d) Skyrizi, (e) Ustekinumab (i.e. Yesintek), (f) Otezla or documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Enbrel (b) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF) (c) Cosentyx (d) Rinvoq/Rinvoq LQ (e) Skyrizi (f) Ustekinumab (i.e. Yesintek) (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Ankylosing spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) upadacitinib (Rinvoq), (e) tofacitinib (Xeljanz/Xeljanz XR) OR documentation demonstrating that a trial may be inappropriate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen).</p>
<b>Age Restrictions</b>	(PsA, AS, nr-axSpA): Member is 18 years of age or older. (PsO): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TARPEYO 2025

## Products Affected

- TARPEYO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Immunoglobulin A nephropathy (IgAN): (1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) (2) Member is at risk of rapid disease progression [e.g. generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such as clinical risk scoring using the international IgAN Prediction Tool] (3) Used to reduce proteinuria (4) Estimated glomerular filtration rate (eGFR) greater than or equal to 35 ml/min/1.73 m <sup>2</sup> (5) One of the following: (a) Member has been on a minimum 90-day trial of maximally tolerated dose and will continue to receive therapy with one of the following: (i) an angiotensin-converting enzyme (ACE) inhibitor (e.g. benazepril, lisinopril), (ii) An angiotensin II receptor blocker (ARB) (e.g. losartan, valsartan), (b) Member is unable to tolerate both ACE inhibitors and ARBs (6) Inadequate response or inability to tolerate another glucocorticoid (e.g. prednisone, methylprednisolone)
<b>Age Restrictions</b>	(IgAN): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(IgAN): Prescribed by or in consultation with a nephrologist
<b>Coverage Duration</b>	9 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TAVALISSE 2025

## Products Affected

- TAVALISSE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Immune Thrombocytopenia (ITP)(Initial): (1) Diagnosis of Chronic Immune Thrombocytopenia (ITP) (2) Documentation of baseline platelet count less than 30,000/mcL, (3) Inadequate response or inability to tolerate ONE of the following: (a) Corticosteroids, (b) Immunoglobulins, (c) Splenectomy, (d) Thrombopoietin receptor agonists (e.g. Nplate, Promacta), or (e) rituximab (Rituxan).
<b>Age Restrictions</b>	(ITP)(Initial, Continuation): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ITP)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(ITP)(Continuation): (1) Positive clinical response to Tavalisse therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	Yes

# TAVNEOS 2025

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) (ANCA-V(GPA)(MPA))(Initial): (1) Diagnosis of Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) AND 2) Used as adjunct to standard therapy, and glucocorticoids
<b>Age Restrictions</b>	(ANCA-V(GPA)(MPA))(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ANCA-V(GPA)(MPA))(Initial, Reauth): Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.
<b>Coverage Duration</b>	(Initial): 6 Months (Reauth): 1 year
<b>Other Criteria</b>	(ANCA-V(GPA)(MPA))(Reauth): (1) Positive clinical response to therapy defined as sustained remission as assessed by the Birmingham Vasculitis Activity Score (BVAS). (2) Used as adjunct to standard therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TERIPARATIDE 2025

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 560 MCG/2.24ML
- *teriparatide subcutaneous solution pen-injector*  
620 mcg/2.48ml

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Primary or Hypogonadal Osteoporosis (HGO)(Initial): (1) Diagnosis of HGO in men. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T-score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.). (3) Inadequate response or inability to tolerate (a) bisphosphonates or (b) hormone replacement therapy.</p> <p>Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia).</p>
<b>Age Restrictions</b>	(HGO, PMO, GCO) (Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial and Reauth): Remainder of contract year

PA Criteria	Criteria Details
<b>Other Criteria</b>	Glucocorticoid Induced Osteoporosis (GCO)(Initial): (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), or (d) Denosumab (Prolia). (HGO, PMO, GCO) (Reauth): One of the following: (1) Cumulative lifetime therapy does not exceed 2 years [applies to Teriparatide and Forteo], OR (2) member remains at or has returned to having a high risk for fracture despite a total of 24 months of use of parathyroid hormones [applies to Forteo only].
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TESTOSTERONE PRODUCTS 2025

## Products Affected

- AVEED 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%),
- DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)
- JATENZO • testosterone transdermal solution
- testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml • TLANDO
- testosterone enanthate intramuscular solution • UNDECATREX
- testosterone transdermal gel 10 mg/act (2%), • XYOSTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Delayed Puberty (DP): (1) Diagnosis of delayed puberty in male members (Applies to Testosterone Enanthate only). Breast Cancer (BC): (1) Diagnosis of inoperable breast cancer in female members (Applies to Testosterone Enanthate only) (2) Used for palliative treatment Hypogonadism (HG)(New starts only): (1) Attestation that diagnosis was initially confirmed by ALL of the following: (A) Two early morning total testosterone levels below 300 ng/dL measured on separate occasions, (B) Normal Prolactin Level, and (C) Physical or cognitive symptoms of testosterone deficiency (e.g. physical: fatigue, sleep disturbances, decreased activity, cognitive: depressive symptoms, cognitive dysfunction, loss of concentration, poor memory, irritability), (2) ONE of the following (A) negative history of prostate and breast cancer OR (B) Both of the following (i) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (ii) documentation that the risk versus benefit has been assessed.
<b>Age Restrictions</b>	(HG) Member is 12 years of age or older (applies to generic testosterone cypionate only) and member is 18 years of age or older for all other products
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(DP, BC): Indefinite (HG)(New Starts, Continuation): Indefinite
<b>Other Criteria</b>	(HG)(Continuation): ONE of the following (1) negative history of prostate and breast cancer OR (2) Both of the following (a) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (b) documentation that the risk versus benefit has been assessed
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# TOCILIZUMAB SQ 2025

## Products Affected

- TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PJIA, SJIA, RA, GCA, SSc-ILD): Concurrent therapy with other biologic disease modifying antirheumatic drug (DMARD), e.g. tumor necrosis factor antagonists.
<b>Required Medical Information</b>	Part D is medically necessary when there is documentation of the following: Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) etanercept (Enbrel), (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ OR documentation demonstrating that a trial may be inappropriate. Systemic Juvenile Idiopathic Arthritis (SJIA): (1) Diagnosis of SJIA. (2) Inadequate response or inability to tolerate ONE of the following: (a) Non-steroidal antiinflammatory drug (NSAID), (b) Systemic glucocorticoid, (c) Methotrexate. Moderate to severe rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia, OR documentation demonstrating that a trial may be inappropriate. Giant Cell Arteritis (GCA): (1) Diagnosis of GCA. (2) Documentation of inadequate response/inability to tolerate oral corticosteroids. Systemic Sclerosis (SSc-ILD) (1): Diagnosis of SSc-ILD (2) Documentation of inadequate response/inability to tolerate a 3-month trial of ONE of the following: (a) mycophenolate mofetil, (b) cyclophosphamide, OR (c) azathioprine (3) Diagnosis of SSc-ILD confirmed by a high-resolution CT scan or biopsy
<b>Age Restrictions</b>	(PJIA, SJIA): Member is 2 years of age or older (RA, GCA, SSc-ILD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PJIA, SJIA, RA, GCA): Prescribed by or in consultation with a Rheumatologist (SSc-ILD) -Prescribed by or in consultation with a rheumatologist or pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TOPICAL CHEMO AGENTS 2025

## Products Affected

- *bexarotene*
- TARGRETIN
- VALCHLOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TOPICAL RETINOID PRODUCTS 2025

## Products Affected

- *adapalene external cream*
- *adapalene external gel 0.3 %*
- *adapalene external pad*
- *adapalene-benzoyl peroxide external gel*
- AKLIEF
- ALTRENO
- ATRALIN
- CABTREO
- *clindamycin-tretinoin*
- DIFFERIN EXTERNAL CREAM
- DIFFERIN EXTERNAL GEL 0.3 %
- EPIDUO
- EPIDUO FORTE
- RETIN-A
- RETIN-A MICRO
- RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 %
- *tretinoin external*
- *tretinoin microsphere external gel 0.04 %, 0.1 %*
- *tretinoin microsphere pump external gel 0.08 %*
- TWYNEO
- ZIANA

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TRACLEER 2025

## Products Affected

- *bosentan*
- TRACLEER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) Inadequate response or inability to tolerate bosentan (applies to brand Tracleer only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TREMFYA 2025

## Products Affected

- TREMFYA ONE-PRESS PREFILLED SYRINGE
- TREMFYA PEN SUBCUTANEOUS SOLUTION  
AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, UC, CD): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	<p>Plaque psoriasis (PsO): (1) Diagnosis or moderate to severe PsO. (2) Inadequate response or inability to tolerate two of the following: (a) Cosentyx, (b) Enbrel, (c) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (d) Skyrizi, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF) (b) Enbrel (c) Cosentyx (d) Rinvoq/Rinvoq LQ (e) Skyrizi (f) Ustekinumab (i.e. Yesintek) (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla or documentation demonstrating that a trial may be inappropriate. Ulcerative colitis (UC) (Initial): (1) Diagnosis of moderately to severely active UC (2) ONE of the following: (a) Inadequate response or inability to tolerate two of the following: (i) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF), (ii) ustekinumab (i.e. Yesintek), (iii) upadacitinib (Rinvoq), (iv) tofacitinib (Xeljanz/Xeljanz XR), (v) risankizumab (Skyrizi) OR documentation demonstrating that a trial may be inappropriate (b) Will be used as a maintenance dose following the intravenous induction doses Crohn's Disease (CD)(Initial): (1) Diagnosis of moderately to severely active CD (2) One of the following: (A) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, adalimumab-adb, Adalimumab-AACF), (b) Ustekinumab (i.e. Yesintek), (c) Skyrizi, (d) Rinvoq or documentation demonstrating that a trial may be inappropriate. (B) Will be used as a maintenance dose following the intravenous induction doses</p>
<b>Age Restrictions</b>	(PsO, PsA, UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (UC)(CD): Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	(PSO, PSA, UC) Indefinite (CD): 12 months



PA Criteria	Criteria Details
<b>Other Criteria</b>	(CD)(Reauth): Member demonstrates positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIKAFTA 2025

## Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis. (2) Member has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene as detected by an FDA-cleared cystic fibrosis mutation test OR a mutation in the CFTR gene that is responsive based on in vitro data.
Age Restrictions	(CF): Member is 2 years of age or older
Prescriber Restrictions	(CF): Prescribed by or in consultation with a pulmonologist or Specialist affiliated with a CF care center
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TRYVIO 2025

## Products Affected

- TRYVIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hypertension (HTN)(Initial): (1) Diagnosis of hypertension (2) Member has not achieved target blood pressure (e.g., systolic blood pressure [SBP] less than 130 mmHg) after treatment with at least THREE of the following antihypertensive medications from different classes for a minimum of 4 weeks each at maximally tolerate doses: (a) One of the following: (i) Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril) (ii) Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan) (b) Diuretic (e.g., hydrochlorothiazide, chlorthalidone) (c) Calcium channel blocker (e.g., amlodipine, nifedipine) (d) Mineralocorticoid receptor antagonist (MRA) [e.g., eplerenone, spironolactone] (3) Provider attests other causes of hypertension have been ruled out (e.g., secondary causes [primary hyperaldosteronism], white coat effect, medication nonadherence) (4) Medication will be used in combination with at least 3 antihypertensive medications from different classes
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a specialist experienced in the treatment of resistant hypertension (e.g., cardiologist, nephrologist)
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(HTN)(Reauth) (1) Member demonstrates positive clinical response to therapy (2) Member continues to use Tryvio in combination with at least 3 antihypertensive medications from different classes
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TYMLOS 2025

## Products Affected

- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. Low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.) (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). Osteoporosis at high risk for fracture in men (OSTm) (Initial): (1) Diagnosis of primary or hypogonadal osteoporosis (2) Both of the following: (a) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) (b) One of the following (i) History of low-trauma fracture of the hip, spine, pelvis, or distal forearm (ii) inadequate response or inability to tolerate at least one osteoporosis treatment (e.g. alendronate, risedronate, zoledronic acid, Prolia [denosumab])
<b>Age Restrictions</b>	(PMO, OSTm) (Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial and Reauth): Remainder of contract year
<b>Other Criteria</b>	(PMO, OSTm)(Reauth): Cumulative lifetime therapy does not exceed 2 years
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TYVASO DPI 2025

## Products Affected

- TYVASO DPI MAINTENANCE KIT INHALATION  
POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG
- TYVASO DPI TITRATION KIT INHALATION  
POWDER 16 & 32 & 48 MCG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (Initial): (1) Diagnosis of pulmonary hypertension associated with interstitial lung disease (PHILD) WHO Group 3. (2) Diagnosis confirmed by diagnostic test(s) (e.g. right heart catheterization, doppler echocardiogram, computerized tomography imaging).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(PH-ILD)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	(PAH)(PH-ILD)(CONTINUATION): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# UBRELVY 2025

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Will be used for preventative treatment of migraine. Medication will be used in combination with another oral CGRP inhibitor.
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan.
<b>Age Restrictions</b>	(AM)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(Initial): 6 months. (AM)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# UPTRAVI 2025

## Products Affected

- UPTRAVI ORAL
- UPTRAVI TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH)(Initial, Reauth): Taken in combination with a prostanoid/prostacyclin analogue (e.g. epoprostenol, iloprost, treprostinil)
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV AND (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion AND (4) inadequate response or inability to tolerate TWO of the following (a) an endothelin receptor antagonist (Tracleer if naive to the class) (b) a phosphodiesterase inhibitor (sildenafil if naive to the class) (c) riociguat (Adempas).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): 12 months.
<b>Other Criteria</b>	(PAH)(REAUTH): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VECAMEYL 2025

---

## Products Affected

- VECAMEYL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(EHTN, MHTN): Uremia, glaucoma, organic pyloric stenosis, coronary insufficiency, recent myocardial infarction
<b>Required Medical Information</b>	Essential Hypertension (EHTN): (1) Diagnosis of moderately severe to severe essential hypertension (2) an inadequate response or inability to tolerate at least two antihypertensive medications in different classes. Malignant Hypertension (MHTN): (1) Diagnosis of malignant hypertension, (2) An inadequate response or inability to tolerate at least two antihypertensive medications in different classes.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# VELSIPITY 2025

## Products Affected

- VELSIPITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Ulcerative Colitis (UC): (1) Diagnosis of moderately to severely active Ulcerative Colitis (2) Inadequate response or inability to tolerate TWO of the following (a) Adalimumab (i.e. Humira, Adalimumab-ADB, Adalimumab-AACF) (b) Xeljanz/Xeljanz XR (c) Ustekinumab (i.e. Yesintek) (d) Rinvoq, (e) Skyrizi OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(UC): Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VEOZAH 2025

## Products Affected

- VEOZAH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(VMS)(Initial): (1) Diagnosis of moderate to severe vasomotor symptoms due to menopause (2) Inadequate response or inability to tolerate one of the following (a) menopausal hormone therapy (e.g. estradiol tablets) (b) non-hormonal therapy (e.g. paroxetine, venlafaxine, clonidine, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(VMS)(Initial): 6 months, (Reauth): 12 months
<b>Other Criteria</b>	(VMS)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. decrease in frequency and severity of vasomotor symptoms from baseline, etc.)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VERKAZIA 2025

## Products Affected

- VERKAZIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): (1) Diagnosis of moderate to severe vernal keratoconjunctivitis confirmed by the presence of clinical signs and symptoms (e.g. itching, photophobia, giant papillae at the upper tarsal conjunctiva or at the limbus, thick mucus discharge, conjunctival hyperemia). (2) Inadequate response or inability to tolerate one of the following: (a) Topical ophthalmic "dual-acting" mast cell stabilizer and antihistamine (e.g. olopatadine, azelastine), (b) Topical ophthalmic mast cell stabilizers (e.g. cromolyn). (3) Inadequate response or inability to tolerate short term use (up to 2 to 3 weeks), of topical ophthalmic corticosteroids (e.g. dexamethasone, prednisolone, fluorometholone).
<b>Age Restrictions</b>	(Initial, reauth): Member is 4 years of age or older
<b>Prescriber Restrictions</b>	(Initial, reauth): Prescribed by or in consultation with an ophthalmologist or optometrist
<b>Coverage Duration</b>	(Initial): 6 months, (reauth): 12 months
<b>Other Criteria</b>	(Reauth): Documentation of positive clinical response to therapy as evidenced by an improvement in clinical signs and symptoms (e.g. itching, photophobia, papillary hypertrophy, mucus discharge, conjunctival hyperemia)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIJOICE 2025

## Products Affected

- VIJOICE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PROS) (Initial): (1) Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS) (2) Documentation of mutation in the PIK3CA gene (3) Documentation of severe clinical manifestations (e.g. Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal [CLOVES], Facial Infiltrating Lipomatosis [FIL], Klippel-Trenaunay Syndrome [KTS], Megalencephaly-Capillary Malformation Polymicrogyria [MCAP])
<b>Age Restrictions</b>	(PROS) (Initial, Reauth): member is 2 years of age or older
<b>Prescriber Restrictions</b>	(PROS) (Initial, Reauth): Prescribed by or in consultation with a physician who specializes in the treatment of PROS
<b>Coverage Duration</b>	Initial: 6 months. Reauthorization: 12 months
<b>Other Criteria</b>	(PROS) (Reauth): (1) Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIVJOA 2025

## Products Affected

- VIVJOA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Recurrent vulvovaginal candidiasis (RVVC): Member is of reproductive potential
<b>Required Medical Information</b>	(RVVC): (1) Diagnosis of recurrent vulvovaginal candidiasis (RVVC) (2) Diagnosis of RVVC confirmed by one of the following: (a) positive potassium hydroxide (KOH) preparation (b) vaginal fungal culture (3) Member has experienced 3 or more symptomatic episodes of vulvovaginal candidiasis (VVC) within the past 12 months (4) Inadequate response or inability to tolerate BOTH of the following: (a) one intravaginal product (e.g. clotrimazole, miconazole, terconazole) (b) oral fluconazole
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	4 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VOQUEZNA PAK 2025

## Products Affected

- VOQUEZNA DUAL PAK
- VOQUEZNA TRIPLE PAK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(H. pylori): (1) Diagnosis of Helicobacter pylori infection (2) Inadequate response or inability to tolerate ONE of the following first line treatment regimens: (a) Clarithromycin based therapy (e.g. clarithromycin based triple therapy, clarithromycin based concomitant therapy), (b) Bismuth quadruple therapy (e.g. bismuth and metronidazole and tetracycline and proton pump inhibitor [PPI])
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(H. pylori): 1 month
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VOQUEZNA TABLETS 2025

## Products Affected

- VOQUEZNA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(H. pylori): (1) Diagnosis of Helicobacter pylori infection (2) One of the following: (a) Used in combination with amoxicillin and clarithromycin for the treatment of H. pylori infection OR (b) Used in combination with amoxicillin for the treatment of H. pylori infection (3) An inadequate response or inability to tolerate ONE of the following: (a) Clarithromycin based therapy (e.g. clarithromycin based triple therapy, clarithromycin based concomitant therapy) OR (b) Bismuth quadruple therapy (e.g. bismuth and metronidazole and tetracycline and proton pump inhibitor [PPI]). Erosive Esophagitis (EE): (1) ONE of the following: (a) Used for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis OR (b) Used to maintain healing and relief of heartburn associated with erosive esophagitis (2) An inadequate response or inability to tolerate TWO of the following generic proton pump inhibitors (PPI's): omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	H. pylori: 1 month Healing of EE: 8 weeks. Maintenance of EE: 6 month GERD: 1 month
<b>Other Criteria</b>	Heartburn with GERD: (1) Diagnosis of non-erosive Gastroesophageal Reflux Disease (GERD) (2) BOTH of the following: (a) Member has history of heartburn for at least 6 months (b) Heartburn symptoms are present for at least 4 days during any consecutive 7-day period (3) An inadequate response (minimum 8-week supply) or inability to tolerate TWO of the following generic proton pump inhibitors (PPI's): omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No



# VOWST 2025

## Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prevention of the recurrence of Clostridioides difficile infection (PCDI): (1) Diagnosis of recurrent Clostridioides difficile infection as defined by both of the following: (a) Presence of diarrhea defined as passage of 3 or more loose bowel movements within a 24-hour period for at least 2 consecutive days (b) a positive stool test for C. difficile toxin or toxigenic C. difficile (2) Member has a history of two or more recurrent episodes of CDI within 12 months (3) Member has completed at least 10 consecutive days of one of the following antibiotic therapies 2-4 days prior to initiating Vowst: (a) oral vancomycin (b) Difacid (fidaxomicin) (4) Member has completed the recommended bowel prep (e.g. 296mL of magnesium citrate) the day before and at least 8 hours prior to initiating Vowst (5) Previous episode of CDI is under control (e.g. less than 3 unformed or loose [i.e., Bristol Stool Scale type 6-7] stools per day for at least 2 consecutive days)
<b>Age Restrictions</b>	(PCDI): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PCDI): Prescribed by or in consultation with gastroenterologist or infectious disease specialist
<b>Coverage Duration</b>	(PCDI): 14 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VOXZOGO 2025

## Products Affected

- VOXZOGO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Achondroplasia) (Initial): (1) Member has open epiphyses, (2) Diagnosis of achondroplasia as confirmed by both of the following, (i) Member has clinical manifestations characteristic of achondroplasia (e.g. macrocephaly, frontal bossing, midface retrusion, disproportionate short stature with rhizomelic shortening of the arms and the legs, brachydactyly, trident configuration of the hands, thoracolumbar kyphosis, and accentuated lumbar lordosis), (ii) Member has radiographic findings characteristic of achondroplasia (e.g. large calvaria and narrowing of the foramen magnum region, undertubulated, shortened long bones with metaphyseal abnormalities, narrowing of the interpedicular distance of the caudal spine, square ilia and horizontal acetabula, small sacroscliotic notches, proximal scooping of the femoral metaphysis, and short and narrow chest)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Achondroplasia) (Initial) (Reauth): Prescribed by or in consultation with one of the following: (1) clinical geneticist, (2) endocrinologist, (3) a physician who has specialized expertise in the management of achondroplasia
<b>Coverage Duration</b>	(Initial) (Reauth): 12 months
<b>Other Criteria</b>	(Achondroplasia) (Reauth): (1) member has open epiphyses, (2) Documentation of positive clinical response to therapy [e.g. improvement in annualized growth velocity (AGV) compared to baseline].
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VOYDEYA 2025

## Products Affected

- VOYDEYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Paroxysmal nocturnal hemoglobinuria (PNH)(Initial): (1) Diagnosis of Paroxysmal nocturnal hemoglobinuria (PNH) (2) Medication will be used as add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) (3) Hemoglobin levels are less than or equal to 9.5 g/dL (4) Absolute reticulocyte count greater than or equal to 120 x 10 <sup>9</sup> /L.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PNH)(Initial, Continuation): Prescribed by or in consultation with a hematologist/oncologist
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(PNH)(Continuation): (1) Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) (2) Positive clinical response to therapy (e.g., hemoglobin stabilization, decrease in the number of red blood cell transfusions) (3) Will be used as add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VTAMA 2025

## Products Affected

- VTAMA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PsO) (Initial): (1) Diagnosis of plaque psoriasis (2) Inadequate response or inability to tolerate TWO of the following topical therapies for sufficient duration (e.g. minimum of 4 weeks): (a) corticosteroids (e.g. betamethasone, clobetasol) (b) Vitamin D analogs (e.g. calcitriol, calcipotriene) (c) Concurrent combination of Vitamin D analog and corticosteroid (e.g. Enstilar, Taclonex) (d) tazarotene (e) Calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) Atopic Dermatitis (AD) (Initial): (1) Diagnosis of atopic dermatitis (2) Inadequate response or inability to tolerate TWO of the following: (a) Medium or higher potency topical corticosteroid (b) Elidel (pimecrolimus) cream (c) Tacrolimus ointment (d) Eucrisa (crisaborole) ointment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PsO, AD) (Initial, Reauth): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauthorization): 12 months
<b>Other Criteria</b>	(PsO) (Reauthorization): (1) Documentation of positive clinical response to therapy (e.g. reduction in the body surface area (BSA) involvement from baseline, improvement in symptoms such as pruritus or inflammation from baseline) (AD)(Reauth):(1) Member demonstrates positive clinical response to therapy as evidenced by ONE of the following : (a) Reduction in body surface area involvement from baseline (b) Reduction in pruritus severity from baseline (c) Improvement in quality of life from baseline
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VUITY 2025

## Products Affected

- VUITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Presbyopia) (Initial): (1) Diagnosis of presbyopia (2) Provider confirms valid clinical rationale, which excludes lifestyle choice, as to why patient is unable to use corrective lenses (e.g. eyeglasses or contact lenses)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Presbyopia) (Initial) (Reauth): prescribed by or in consultation with one of the following (1) Ophthalmologist, (2) Optometrist
<b>Coverage Duration</b>	(Initial): 3 months, (Reauth): 6 months
<b>Other Criteria</b>	(Presbyopia) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. improvement in near vision in low light conditions without loss of distance vision)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VYVANSE 2025

## Products Affected

- *lisdexamfetamine dimesylate*
- VYVANSE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Attention Deficit Hyperactivity Disorder (ADHD): (1) Diagnosis of ADHD (2) inadequate response or inability to tolerate one of the following: immediate release formulations of amphetamine, dextroamphetamine, or methylphenidate Binge Eating Disorder (BED): (1)Diagnosis of BED. (2) Member has BED for 3 months or longer.
Age Restrictions	(ADHD): Member is 6 years of age or older (BED): Member is 18 years of age or older.
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# WAINUA 2025

## Products Affected

- WAINUA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(hATTR amyloidosis)(Initial): (1) Diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy (2) Member has a transthyretin (TTR) mutation (e.g., V30M) (3) One of the following: (a) Member has a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2 (b) member has a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130 (c) Member has a baseline Karnofsky Performance Status score greater than 50 percent (4) Presence of clinical signs and symptoms of the disease (e.g., neuropathy)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(hATTR amyloidosis)(Initial, Cont): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(hATTR amyloidosis)(Initial, Cont): 12 months
<b>Other Criteria</b>	(hATTR amyloidosis)(Cont): (1) Member demonstrates positive clinical response to therapy (2) One of the following: (a) Member continues to have a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2 (b) member continues to have a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130 (c) Member continues to have a baseline Karnofsky Performance Status score greater than 50 percent
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# WAKIX 2025

## Products Affected

- WAKIX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Narcolepsy type 1: (1) Diagnosis of cataplexy with narcolepsy (Type 1). (2) ONE of the following: (a) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT), (b) prescriber provides justification confirming that a sleep study would not be feasible and (3) Symptoms of cataplexy are present. Narcolepsy (Type 2): (1) Diagnosis of excessive daytime sleepiness in Narcolepsy (Type 2). (2) ONE of the following: (a) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT), (b) prescriber provides justification confirming that a sleep study would not be feasible and (3) Inadequate response or inability to tolerate modafinil or armodafinil.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# WEGOVY 2025

## Products Affected

- WEGOVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of other GLP-1 receptor agonist (e.g. Adlyxin, Byetta, Bydureon, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza)
<b>Required Medical Information</b>	(Initial): (1) Documentation of both of the following: (a) BMI greater than or equal to 27 kg/m2 (b) member has a history of cardiovascular disease, as evidenced by at least one of the following: (i) prior myocardial infarction (ii) prior stroke (ischemic and hemorrhagic stroke) (iii) symptomatic peripheral arterial disease, as evidenced by intermittent claudication with ankle-brachial index less than 0.85, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease and (2) Documentation showing member is on guideline therapy management for multiple risk factors (e.g. dyslipidemia, hypertension) associated with cardiovascular disease as evidenced by presence of all of the following: (a) one of the following: (i) platelet aggregation inhibitor (e.g. acetylsalicylic acid, P2Y12 receptor inhibitors) or anti-thrombotic medication (e.g. vitamin K antagonists, direct oral anticoagulants) (ii) member has inability to tolerate platelet aggregation inhibitor or anti-thrombotic medication (b) one of the following: (i) lipid-lowering medications (e.g. statins, ezetimibe, fibrate, PCSK-9 inhibitors) or (ii) member has inability to tolerate lipid-lowering medications (c) one of the following: (i) other cardiac medications including beta blocker, angiotensin-converting-enzyme inhibitor, angiotensin-receptor blocker, calcium channel blocker (ii) member has inability to tolerate other cardiac medications including beta blocker, angiotensin converting-enzyme inhibitor, angiotensin-receptor blocker, calcium channel blocker (3) Member does not have a history of Type 1 or Type 2 Diabetes Mellitus
<b>Age Restrictions</b>	Member is 45 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): End of contract year

PA Criteria	Criteria Details
<b>Other Criteria</b>	(Reauth): (1) Documentation showing member is on guideline therapy management for multiple risk factors (e.g. dyslipidemia, hypertension) associated with cardiovascular disease as evidenced by presence of all of the following: (a) one of the following: (i) platelet aggregation inhibitor (e.g. acetylsalicylic acid, P2Y12 receptor inhibitors) or anti-thrombotic medication (e.g. vitamin K antagonists, direct oral anticoagulants) (ii) member has inability to tolerate platelet aggregation inhibitor or anti-thrombotic medication (b) one of the following: (i) lipid-lowering medications (e.g. statins, ezetimibe, fibrates, PCSK-9 inhibitors) or (ii) member has inability to tolerate lipid-lowering medications (c) one of the following: (i) other cardiac medications including beta blocker, angiotensin-converting-enzyme inhibitor, angiotensin-receptor blocker, calcium channel blocker (ii) member has inability to tolerate other cardiac medications including beta blocker, angiotensin converting-enzyme inhibitor, angiotensin-receptor blocker, calcium channel blocker (2) Documentation is provided confirming one of the following: (a) Member has not experienced a cardiovascular event since starting treatment (i.e., nonfatal myocardial infarction, nonfatal stroke) (b) Member has experienced a non-fatal myocardial infarction or nonfatal stroke since starting treatment, but the prescriber attests the benefit outweighs risk for member to continue treatment with semaglutide (Wegovy)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# WILSONS DISEASE 2025

## Products Affected

- CUVRIOR
- *trientine hcl oral capsule 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Wilson's disease (WD): (1) Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration) (2) Inadequate response or inability to tolerate a penicillamine product (e.g. Depen, Cuprimine)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# XDEMVY 2025

---

## Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of treatment of demodex blepharitis
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or optometrist
Coverage Duration	6 weeks
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# XELJANZ 2025

## Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, UC, PJIA, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), Janus kinase (JAK) inhibitors or potent immunosuppressants (e.g. azathioprine, cyclosporine)
<b>Required Medical Information</b>	Rheumatoid arthritis (RA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine), (3) Member had inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate at least ONE conventional therapy (e.g. corticosteroid, aminosalicylate, azathioprine or 6-mercaptopurine) (3) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), adalimumab-ADB, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJIA) [applies to Xeljanz tablets/oral solution]: (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), etanercept (Enbrel), adalimumab-ADB, Adalimumab-AACF) OR documentation demonstrating that a trial may be inappropriate. (3) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine.
<b>Age Restrictions</b>	(RA, PsA, UC, AS): Member is 18 years of age or older. (PJIA): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (UC): Prescribed by or in consultation with a gastroenterologist.

PA Criteria	Criteria Details
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of ankylosing spondylitis. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira, adalimumab-ADB, adalimumab-AACF), etanercept (Enbrel)) OR documentation that a trial may be inappropriate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XENAZINE 2025

## Products Affected

- *tetrabenazine*
- XENAZINE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Tourette's Syndrome (TS): (1) Diagnosis of TS, (2) Member has tics associated with Tourette's syndrome, (3) Inadequate response or inability to tolerate haloperidol or risperidone. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(TS, CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Reauth): Prescribed by or in consultation with a neurologist or a psychiatrist.
<b>Coverage Duration</b>	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (TS, CHD): Indefinite.
<b>Other Criteria</b>	(TD)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XERMELO 2025

## Products Affected

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Carcinoid Syndrome Diarrhea (CSD)(Initial): (1) Diagnosis of carcinoid syndrome diarrhea, (2) Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g. octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months, (3) Used in combination with SSA therapy
<b>Age Restrictions</b>	(CSD)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CSD)(Initial, Reauth): Prescribed by or in consultation with an Oncologist, Endocrinologist, or Gastroenterologist
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): Indefinite
<b>Other Criteria</b>	(CSD)(Reauth): (1) Positive clinical response to Xermelo therapy, (2) Xermelo will continue to be used in combination with SSA therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# XGEVA 2025

## Products Affected

- XGEVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when: Prevention of Skeletal Related Events in Multiple Myeloma or Bone Metastases from Solid Tumors (MM-BMST) : (1) For prevention of skeletal related events in multiple myeloma or bone metastases from solid tumors. Giant Cell Tumor of the Bone (GCTB): (1) Diagnosis of GCTB. (2) Member is (a) adult or (b) adolescent that is skeletally mature. (3) Tumor is unresectable or surgical resection is likely to result in severe morbidity. Hypercalcemia of Malignancy Refractory to Bisphosphonates (HCMRB): (1) Diagnosis of HCMRB.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(GCTB, HCMRB): Prescribed by or in consultation with an urologist, oncologist or hematologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review. (All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XIFAXAN 2025

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Prophylaxis for Hepatic Encephalopathy (HE): (1) Diagnosis of hepatic disease with risk for hepatic encephalopathy (i.e. previous episode of hepatic encephalopathy, advanced liver disease, hepatocellular carcinoma), (2) Inadequate response or inability to tolerate lactulose. Irritable Bowel Syndrome (IBS): (1) Diagnosis of irritable bowels syndrome- diarrhea, (2) Inadequate response or inability to tolerate BOTH of the following: (A) ONE of the following: (i) ONE Tricyclic antidepressant or (ii)selective serotonin reuptake inhibitor and (B) dicyclomine (3): BOTH of the following: (A) Member does not exceed 3 total courses (42 days in total) of therapy, (B) Member experiences irritable bowel syndrome with diarrhea (IBS-D) symptoms. Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) (Initial): (1) Diagnosis of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(HE): Indefinite. (IBS): 2 weeks. (SBBO/SIBO): Initial and Reauth: 2 weeks.
<b>Other Criteria</b>	(SBBO/SIBO) (Reauth): (1) Documentation of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) recurrence following successful initial treatment
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XOLAIR 2025

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic agents for asthma/allergic conditions (e.g., benralizumab [Fasenra], dupilumab [Dupixent], mepolizumab [Nucala], omalizumab [Xolair])
<b>Required Medical Information</b>	Part D is medically necessary for: Moderate to Severe Persistent Allergic Asthma (PAA)(Initial): (1) Diagnosis of moderate to severe persistent allergic asthma (2) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (3) The individual has a baseline serum IgE level of between 30 IU/mL and 1300 IU/mL, (4) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). Chronic Urticaria (CU)(Initial): (1) Diagnosis of chronic urticaria (2) an inadequate response, contraindication or inability to tolerate ONE second-generation H1 antihistamine at the maximally tolerated dose in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g. montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second- generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine, (3) will be used concurrently with an h1 antihistamine, unless there is contraindication or intolerance to H1 antihistamines. Nasal Polyps (NP)(Initial): (1) Diagnosis of nasal polyps. (2) Member will use concurrently with nasal corticosteroid. (3) Member had inadequate response or inability to tolerate an intranasal corticosteroid. (4) Member has a baseline serum IgE level of between 30 IU/mL and 1500 IU/mL
<b>Age Restrictions</b>	(PAA)(Initial, Reauth): Member is 6 years of age or older (CU)(Initial, Reauth): Member is 12 years of age and older (NP)(Initial, Reauth): Member is 18 years of age and older (IMFA)(Initial, Reauth): Member is 1 year of age and older
<b>Prescriber Restrictions</b>	PAA)(Initial, Reauth): Prescribed by or in consultation with an Allergist, Immunologist, or Pulmonologist. (CU)(Initial, Reauth): Prescribed by or in consultation with allergist/immunologist, dermatologist. (NP)(Initial, Reauth): Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or ENT specialist. (IMFA)(Initial, Reauth): Prescribed by or in consultation with an Allergist or Immunologist

PA Criteria	Criteria Details
<b>Coverage Duration</b>	(Initial): 12 months. (Reauth): 12 months.
<b>Other Criteria</b>	<p>Subject to Part B vs Part D review. IgE-Mediated Food Allergy (IMFA) (initial): (1) One of the following: (A) Both of the following (i) Diagnosis of IgE-Mediated Food Allergy (ii) Clinical history of IgE Mediated Food Allergy (B) Documentation that the member has a history of severe allergic response, including anaphylaxis, following exposure to one or more foods (2) Used in conjunction with food allergen avoidance (3) Both of the following (A) Baseline (pre- Xolair treatment) serum total IgE level is greater than or equal to 30 IU/mL and less than or equal to 1850 IU/mL (B) Dosing is according to serum total IgE levels and body weight (PAA)(Reauth): (1) Documentation of positive clinical response to therapy (e.g., reduction in number of asthma exacerbations, improvement in forced expiratory volume in 1 second (FEV1), or decreased use of rescue medications). (CU)(Reauth): (1) Member's disease status has been re- evaluated since the last authorization to confirm the member's condition warrants continued treatment (2) member has experienced one or both of the following:(a) Reduction in itching severity from baseline (b) Reduction in number of hives from baseline. (NP)(Reauth): (1) Documentation of positive clinical response to therapy (e.g., reduction in nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NCS: 0-3 scale]) (2) Used in combination with another agent for nasal polyps. (IMFA)(Reauth) (1) Documentation of positive clinical response to therapy (2) Used in conjunction with food allergen avoidance. (3) Dosing will continue to be based on body weight and pretreatment total IgE serum levels</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XOLREMDI 2025

## Products Affected

- XOLREMDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(WHIM)(Initial): (1) Diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome (2) Member has genotype confirmed variant of CXCR4 as detected by an FDA-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA) (3) Member has an absolute neutrophil count (ANC) less than or equal to 500 cells /?L
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(WHIM) (Initial) (Reauth): Prescribed by or in consultation with immunologist, hematologist, geneticist or allergist
<b>Coverage Duration</b>	(Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	(WHIM)(Reauth): Documentation of positive clinical response to therapy (e.g., improvement in ANC, reduction in infections)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYREM 2025

## Products Affected

- *sodium oxybate*
- XYREM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CN, EDSN (Initial, Reauth): Concurrent use of sedative hypnotics and alcohol
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy, (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible and (3) Inadequate response or inability to modafinil or armodafinil. (adult use only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CN, EDSN)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYWAV 2025

## Products Affected

- XYWAV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Inadequate response or inability to modafinil. Idiopathic Hypersomnia (IH) (Initial): (1) Diagnosis of Idiopathic Hypersomnia as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), (2) Symptoms of excessive daytime sleepiness (e.g. nap duration of longer than 60 minutes) are present
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CN, EDSN, IH)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months. (IH) (Reauth): (1) Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# YORVIPATH 2025

## Products Affected

- YORVIPATH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hypoparathyroidism (initial): (1) Diagnosis of hypoparathyroidism, (2) Requested drug is not being used in the setting of acute post-surgical hypoparathyroidism, (3) Member has achieved albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D (e.g., calcitriol) treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or nephrologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	Hypoparathyroidism (Reauth): Member demonstrates positive clinical response to therapy as evidenced by maintenance of normal calcium levels compared to baseline.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ZAVESCA 2025

## Products Affected

- *miglustat*
- YARGESA
- ZAVESCA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Type 1 Gaucher's Disease (T1GD): (1) Diagnosis of mild to moderate T1GD, (2) enzyme replacement therapy is not a therapeutic option (e.g. because of allergy, hypersensitivity, or poor venous access).
<b>Age Restrictions</b>	(T1GD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZAVZPRET 2025

## Products Affected

- ZAVZPRET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Will be used for preventative treatment of migraine. Medication will be used in combination with another oral CGRP inhibitor
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan (4) Inadequate response or inability to tolerate ONE of the following: (a) Nurtec ODT (b) Ubrelvy
<b>Age Restrictions</b>	(AM)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(Initial): 6 months. (AM)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZEPBOUND 2025

## Products Affected

- ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Obstructive Sleep Apnea (OSA)(Initial): (1) Submission of medical records (e.g., chart notes) confirming disease is moderate to severe as evidenced by BOTH of the following: (a) Polysomnography (PSG) or home sleep apnea test (HSAT) confirming the apnea-hypopnea index (AHI) greater than or equal to 15 obstructive respiratory events per hour and (b) ALL of the following conditions affecting breathing have been ruled out: (i) Diagnosis of central or mixed sleep apnea and (ii) Diagnosis of Cheyne-Stokes respiration and (iii) Diagnosis of obesity hypoventilation syndrome or daytime hypercapnia and (iv) Presence of significant craniofacial abnormalities and (2) Submission of medical records (e.g., chart notes) confirming Body Mass Index (BMI) of greater than or equal to 30kg/m2 and (3) Submission of medical records (e.g., chart notes) confirming ALL of the following: (a) HbA1c less than 6.5% in the past 12 months and (b) Member does not have diagnosis of Type 1 or Type 2 Diabetes and (4) Submission of medical records (e.g., chart notes) or absence of paid claims confirming medication is not being co-administered with tirzepatide-containing products (e.g., Mounjaro) or GLP-1 receptor agonists (e.g., Ozempic, Rybelsus, Trulicity)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a sleep specialist
Coverage Duration	6 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	(OSA)(Reauth): (1) Submission of medical records (e.g., chart notes) confirming member is currently on a maintenance dose of 10mg or 15mg once weekly and (2) Submission of medical records (e.g., chart notes) confirming member has experienced improvement in obstructive sleep apnea symptoms (e.g., less daytime sleepiness, fewer nighttime awakenings, fewer partner- reported snoring episodes or pauses in breathing, member no longer requires the use of CPAP) and (3) Submission of medical records (e.g., chart notes) confirming ALL of the following: (a) HbA1c less than 6.5% in the past 12 months and (b) Member has not developed Type 2 Diabetes and (4) Submission of medical records (e.g., chart notes) or absence of paid claims confirming medication is not being co-administered with tirzepatide-containing products (e.g., Mounjaro) or GLP-1 receptor agonists (e.g., Ozempic, Rybelsus, Trulicity)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZEPOSIA 2025

## Products Affected

- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT ORAL CAPSULE  
THERAPY PACK 0.23MG & 0.46MG 0.92MG(21)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Multiple Sclerosis (MS): (1) Diagnosis of relapsing form of multiple sclerosis (MS) (e.g. clinically isolated syndrome, relapsing-remitting disease, secondary progressive disease, including active disease with new brain lesions) (2) Inadequate response or inability to tolerate at least 4 weeks trial of the following medications: (a) Avonex (interferon beta-1a), (b) Betaseron (interferon beta-1b), (c) Glatopa (glatiramer acetate), (d) Tecfidera (Dimethyl Fumarate), (e) Gilenya (fingolimod), or (f) teriflunomide OR documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of ulcerative colitis, (2) Inadequate response or inability to tolerate TWO of the following (a) Adalimumab (i.e. Humira, Adalimumab-ADBM, Adalimumab-AACF) (b) Xeljanz/Xeljanz XR (c) Ustekinumab (i.e. Yesintek) (d) Rinvoq (e) Skyrizi OR documentation demonstrating that a trial may be inappropriate. (3) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine)
<b>Age Restrictions</b>	(MS) (UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(UC): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	(MS, UC): Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZILBRYSQ 2025

## Products Affected

- ZILBRYSQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(gMG)(Initial): (1) Diagnosis of generalized myasthenia gravis (gMG) (2) Member is anti-acetylcholine receptor (AChR) antibody positive (3) One of the following: (a) Inadequate response or inability to tolerate two immunosuppressive therapies (e.g., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus) (b) Both of the following: (i) Inadequate response or inability to tolerate one immunosuppressive therapy (e.g., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus) (ii) Inadequate response or inability to tolerate one of the following: (1) Chronic plasmapheresis or plasma exchange (PE) (2) Intravenous immunoglobulin (IVIG)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(gMG) (Initial, Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(gMG) (Initial, Reauth): 12 months
<b>Other Criteria</b>	(gMG) (Reauth): Member demonstrates positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZORYVE 0.15% CREAM 2025

## Products Affected

- ZORYVE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD) (Initial): (1) Diagnosis of mild to moderate atopic dermatitis, (2) ONE of the following: (a) Greater than or equal to 3% body surface area (BSA) involvement (b) Involvement of sensitive body areas (e.g., face, hands, feet, scalp, groin), (3) Inadequate response or inability to tolerate (minimum 30-day supply or 14-day supply for topical corticosteroids), ONE of the following: (i) Medium or higher potency topical corticosteroid, (2) Elidel (pimecrolimus) cream, (3) Tacrolimus ointment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial)(Reauth): Prescribed by or in consultation with a Dermatologist or Allergist/Immunologist
<b>Coverage Duration</b>	Initial) 6 months (Reauth) 12 months
<b>Other Criteria</b>	Atopic Dermatitis (AD) (Reauth): (1) Member demonstrates positive clinical response to therapy as evidenced by ONE of the following (a) Reduction in body surface area involvement from baseline, (b) Reduction in pruritus severity from baseline, (c) Improvement in quality of life from baseline
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZORYVE 2025

## Products Affected

- ZORYVE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PsO) (Initial): (1) Diagnosis of plaque psoriasis (2) Inadequate response or inability to tolerate TWO of the following topical therapies for sufficient duration (e.g. minimum of 4 weeks): (a) corticosteroids (e.g. betamethasone, clobetasol) (b) Vitamin D analogs (e.g. calcitriol, calcipotriene) (c) Concurrent combination of Vitamin D analog and corticosteroid (e.g. Enstilar, Taclonex) (d) Tazarotene (e) Calcineurin inhibitors (e.g. tacrolimus, pimecrolimus)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PsO) (Initial, Reauth): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauthorization): 12 months
<b>Other Criteria</b>	(PsO) (Reauthorization): (1) Documentation of positive clinical response to therapy (e.g. reduction in the body surface area (BSA) involvement from baseline, improvement in symptoms such as pruritus or inflammation from baseline)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ZORYVE FOAM 2025

## Products Affected

- ZORYVE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(SD)(Initial): (1) Diagnosis of seborrheic dermatitis (2) Inadequate response or inability to tolerate a minimum of a 4-week trial of TWO of the following generic topical therapies: (a) corticosteroids (e.g. betamethasone, clobetasol) (b) Antifungals (e.g. ciclopirox, ketoconazole) (c) calcineurin inhibitors (e.g. tacrolimus)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SD) (Initial, Reauth): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(SD) (Reauth): Documentation of positive clinical response to therapy (e.g. reduction in the body surface area (BSA) involvement from baseline, improvement in symptoms such as pruritus or inflammation from baseline)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZTALMY 2025

## Products Affected

- ZTALMY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(CDKL5): (1) Diagnosis of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (2) Documentation of mutation in the CDKL5 gene (3) member is experiencing motor seizures (e.g. bilateral tonic, generalized tonic-clonic, bilateral clonic, atonic, focal, or bilateral tonic-clonic) (4) Inadequate response or inability to tolerate two formulary anticonvulsants (e.g. valproic acid, levetiracetam, lamotrigine)
<b>Age Restrictions</b>	(CDKL5): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(CDKL5): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Approve if for continuation of therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZURZUVAE 2025

## Products Affected

- ZURZUVAE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PPD): (1) Diagnosis of Postpartum depression (PPD) (2) Inadequate response or inability to tolerate (a) one generic Selective serotonin reuptake inhibitor (SSRI) (b) One generic Serotonin-Norepinephrine reuptake inhibitor (SNRI) (3) Medication will not be used for greater than 14 days
<b>Age Restrictions</b>	Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	14 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZYMFENTRA SQ 2025

## Products Affected

- ZYMFENTRA (2 PEN)
- ZYMFENTRA (2 SYRINGE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(UC, CD): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ulcerative Colitis (UC): (1) Diagnosis of moderately to severely active Ulcerative Colitis (2) Member has achieved a clinical response following a minimum of 10 weeks of one of the following: (a) Remicade (b) Infliximab. Crohn's Disease (CD): (1) Diagnosis of moderately to severely active CD (2) Member has achieved a clinical response following a minimum of 10 weeks of one of the following: (a) Remicade (b) Infliximab.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(UC, CD): Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	(UC, CD)(initial): 6 months, (Reauth): 12 months
<b>Other Criteria</b>	(UC, CD)(Reauth): (1) Positive clinical response to therapy as evidenced by ONE of the following: (A) Improvement in intestinal inflammation (e.g. mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline (B) Reversal of high fecal output state
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	Yes

## Index

<i>abiraterone acetate</i> .....	194	ALLZITAL.....	115
ABIRTEGA.....	194	ALTRENO.....	270
ABRILADA (1 PEN).....	10	ALUNBRIG.....	194
ABRILADA (2 SYRINGE).....	10	ALVAIZ.....	22
ACTEMRA ACTPEN.....	4	ALYQ.....	208
ACTEMRA SUBCUTANEOUS.....	4	AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG.....	119
ACTHAR.....	6	AMBIEN ORAL TABLET 10 MG.....	119
ACTHAR GEL SUBCUTANEOUS PEN- INJECTOR.....	6	<i>ambrisentan</i> .....	24
ACTIVELLA ORAL TABLET 1-0.5 MG.....	117	AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	10
<i>adalimumab-aacf (2 pen)</i> .....	13	AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8ML.....	10
<i>adalimumab-aacf (2 syringe)</i> .....	13	AMJEVITA-PED 10KG TO <15KG.....	10
<i>adalimumab-aacf(cd/uc/hs strt)</i> .....	13	AMJEVITA-PED 15KG TO <30KG.....	10
<i>adalimumab-aacf(ps/uv starter)</i> .....	13	<i>amphetamine sulfate</i> .....	90
<i>adalimumab-aaty (1 pen) subcutaneous auto- injector kit 80 mg/0.8ml</i> .....	10	AMPYRA.....	25
<i>adalimumab-aaty (2 pen)</i> .....	10	AMRIX.....	116
<i>adalimumab-aaty (2 syringe)</i> .....	10	ANGELIQ.....	117
<i>adalimumab-adaz</i> .....	10	APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE.....	28
<i>adalimumab-adbm (2 pen)</i> .....	13	<i>apomorphine hcl subcutaneous</i> .....	28
<i>adalimumab-adbm (2 syringe)</i> .....	13	AQNEURSA.....	29
<i>adalimumab-adbm(cd/uc/hs strt)</i> .....	13	ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG.....	228
<i>adalimumab-adbm(ps/uv starter)</i> .....	13	ARIKAYCE.....	30
<i>adalimumab-fkjp (2 pen)</i> .....	10	<i>armodafinil</i> .....	31
<i>adalimumab-fkjp (2 syringe)</i> .....	10	ASCOMP-CODEINE.....	115
<i>adalimumab-ryvk (2 pen)</i> .....	10	ATRALIN.....	270
<i>adalimumab-ryvk (2 syringe)</i> .....	10	ATTRUBY.....	32
<i>adapalene external cream</i> .....	270	AUGTYRO.....	194
<i>adapalene external gel 0.3 %</i> .....	270	AUSTEDO.....	33
<i>adapalene external pad</i> .....	270	AUSTEDO XR.....	33
<i>adapalene-benzoyl peroxide external gel</i> .....	270	AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG.....	33
ADBRY.....	15	AUVELITY.....	35
ADCIRCA.....	208	AVEED.....	265
ADEMPAS.....	16	AYVAKIT.....	194
AFINITOR.....	194	BALVERSA.....	194
AFINITOR DISPERZ.....	194	BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG.....	112
AFREZZA INHALATION POWDER 12 UNIT, 4 UNIT, 60X4 & 60X8 & 60X12 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT.....	17	BENLYSTA SUBCUTANEOUS.....	36
AGAMREE.....	18	BERINERT.....	8
AIMOVIG.....	19	BESREMI.....	37
AJOVY.....	20		
AKEEGA.....	194		
AKLIEF.....	270		
ALECENSA.....	194		

<i>bexarotene</i> .....	194, 269	COBENFY STARTER PACK.....	54
BIJUVA.....	117	COMETRIQ (100 MG DAILY DOSE) ORAL KIT	
BIMZELX.....	38	80 & 20 MG.....	194
BIVIGAM INTRAVENOUS SOLUTION 5		COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3	
GM/50ML.....	130	X 20 MG & 80 MG.....	194
<i>bosentan</i> .....	271	COMETRIQ (60 MG DAILY DOSE).....	194
BOSULIF.....	194	COPIKTRA.....	194
BRAFTOVI ORAL CAPSULE 75 MG.....	194	CORLANOR.....	56
BRUKINSA.....	194	CORTROPHIN.....	6
<i>butalbital-acetaminophen oral capsule</i> .....	115	COSENTYX (300 MG DOSE).....	57
<i>butalbital-acetaminophen oral tablet 50-300</i>		COSENTYX SENSOREADY (300 MG).....	57
<i>mg, 50-325 mg</i> .....	115	COSENTYX SUBCUTANEOUS SOLUTION	
<i>butalbital-apap-caff-cod</i> .....	115	PREFILLED SYRINGE 75 MG/0.5ML.....	57
<i>butalbital-apap-caffeine oral capsule</i> .....	115	COSENTYX UNOREADY.....	57
<i>butalbital-apap-caffeine oral tablet 50-325-</i>		COTELLIC.....	194
<i>40 mg</i> .....	115	CRENESSITY.....	58
<i>butalbital-asa-caff-codeine</i> .....	115	CRESEMBA ORAL.....	59
<i>butalbital-aspirin-caffeine oral capsule</i> .....	115	CREXONT.....	60
BYLVAY.....	41	CRINONE.....	207
BYLVAY (PELLETS).....	41	CUVRIOR.....	299
CABOMETYX.....	194	<i>cyclobenzaprine hcl er</i> .....	116
CABTREO.....	270	<i>cyclobenzaprine hcl oral</i> .....	116
CALQUENCE ORAL TABLET.....	194	CYLTEZO (2 PEN).....	10
CAMZYOS.....	43	CYLTEZO (2 SYRINGE).....	10
CAPLYTA.....	44	CYLTEZO-CD/UC/HS STARTER.....	10
CAPRELSA.....	194	CYLTEZO-PSORIASIS/UV STARTER.....	10
CARBAGLU ORAL TABLET SOLUBLE.....	45	CYSTADROPS.....	61
<i>carbinoxamine maleate oral solution</i> .....	115	CYSTARAN.....	61
<i>carbinoxamine maleate oral tablet</i> .....	115	<i>dalfampridine er</i> .....	62
<i>carglumic acid oral tablet soluble</i> .....	45	DALVANCE.....	168
<i>carisoprodol oral</i> .....	121	DANZITEN.....	194
CAYSTON.....	46	<i>dapagliflozin pro-metformin er</i> .....	34
CERDELGA.....	47	<i>dapagliflozin propanediol</i> .....	34
<i>chlordiazepoxide-clidinium</i> .....	26	<i>dasatinib</i> .....	194
<i>chlorzoxazone oral</i> .....	115	DAURISMO.....	194
CHOLBAM.....	48	DAYBUE.....	63
CIALIS ORAL TABLET 5 MG.....	49	DAYVIGO.....	64
CIBINQO.....	50	<i>deferasirox granules</i> .....	65
CIMZIA (2 SYRINGE).....	51	<i>deferasirox oral tablet</i> .....	65
CIMZIA SUBCUTANEOUS KIT 2 X 200 MG.....	51	<i>deferasirox oral tablet soluble</i> .....	65
CINRYZE.....	53	<i>deferiprone</i> .....	98
<i>clemastine fumarate oral syrup</i> .....	115	<i>deflazacort</i> .....	78
<i>clemastine fumarate oral tablet 2.68 mg</i> .....	115	DEMEROL INJECTION SOLUTION 25 MG/ML,	
CLIMARA.....	117	50 MG/ML.....	115
CLIMARA PRO.....	117	DEPO-TESTOSTERONE INTRAMUSCULAR	
<i>clindamycin-tretinoin</i> .....	270	SOLUTION.....	265
COBENFY.....	54	DETROL ORAL TABLET 2 MG.....	204

DIACOMIT .....	66	<i>estradiol-norethindrone acet</i> .....	117
<i>diclofenac epolamine external</i> .....	69	<i>eszopiclone oral tablet 3 mg</i> .....	119
<i>diclofenac sodium external gel 3 %</i> .....	68	EUCRISA .....	89
DIFFERIN EXTERNAL CREAM .....	270	EVAMIST .....	117
DIFFERIN EXTERNAL GEL 0.3 % .....	270	EVEKEO .....	90
DILAUDID ORAL TABLET 4 MG, 8 MG .....	112	EVENITY .....	91
<i>dipyridamole oral</i> .....	115	<i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5</i>	
DIVIGEL .....	117	<i>mg</i> .....	194
DOJOLVI .....	70	<i>everolimus oral tablet soluble</i> .....	194
DOPTELET ORAL TABLET 20 MG .....	71	EVRYSDI .....	92
DOTTI .....	117	EXJADE .....	65
DUPIXENT SUBCUTANEOUS SOLUTION		EYSUVIS .....	94
AUTO-INJECTOR .....	72	FABHALTA .....	95
DUPIXENT SUBCUTANEOUS SOLUTION		FASENRA .....	96
PREFILLED SYRINGE 200 MG/1.14ML, 300		FASENRA PEN .....	96
MG/2ML .....	72	<i>fentanyl transdermal patch 72 hour 100</i>	
DUVYZAT .....	75	<i>mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr,</i>	
EBGLYSS .....	76	<i>62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr</i> .....	112
EDLUAR SUBLINGUAL TABLET SUBLINGUAL		FERRIPROX ORAL SOLUTION .....	98
10 MG .....	119	FERRIPROX ORAL TABLET 1000 MG .....	98
EGRIFTA SV .....	77	FERRIPROX TWICE-A-DAY .....	98
ELESTRIN .....	117	FILSPARI .....	99
EMFLAZA .....	78	FILSUVEZ .....	100
EMGALITY .....	79	FINTEPLA .....	101
EMGALITY (300 MG DOSE) .....	79	FIORICET ORAL CAPSULE .....	115
EMSAM .....	81	FIORICET/CODEINE ORAL CAPSULE 50-300-	
ENBREL MINI .....	82	40-30 MG .....	115
ENBREL SUBCUTANEOUS SOLUTION 25		FIRAZYR SUBCUTANEOUS SOLUTION	
MG/0.5ML .....	82	PREFILLED SYRINGE .....	8
ENBREL SUBCUTANEOUS SOLUTION		FIRDAPSE .....	102
PREFILLED SYRINGE .....	82	FLECTOR EXTERNAL .....	69
ENBREL SURECLICK SUBCUTANEOUS		<i>fluticasone furoate-vilanterol inhalation</i>	
SOLUTION AUTO-INJECTOR .....	82	<i>aerosol powder breath activated 100-25</i>	
ENDARI .....	83	<i>mcg/act, 200-25 mcg/act</i> .....	34
ENSPRYNG .....	84	<i>fluticasone-salmeterol inhalation aerosol</i> .....	34
ENTYVIO PEN .....	85	FORTEO SUBCUTANEOUS SOLUTION PEN-	
EPCLUSA .....	212	INJECTOR 560 MCG/2.24ML .....	263
EPIDIOLEX .....	86	FOTIVDA .....	194
EPIDUO .....	270	FRUZAQLA .....	194
EPIDUO FORTE .....	270	FYAVOLV .....	117
EPSOLAY .....	87	<i>gabapentin (once-daily)</i> .....	106
ERIVEDGE .....	194	GALAFOLD .....	103
ERLEADA .....	194	GAMMAGARD INJECTION SOLUTION 2.5	
<i>erlotinib hcl</i> .....	194	GM/25ML .....	130
ESBRIET .....	88	GAMMAGARD S/D LESS IGA .....	130
ESTRACE ORAL .....	117	GAMMAKED INJECTION SOLUTION 1	
<i>estradiol transdermal</i> .....	117	GM/10ML .....	130

GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML.....	130	<i>hydromorphone hcl er oral tablet extended release 24 hour.....</i>	112
GAMUNEX-C INJECTION SOLUTION 1 GM/10ML.....	130	<i>hydromorphone hcl oral tablet 4 mg, 8 mg.....</i>	112
GATTEX.....	104	HYFTOR.....	122
GAVRETO.....	194	HYRIMOZ SUBCUTANEOUS SOLUTION AUTO- INJECTOR.....	10
<i>gefitinib</i> .....	194	HYRIMOZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML.....	10
GENOTROPIN MINISUBCUTANEOUS PREFILLED SYRINGE.....	107	HYRIMOZ-CROHNS/UC STARTER.....	10
GENOTROPIN SUBCUTANEOUS CARTRIDGE..	107	HYRIMOZ-PED<40KG CROHN STARTER .....	10
GILOTRIF .....	194	HYRIMOZ-PED>=40KG CROHN START .....	10
GLASSIA INTRAVENOUS SOLUTION 1000 MG/50ML.....	228	HYRIMOZ-PLAQ PSOR/UEIT START .....	10
GLEEVEC.....	194	HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 100 MG.....	112
GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG.....	194	HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 20 MG, 30 MG, 40 MG, 60 MG, 80 MG.....	3
GOCOVRI.....	105	IBRANCE.....	194
GOMEKLI.....	194	<i>ibuprofen-famotidine</i> .....	55
GRALISE ORAL TABLET .....	106	<i>icatibant acetate subcutaneous solution prefilled syringe</i> .....	8
GRASTEK.....	21	ICLUSIG.....	194
HADLIMA.....	10	IDHIFA.....	194
HADLIMA PUSHTOUCH.....	10	ILUMYA.....	123
HAEGARDA.....	109	<i>imatinib mesylate oral</i> .....	194
HARVONI.....	212	IMBRUVICA ORAL CAPSULE.....	194
HETLIOZ.....	110	IMBRUVICA ORAL SUSPENSION.....	194
HETLIOZ LQ.....	111	IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG.....	194
HORIZANT ORAL TABLET EXTENDED RELEASE.....	114	<i>imkeldi</i> .....	194
HULIO (2 PEN).....	10	IMVEXXY MAINTENANCE PACK.....	207
HULIO (2 SYRINGE).....	10	IMVEXXY STARTER PACK.....	207
HUMATROPE INJECTION CARTRIDGE.....	107	INBRIJA.....	124
HUMIRA (2 PEN) SUBCUTANEOUS AUTO- INJECTOR KIT .....	13	INCRELEX.....	125
HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML.....	13	INDOCIN ORAL.....	115
HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML.....	13	INDOCIN RECTAL.....	115
HUMIRA-PSORIASIS/UEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	13	<i>indomethacin oral suspension</i> .....	115
<i>hydrocodone bitartrate er oral capsule extended release 12 hour</i> .....	3	<i>indomethacin rectal suppository 50 mg</i> .....	115
<i>hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent</i> .....	3, 112	INGREZZA.....	126
		INLYTA.....	194
		INQOVI.....	194
		INREBIC.....	194
		<i>insulin glargine max solostar</i> .....	129
		<i>insulin glargine solostar subcutaneous solution pen-injector 300 unit/ml</i> .....	129
		INTRAROSA.....	207



IQIRVO .....	132	<i>lidocaine external patch 5 %</i> .....	144
IRESSA .....	194	LIDOCAN .....	144
ISTURISA ORAL TABLET 1 MG, 5 MG .....	133	<i>liraglutide</i> .....	211
ITOVEBI .....	194	<i>lisdexamfetamine dimesylate</i> .....	294
<i>ivabradine hcl</i> .....	56	LITFULO .....	145
IWILFIN .....	194	LIVDELZI .....	146
JADENU .....	65	LIVMARLI ORAL SOLUTION .....	147
JADENU SPRINKLE .....	65	LIVTENCITY .....	149
JAKAFI .....	194	LODOCO .....	150
JATENZO .....	265	LONSURF .....	194
JAYPIRCA .....	194	LORBRENA .....	194
JINTELI .....	117	LUMAKRAS .....	194
JOENJA .....	134	LUMRYZ .....	151
JUBLIA .....	188	LUMRYZ STARTER PACK .....	151
JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG .....	135	LUNESTA ORAL TABLET 3 MG .....	119
JYNARQUE .....	137	LYBALVI .....	40
KALYDECO .....	138	LYLLANA .....	117
KERENDIA .....	139	LYNPARZA ORAL TABLET .....	194
<i>ketorolac tromethamine oral</i> .....	118	LYRICA CR .....	152
KEVEYIS .....	67	LYTGOBI (12 MG DAILY DOSE) .....	194
KEVZARA .....	140	LYTGOBI (16 MG DAILY DOSE) .....	194
KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	141	LYTGOBI (20 MG DAILY DOSE) .....	194
KISQALI (200 MG DOSE) .....	194	MAVYRET .....	212
KISQALI (400 MG DOSE) .....	194	MEKINIST .....	194
KISQALI (600 MG DOSE) .....	194	MEKTOVI .....	194
KORLYM .....	142	MENOSTAR .....	117
KOSELUGO .....	194	<i>meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml</i> .....	115
KRAZATI .....	194	<i>meperidine hcl oral solution</i> .....	115
<i>lapatinib ditosylate</i> .....	194	<i>meperidine hcl oral tablet 50 mg</i> .....	115
LAZCLUZE .....	194	<i>meprobamate</i> .....	115
<i>ledipasvir-sofosbuvir</i> .....	212	<i>metaxalone oral tablet 400 mg, 800 mg</i> .....	115
<i>lenalidomide</i> .....	194	<i>metformin hcl er (mod)</i> .....	93
LENVIMA (10 MG DAILY DOSE) .....	194	<i>metformin hcl oral tablet 625 mg, 750 mg</i> .....	153
LENVIMA (12 MG DAILY DOSE) .....	194	<i>methadone hcl oral solution</i> .....	112
LENVIMA (14 MG DAILY DOSE) .....	194	<i>methadone hcl oral tablet</i> .....	112
LENVIMA (18 MG DAILY DOSE) .....	194	<i>methocarbamol oral tablet 1000 mg</i> .....	154
LENVIMA (20 MG DAILY DOSE) .....	194	<i>mifepristone oral tablet 300 mg</i> .....	142
LENVIMA (24 MG DAILY DOSE) .....	194	<i>miglustat</i> .....	313
LENVIMA (4 MG DAILY DOSE) .....	194	MIMVEY .....	117
LENVIMA (8 MG DAILY DOSE) .....	194	MINIVELLE .....	117
LETAIRIS .....	143	MIPLYFFA .....	155
<i>levorphanol tartrate oral tablet 3 mg</i> .....	112	<i>mirabegron er</i> .....	34
<i>l-glutamine oral packet</i> .....	83	<i>modafinil oral</i> .....	156
LIBRAX .....	26	<i>morphine sulfate er beads oral capsule extended release 24 hour 120 mg</i> .....	112
LICART EXTERNAL .....	69		

<i>morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg</i> .....	112	OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML.....	130
<i>morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg</i> .....	112	ODACTRA.....	21
MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	211	ODOMZO.....	194
MS CONTIN ORAL TABLET EXTENDED RELEASE 60 MG.....	112	OFEV.....	183
MULPLETA.....	158	OGSIVEO.....	194
MYALEPT.....	159	OHTUVAYRE.....	184
MYCAPSSA.....	160	OJEMDA ORAL SUSPENSION RECONSTITUTED.....	194
MYFEMBREE.....	161	OJEMDA ORAL TABLET 100 MG.....	194
MYTESI.....	163	OJJAARA.....	194
<i>naproxen-esomeprazole mg</i> .....	55	OLUMIANT.....	185
NAYZILAM.....	9	OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE.....	107
NEMLUVIO.....	164	OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED.....	107
NERLYNX.....	194	OMVOH (300 MG DOSE).....	186
NEXAVAR.....	194	OMVOH SUBCUTANEOUS.....	186
NEXLETOL.....	165	ONGENTYS.....	187
NEXLIZET.....	165	ONUREG.....	194
NGENLA.....	167	ONYDA XR.....	189
NINLARO.....	194	OPIPZA.....	190
NORDITROPIN FLEXPPO SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107	OPSUMIT.....	197
<i>norethindrone-eth estradiol</i> .....	117	OPSYNVI.....	191
NORGESIC.....	120	OPZELURA.....	192
<i>norgesic forte</i> .....	120	ORENCIA CLICKJECT.....	198
NOURIANZ.....	174	ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	198
NOXAFIL ORAL PACKET.....	176	ORENITRAM.....	197
NOXAFIL ORAL SUSPENSION.....	175	ORENITRAM MONTH 1.....	197
NUBEQA.....	194	ORENITRAM MONTH 2.....	197
NUCALA.....	177	ORENITRAM MONTH 3.....	197
NUCYNTA ER.....	3, 112	ORGOVYX.....	194
NUCYNTA ORAL TABLET 100 MG, 75 MG.....	112	ORIAHNN.....	199
NUDEXTA.....	179	ORILISSA.....	200
NUPLAZID ORAL CAPSULE.....	180	ORKAMBI.....	201
NUPLAZID ORAL TABLET 10 MG.....	180	ORLADEYO.....	202
NURTEC.....	181	ORMALVI.....	67
NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107	<i>orphenadrine citrate er</i> .....	26
NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107	<i>orphenadrine-aspirin-caffeine oral tablet 25-385-30 mg</i> .....	120
NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107	ORSERDU.....	194
NUVIGIL.....	31	OSPHENA.....	207
NUZYRA.....	168, 193	OTEZLA.....	203
OALIVA.....	182		

OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML.....	128	<i>promethazine hcl oral tablet</i> .....	26
OTULFI SUBCUTANEOUS.....	172	<i>promethazine hcl rectal suppository 12.5 mg, 25 mg</i> .....	26
OXERVATE.....	205	<i>promethazine-phenylephrine</i> .....	26
<i>oxycodone hcl oral tablet 30 mg</i> .....	112	PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG.....	26
<i>oxycodone hcl oral tablet abuse-deterrent ....</i>	3, 112	PROVIGIL.....	156
OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT .....	3, 112	PYRUKYND.....	219
<i>oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg</i> .....	112	PYRUKYND TAPER PACK.....	219
<i>oxymorphone hcl er oral tablet extended release 12 hour 40 mg</i> .....	112	PYZCHIVA SUBCUTANEOUS.....	172
<i>oxymorphone hcl oral tablet 10 mg</i> .....	112	QINLOCK.....	194
OXYTROL.....	204	<i>quinine sulfate oral</i> .....	220
OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML.....	211	QULIPTA.....	221
OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML.....	211	QUVIVIQ.....	222
OZEMPIC (2 MG/DOSE).....	211	RADICAVA ORS STARTER KIT .....	223
PALYNZIQ.....	206	RASUVO SUBCUTANEOUS SOLUTION AUTO- INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML.....	128
PANZYGA.....	130	RAVICTI.....	224
PAXIL ORAL TABLET.....	27	RECORLEV.....	225
<i>pazopanib hcl</i> .....	194	REPATHA.....	226
PEMAZYRE.....	194	REPATHA PUSHTRONEX SYSTEM.....	226
<i>pentazocine-naloxone hcl</i> .....	115	REPATHA SURECLICK.....	226
PIQRAY (200 MG DAILY DOSE).....	194	RETEVMO ORAL TABLET .....	194
PIQRAY (250 MG DAILY DOSE).....	194	RETIN-A.....	270
PIQRAY (300 MG DAILY DOSE).....	194	RETIN-A MICRO .....	270
<i>pirfenidone</i> .....	88	RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 %.....	270
POMALYST.....	194	REVATIO ORAL TABLET .....	238
<i>posaconazole oral</i> .....	175	REVLIMID.....	194
PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	209	REVUFORJ.....	194
<i>pregabalin er</i> .....	152	REZDIFFRA.....	229
PREMARIN ORAL.....	117	REZLIDHIA.....	194
<i>pretomanid</i> .....	213	REZUROCK.....	230
PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML.....	130	RINVOQ.....	231
PROCYSBI ORAL PACKET .....	214	RINVOQ LQ.....	233
PROLASTIN-C INTRAVENOUS SOLUTION.....	228	RIVFLOZA.....	234
PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	215	ROMVIMZA.....	194
PROMACTA.....	217	ROXICODONE ORAL TABLET 30 MG.....	112
<i>promethazine hcl oral solution 6.25 mg/5ml</i> .....	115	ROXYBOND.....	3, 112
		ROZLYTREK.....	194
		RUBRACA.....	194
		RUCONEST.....	8
		RYBELSUS.....	211
		RYDAPT.....	194

RYVENT .....	115	SUTENT .....	194
SAJAZIR SUBCUTANEOUS SOLUTION		SYMDEKO .....	253
PREFILLED SYRINGE .....	8	SYMLINPEN 120 SUBCUTANEOUS SOLUTION	
SAMSCA .....	235	PEN-INJECTOR .....	254
SCEMBLIX .....	194	SYMLINPEN 60 SUBCUTANEOUS SOLUTION	
SELARSDI SUBCUTANEOUS .....	172	PEN-INJECTOR .....	254
SEROSTIM SUBCUTANEOUS SOLUTION		TABRECTA .....	194
RECONSTITUTED 4 MG, 5 MG, 6 MG .....	236	<i>tadalafil (pah)</i> .....	208
SIGNIFOR .....	237	<i>tadalafil oral tablet 2.5 mg, 5 mg</i> .....	49
<i>sildenafil citrate oral suspension reconstituted</i> .....	238	TADLIQ .....	255
<i>sildenafil citrate oral tablet 20 mg</i> .....	238	TAFINLAR .....	194
SILIQ .....	239	TAGRISSO .....	194
SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-		TAKHZYRO .....	257
INJECTOR KIT 80 MG/0.8ML .....	10	TALTZ .....	258
SIMLANDI (1 SYRINGE) .....	10	TALZENNA .....	194
SIMLANDI (2 PEN) .....	10	TANLOR .....	154
SIMLANDI (2 SYRINGE) .....	10	TARGRETIN .....	194, 269
SIMPONI SUBCUTANEOUS SOLUTION AUTO-		TARPEYO .....	260
INJECTOR .....	240	TASIGNA .....	194
SIMPONI SUBCUTANEOUS SOLUTION		<i>tasimelteon</i> .....	110
PREFILLED SYRINGE .....	240	<i>tavaborole</i> .....	188
SIRTURO .....	242	TAVALISSE .....	261
SIVEXTRO .....	168, 193	TAVNEOS .....	262
SKYCLARYS .....	243	TAZVERIK .....	194
SKYRIZI PEN .....	244	TENCON ORAL TABLET 50-325 MG .....	115
SKYRIZI SUBCUTANEOUS .....	244	TEPMETKO .....	194
SKYTROFA .....	245	<i>teriparatide subcutaneous solution pen-injector</i>	
<i>sodium oxybate</i> .....	310	<i>620 mcg/2.48ml</i> .....	263
<i>sofosbuvir-velpatasvir</i> .....	212	<i>testosterone cypionate intramuscular solution</i>	
SOGROYA .....	246	<i>100 mg/ml, 200 mg/ml</i> .....	265
SOHONOS .....	247	<i>testosterone enanthate intramuscular solution</i> .....	265
SOLQUA .....	170	<i>testosterone transdermal gel 10 mg/act (2%),</i>	
SOMA .....	121	<i>12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%),</i>	
<i>sorafenib tosylate</i> .....	194	<i>20.25 mg/act (1.62%), 25 mg/2.5gm (1%),</i>	
SOTYKTU .....	249	<i>40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> .....	265
SOVALDI .....	171	<i>testosterone transdermal solution</i> .....	265
SPEVIGO SUBCUTANEOUS .....	250	<i>tetrabenazine</i> .....	303
SPRIX .....	118	THALOMID ORAL CAPSULE 100 MG, 50 MG ...	194
SPRYCEL .....	194	TIBSOVO .....	194
STELARA SUBCUTANEOUS SOLUTION 45		TLANDO .....	265
MG/0.5ML .....	251	TOBI PODHALER .....	127
STELARA SUBCUTANEOUS SOLUTION		<i>tolvaptan oral tablet</i> .....	235
PREFILLED SYRINGE .....	251	TORPENZ .....	194
STEQEYMA SUBCUTANEOUS .....	172	TRACLEER .....	271
STIVARGA .....	194	TRELSTAR MIXJECT .....	169
<i>sunitinib malate</i> .....	194	TREMFYA ONE-PRESS .....	272
SUNOSI .....	252		

TREMFYA PEN SUBCUTANEOUS SOLUTION		VESICARE.....	204
AUTO-INJECTOR 200 MG/2ML.....	272	VESICARE LS.....	204
TREMFYA SUBCUTANEOUS SOLUTION		VFEND IV.....	207
PREFILLED SYRINGE.....	272	VICTOZA SUBCUTANEOUS SOLUTION PEN-	
<i>tretinoin external</i> .....	270	INJECTOR.....	211
<i>tretinoin microsphere external gel 0.04 %, 0.1</i>		VIJOICE.....	284
<i>%</i> .....	270	VITRAKVI.....	194
<i>tretinoin microsphere pump external gel 0.08 %</i>		VIVELLE-DOT.....	117
.....	270	VIVJOA.....	285
TRIDACAINE II.....	144	VIZIMPRO.....	194
<i>trientine hcl oral capsule 500 mg</i> .....	299	VONJO.....	194
TRIKAFTA.....	274	VOQUEZNA.....	287
TRULICITY SUBCUTANEOUS SOLUTION		VOQUEZNA DUAL PAK.....	286
AUTO-INJECTOR.....	211	VOQUEZNA TRIPLE PAK.....	286
TRUQAP ORAL TABLET 200 MG.....	194	VORANIGO.....	194
TRYVIO.....	275	<i>voriconazole intravenous</i> .....	207
TUKYSA.....	194	VOSEVI.....	171
TURALIO ORAL CAPSULE 125 MG.....	194	VOTRIENT.....	194
TWYNEO.....	270	VOWST.....	289
TYENNE SUBCUTANEOUS.....	267	VOXZOGO.....	290
TYKERB.....	194	VOYDEYA.....	291
TYMLOS.....	276	VTAMA.....	292
TYVASO DPI MAINTENANCE KIT INHALATION		VUITY.....	293
POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG	277	VYNDAMAX.....	256
TYVASO DPI TITRATION KIT INHALATION		VYNDAQEL.....	256
POWDER 16 & 32 & 48 MCG.....	277	VYVANSE.....	294
UBRELVY.....	278	WAINUA.....	295
UNDECATREX.....	265	WAKIX.....	296
UPTRAVI ORAL.....	279	WEGOVY.....	297
UPTRAVI TITRATION.....	279	WELIREG.....	194
<i>ustekinumab-ttwe subcutaneous</i> .....	172	WEZLANA SUBCUTANEOUS.....	172
VABOMERE.....	168	WINREVAIR.....	248
VALCHLOR.....	269	XALKORI.....	194
VALTOCO 10 MG DOSE.....	9	XDEMVI.....	300
VALTOCO 15 MG DOSE NASAL LIQUID		XELJANZ.....	301
THERAPY PACK 2 X 7.5 MG/0.1ML.....	9	XELJANZ XR.....	301
VALTOCO 20 MG DOSE NASAL LIQUID		XENAZINE.....	303
THERAPY PACK 2 X 10 MG/0.1ML.....	9	XERMELO.....	304
VALTOCO 5 MG DOSE.....	9	XGEVA.....	305
VANFLYTA.....	194	XIFAXAN ORAL TABLET 550 MG.....	306
VECAMYL.....	280	XOLAIR.....	307
VELSIPITY.....	281	XOLREMDI.....	309
VENCLEXTA.....	194	XOSPATA.....	194
VENCLEXTA STARTING PACK.....	194	XPOVIO (100 MG ONCE WEEKLY) ORAL	
VEOZAH.....	282	TABLET THERAPY PACK 50 MG.....	194
VERKAZIA.....	283	XPOVIO (40 MG ONCE WEEKLY) ORAL	
VERZENIO.....	194	TABLET THERAPY PACK 10 MG, 40 MG.....	194

XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG.....	194	ZOMACTON.....	107
XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG.....	194	ZORYVE.....	319, 320, 321
XPOVIO (60 MG TWICE WEEKLY).....	194	ZTALMY.....	322
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG.....	194	ZTLIDO.....	207
XPOVIO (80 MG TWICE WEEKLY).....	194	ZURZUVAE.....	323
XTAMPZA ER.....	3, 112	ZYDELIG.....	194
XTANDI.....	194	ZYKADIA ORAL TABLET.....	194
XULTOPHY.....	170	ZYMFENTRA (2 PEN).....	324
XYOSTED.....	265	ZYMFENTRA (2 SYRINGE).....	324
XYREM.....	310	ZYPREXA ORAL TABLET 20 MG.....	40
XYWAV.....	311	ZYTIGA.....	194
YARGESA.....	313		
YONSA.....	194		
YORVIPATH.....	312		
YUFLYMA (1 PEN).....	10		
YUFLYMA (2 SYRINGE).....	10		
YUFLYMA-CD/UC/HS STARTER.....	10		
YUSIMRY SUBCUTANEOUS SOLUTION AUTO- INJECTOR.....	10		
ZAVESCA.....	313		
ZAVZPRET.....	314		
ZEJULA ORAL TABLET.....	194		
ZELBORAF.....	194		
ZEMAIRA INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG.....	228		
ZEMDRI.....	168		
ZEPATIER.....	171		
ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	315		
ZEPOSIA.....	317		
ZEPOSIA 7-DAY STARTER PACK.....	317		
ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG &0.46MG 0.92MG(21).....	317		
ZERBAXA.....	168		
ZIANA.....	270		
ZILBRYSQ.....	318		
ZOLINZA.....	194		
<i>zolpidem tartrate er oral tablet extended release 12.5 mg.....</i>	119		
<i>zolpidem tartrate oral capsule.....</i>	119		
<i>zolpidem tartrate oral tablet 10 mg.....</i>	119		
<i>zolpidem tartrate sublingual tablet sublingual 3.5 mg.....</i>	119		